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ABSTRACT 
 
Melanie R. Nicol:  Pre-Exposure Prophylaxis for HIV: Linking Antiretroviral Pharmacokinetics and 
Pharmacodynamics to Identify Optimal Dosing Strategies 
Under the direction of: Angela D.M. Kashuba 
 
Despite utilization of potent combination antiretroviral therapy, the incidence of HIV in the U.S. 
has not declined over recent years. Several clinical trials recently demonstrated that antiretrovirals can 
protect vulnerable mucosal surfaces against infection. However, the protection conferred ranged from 0% 
to 73%, underscoring the importance of identifying drug concentrations needed at mucosal surfaces.  
Additionally, antiretrovirals have complex pharmacology in mucosal tissues with unpredictable drug 
penetration within and between drug classes.  The ultimate goal of this work was to identify factors 
influencing variability in drug penetration and to develop an explant tissue culture model that could be 
used to evaluate the efficacy of tenofovir and maraviroc, two antiretroviral candidates for oral pre-
exposure prophylaxis strategies. 
Using real-time PCR and immunochemistry, mRNA and protein expression of three efflux 
(ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and three uptake (SLC22A6/OAT1, SLC22A8/OAT3, 
SLCO1B1/OATP1B1) transporters was described in female genital (FGT) and colorectal tissues (CRT) 
from 99 donors.  Epithelial expression of efflux transporters was found to be two- to four-fold greater in 
FGT than CRT.  These data support clinical findings of higher maraviroc and tenofovir concentrations in 
CRT compared to FGT after oral dosing.  Quantifying mucosal transporter expression and localization 
was a useful technique to understand drug tissue distribution and facilitate antiretroviral selection to target 
these tissues.     
Explant models may be one way to identify target concentrations for prevention but current 
methods are high variable and require long incubation times in culture.  Here, an explant tissue model was 
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developed using the R5, T-tropic strain HIV-1JR-CSF as the inoculum, and was coupled with a novel real-
time PCR assay to quantify spliced RNA that detected replication within 24-72 hours after HIV exposure.  
In this model, concentrations required to protect vaginal explants were 10-1000 fold higher than in a 
TZM-bl cell monolayer.  A single oral dose of tenofovir and maraviroc at 200% treatment doses protected 
cervical and vaginal biopsies in 3/6 healthy volunteer women.  TZM-bl cells over predicted efficacy by 
49%, and tissue explants under predicted by 36%.  This translational approach, comparing 
concentration-response relationships in cells, explant tissue, and healthy volunteers, presents a 
model framework for future investigations of antiretrovirals for prevention.   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
 
 
 
 
 
 
 
To my wonderful and loving family, Mom, Dad, Derek, Ethan, Frances, Stephanie, and Truman 
 
 
 
For those living with HIV/AIDS, those we have lost to HIV/AIDS, and those who love someone 
with HIV/AIDS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
 Completion of this doctoral dissertation would not have been possible without the meaningful 
contributions of many individuals in both my personal and professional life.  
 First, I would like to thank my advisor Angela Kashuba.  Dr. Kashuba has been a phenomenal 
mentor over the past five years and I suspect I will be coming to her for guidance for the rest of my 
career.  Her door was always open for anything and everything I needed.  She was always pushing me to a 
level of achievement that I wouldn’t have thought myself capable of.  I would also like to thank Dr. Hull 
for stepping in as my committee chair. Dr. Hull has been a dedicated educator and I appreciate his ability 
to teach applied statistics in a way relevant to drug research.  Dr. Corbett has been a wonderful role model 
in the clinic and in the classroom.  I appreciate her sharing with me not only her knowledge on 
antiretroviral therapy, but more importantly her approach to solving clinical problems.  Dr. Kroetz’s 
expertise in transporter pharmacology was instrumental to the development of my dissertation.  Lastly, 
Dr. Nelson, always more than generous with her time, proved to be an invaluable advisor on the 
molecular and virologic portions of my project.  Her expertise contributed significantly to the 
multidisciplinary nature of my project and my development as a translational researcher.  
Outside of my committee, there have been many others who have mentored me in my path to 
obtaining a PhD.  Dr. Talbot was the first to introduce me to scientific research and without his 
encouragement, I never would have even considered graduate school. Dr. Patterson was a great clinical 
mentor who took the time to share both inpatient and outpatient experiences with me during my clinical 
rotations.  Her expertise was also greatly appreciated in her role as study physician for my clinical study.  
Likewise, Heather Prince deserves much appreciation for her phenomenal role as study coordinator.  Not 
only does she get all the credit for ensuring my clinical study was completed in time for graduation, but 
vii 
 
the amount I have learned from her about performing clinical research is astounding.  I also want to thank 
Dr. Fedoriw for serving as a collaborator on these studies.  His expertise in tissue pathology proved 
instrumental in moving both the explant and transporter projects along.  Katie Molan, CFAR statistician 
also provided helpful input on the statistical analysis for many of these studies.  I would also like to 
extend a special thanks to Drs. Myron Cohen and Ron Swanstrom for providing valuable feedback at 
various time points throughout the development of my dissertation. 
I want to thank all the members of the Kashuba laboratory group for their support, both personal 
and professional.  Cindi Emerson, Kuo Yang, Julie Dumond, Craig Sykes, Nicole White, Stephanie 
Malone, Ruili Wang, Michelle Brosnan-Cook, and Steve Jennings not only provided excellent analytical 
tools for the completion of my studies, but also contributed to the fantastic working group that made it a 
pleasure to come into the laboratory every day.  I was fortunate to be trained alongside several amazing 
graduate students and fellows during my time in the Kashuba lab.  I am grateful to consider Racheal 
Kendrick, Jessica Adams, Corbin Thompson, Mackenzie Cottrell and Christine Trezza as both friends and 
professional colleagues.   
I need to acknowledge the remarkable core facilities at UNC whose resources allowed for 
experiment completion and whose personnel provided valuable insight into my projects. Tissue 
Procurement Facility provided invaluable services in the steady supply of tissues without which none of 
the research here would have been possible.  The Urogynecology Department at UNC, in particular Dr. 
Elizabeth Geller, deserves thanks for assisting with recruitment of tissue donors.  Tissue processing and 
immunohistochemical staining was performed by the Translational Pathology Laboratory.  Michele 
Mathews in particular was instrumental in the work performed.  The nurses and staff at the Clinical and 
Translational Research Center provided excellent service and assistance in the performance of my clinical 
study.   I would like to acknowledge the subjects who participated in the clinical study.  It is because of 
volunteers like them that drug development is able to move forward.   
 I would like to thank Kathy Maboll, and Arlo Brown, and the administrative staff of 
DPET/ESOP, whose behind the scenes work made the completion of this dissertation possible. I also 
viii 
 
thank the DPET faculty. I feel incredibly fortunate to have been taught by such an esteemed group of 
professors. I also acknowledge the DPET fellows and graduate students that I have interacted with over 
my time here. They were a pleasure to work and learn with.   
 Lastly, I have been blessed with an amazing family and group of friends.  Mom, Dad, Derek, 
Ethan, Frances, Stephanie, and Truman have shown me as no one else could what unconditional love and 
support really means.  I also cannot express enough how much the friendship of Melody, Whitney, Cathy, 
Jasmine, Christina, Chelsey, and many others have meant to me throughout this process and could not 
have done this without them.   
  
ix 
 
 
 
 
TABLE OF CONTENTS 
 
ABSTRACT ............................................................................................................................... iii 
ACKNOWLEDGEMENTS .......................................................................................................... vi 
LIST OF FIGURES ....................................................................................................................xiv 
LIST OF TABLES ...................................................................................................................... xv 
LIST OF ABBREVIATIONS ......................................................................................................xvi 
Chapter I: Background-Pharmacologic Opportunities for HIV Prevention ............................................1 
Summary ............................................................................................................................................. 1 
Introduction ......................................................................................................................................... 1 
Current Approaches to Pre-Exposure Prophylaxis of HIV Infection ..................................................... 3 
Current Approaches to Post-Exposure Prophylaxis ............................................................................ 15 
Current Approaches to Treatment of the Index Case .......................................................................... 17 
Developmental Obstacles in HIV Prevention Studies ......................................................................... 22 
Future Role of Clinical Pharmacology to Bridge the Gaps .................................................................. 25 
Conclusion ........................................................................................................................................ 28 
Specific Aims .................................................................................................................................... 29 
Chapter II:  Expression of Six Drug Transporters in Vaginal, Cervical, and Colorectal Tissues: 
Implications for Drug Disposition in HIV Prevention ....................................................................... 31 
x 
 
Summary ........................................................................................................................................... 31 
Introduction ....................................................................................................................................... 32 
Materials and Methods ...................................................................................................................... 33 
Tissue Procurement ....................................................................................................................... 33 
mRNA Expression ......................................................................................................................... 34 
Protein Expression ......................................................................................................................... 35 
Statistical Analysis ........................................................................................................................ 36 
Results .............................................................................................................................................. 37 
ABC Efflux Transporters: .............................................................................................................. 37 
SLC Uptake Transporters:.............................................................................................................. 45 
Role of Menopause Status in Efflux Transporter mRNA Expression .............................................. 46 
Discussion ......................................................................................................................................... 46 
Chapter III: A Human Tissue Explant Model as a Preclinical Tool to Evaluate HIV                                
Pre-Exposure Prophylaxis Candidates ............................................................................................ 52 
 
Summary ........................................................................................................................................... 52 
Introduction ....................................................................................................................................... 53 
Materials and Methods ...................................................................................................................... 54 
Tissue Procurement ....................................................................................................................... 54 
Immunohistochemistry and Immune Cell Quantification ................................................................ 54 
Ex-vivo Explant Cultures ............................................................................................................... 55 
MTT Viability Assay ..................................................................................................................... 56 
Antiretroviral Drug Disposition...................................................................................................... 56 
xi 
 
Viral Propagation and Explant Infections ....................................................................................... 57 
Immunohistochemistry to Measure Intracellular p24 ...................................................................... 57 
Real-time PCR to Measure Proviral DNA ...................................................................................... 58 
Spliced Viral RNA Assay .............................................................................................................. 59 
Statistical Analysis ........................................................................................................................ 60 
Results .............................................................................................................................................. 61 
Expression and Variability of HIV Target and Immune Cells in Explant Tissues ............................ 61 
Changes in Architecture, Immune Cell Composition, and Viability over Time ............................... 62 
Uptake, Elimination, and Metabolism of Antiretroviral Drugs in Explant Tissues ........................... 64 
Identification and Quantification of HIV Infection in Explant Culture ............................................ 66 
Discussion ......................................................................................................................................... 68 
Chapter IV: Concentration-Response Relationship of Tenofovir and Maraviroc in                              
Human Explant Tissue ................................................................................................................. 73 
 
Summary ........................................................................................................................................... 73 
Introduction ....................................................................................................................................... 74 
Methods ............................................................................................................................................ 75 
Tissue Procurement ....................................................................................................................... 75 
Concentration-Response Relationship in Vaginal Explant Tissue ................................................... 75 
Concentration-Response in TZM-bl Cells ...................................................................................... 76 
Data analysis ................................................................................................................................. 76 
Results .............................................................................................................................................. 77 
TFV Efficacy in Vaginal Explants Determined by TFVdp Concentrations ...................................... 77 
xii 
 
MVC Efficacy in Vaginal Explants is Short Lived ......................................................................... 78 
Additive Efficacy of Tenofovir and Maraviroc in Cell Culture ....................................................... 79 
Prediction of Efficacy from Oral Tenofovir Disoproxil Fumarate and Maraviroc ............................ 79 
Discussion ......................................................................................................................................... 80 
Chapter V: Efficacy of Oral Maraviroc and Tenofovir for HIV Prevention:                                            
Proof of Concept Study to Evaluate Explant Model Predictions......................................................... 84 
 
Summary ........................................................................................................................................... 84 
Introduction ....................................................................................................................................... 84 
Methods ............................................................................................................................................ 85 
Study Design ................................................................................................................................. 85 
Peripheral Blood Mononuclear Cell Stimulation and Infection ....................................................... 86 
Cervical and Vaginal Biopsy Ex-vivo HIV Challenge .................................................................... 87 
Results .............................................................................................................................................. 88 
Study Participants and Adverse Events .......................................................................................... 88 
Oral Maraviroc and Tenofovir Protection of Cervical and Vaginal Biopsies ................................... 89 
PBMC as a Surrogate for Donor Susceptibility to HIV Infection .................................................... 89 
Discussion ......................................................................................................................................... 90 
Chapter VI: Perspectives and Future Directions ............................................................................... 94 
Clinical Pharmacology for HIV Prevention: Advances and Limitations .............................................. 94 
The Future of PrEP ............................................................................................................................ 98 
Applications beyond Prevention ........................................................................................................ 99 
Conclusion ...................................................................................................................................... 100 
xiii 
 
APPENDIX : Transporter Gene Expression Statistical Tables ......................................................... 101 
REFERENCES CITED .............................................................................................................. 107 
 
 
  
xiv 
 
 
LIST OF FIGURES 
Figure 1: Opportunities for prevention ..................................................................................................... 2 
Figure 2: Timeline of mucosal infection................................................................................................. 15 
Figure 3 Relationship of total genital tract exposure to blood plasma protein binding ............................. 22 
Figure 4: What should be measured for accurate PK-PD evaluations? * ................................................. 26 
Figure 5 mRNA expression of three ABC transporters in vaginal, cervical, and colorectal tissues. ......... 40 
Figure 6 Immunohistochemical staining of vaginal, cervical, and colorectal tissues.  . ............................ 41 
Figure 7 Positive and Negative Controls for Transporter Immunohistochemistry.   ................................. 42 
Figure 8 Lower Magnification Images (original objective magnification 20 or 40X. .......................... ….44 
Figure 9: Hypothesized influence of drug transporters on drug exposure in      
colorectal and vaginal tissues.  . ..................................................................................... ……………….47 
Figure 10: HIV target cells and relevant immune cells are expressed in explant tissue sources……….....60 
Figure 11: Explant tissue composition is variable…………………………………………..…………….61 
Figure 12: Sloughing of the epithelial layer and tissue architecture changes……………………………..62 
Figure 13: Rapid changes occur in explant tissue over time in culture…………………….……………..63 
Figure 14: Antiretrovirals are rapidly taken up by tissue and rapidly eliminated…………………………64 
Figure 15: Exlpant tissues can be infected with a clinically relevant strain HIV-1JR-CSF/hPBMC……..….65 
Figure 16: Spliced viral RNA and replication in explant tissue…………………………………………..68 
Figure 17: Inhibition of HIV is correlated with tissue concentrations of TFVdp in 
human vaginal explant tissue……………………………………………………………………………...77  
Figure 18: Maraviroc inhibits HIV infection in vaginal explants for 24 hours. ……………………….…78 
Figure 19: Protection of mucosal biopsies from HIV following oral maraviroc and  
oral tenofovir at 200% dosing……………………………………………………………………………..89  
 
 
 
xv 
 
LIST OF TABLES 
Table 1: Summary of completed clinical trials involving pharmacotherapy for prevention...................... 11 
Table 2: Exposures of antiretrovirals in relevant tissues compared to blood plasma……….………...…..21 
Table 3: Expression and variability in mRNA expression of five endogenous control genes.. ................. 35 
Table 4 Demographics of tissue donors.. ................................................................................................ 38 
Table 5 The proportion of samples for each transporter with quantifiable mRNA expression..... ............. 45 
Table 6: Demographic information for vaginal explant donors used  in spliced RNA assay time course.. 67 
Table 7 Emax model predictions of oral MVC and TDF efficacy at 50, 100 and 200% dosing.. .............. 79 
Table 8 Correlation between PBMC and tissue biopsy susceptibility to HIV infection.  . ........................ 90 
 
 
 
 
 
 
 
 
 
 
  
xvi 
 
 
 
 
LIST OF ABBREVIATIONS 
 
3TC  Lamivudine 
 
3TC-tp  Lamivudine triphosphate 
 
ABC  Abacavir 
 
AIDS  Acquired Immunodeficiency Syndrome 
 
ARV(s)  Antiretroviral(s) 
 
AUC  Area under the curve 
 
BP  Blood plasma 
 
CVF  Cervicovaginal fluid 
 
dATP  deoxyadenosine triphosphate 
 
dCTP  deoxycytidine triphosphate 
 
FGT  Female genital tract 
 
FTC  Emtricitabine 
 
FTC-tp  Emtricitabine triphosphate 
 
HIV  Human Immunodeficiency Virus 
 
IHC  Immunohistochemistry 
 
LC  Liquid chromatography 
 
MDR1  Multidrug resistant protein1 
 
MRP2  Multidrug resistance-associated protein 2 
 
MRP4  Multidrug resistance-associated protein 4 
 
MS  Mass spectrometry 
 
MSM  Men who have sex with men 
xvii 
 
 
MTT  methylthiazolydiphenyl-tetrazolium 
 
MVC  Maraviroc 
 
nPEP  nonoccupational Post-exposure prophyalxis 
 
NRTI  Nucleotide reverse transcriptase inhibitor 
 
NNRTI  Non-nucleotide reverse transcriptase inhibitor 
 
OAT1  Organic anion transporter 1 
 
OAT3  Organic anion transporter 3 
 
OATP1B1 Organic anion transporting polypeptide 1B1 
 
PBMC  Peripheral blood mononuclear cell 
 
PCR  Polymerase chain reaction 
 
PEP  Post-exposure prophyalxis 
 
PD  Pharmacodynamics 
 
PHA  Phytohemagglutinin 
 
PK  Pharmacokinetics 
 
PrEP  Pre-exposure prophylaxis 
 
SHIV  Simian-human (chimeric) immunodeficiency virus 
 
SIV  Simian immunodeficiency virus 
 
TCID50  Tissue culture infectious dose (50%) 
 
TDF  Tenofovir disoproxil fumarate  
 
TFV  Tenofovir 
 
TFVdp  Tenofovir diphosphate 
 
TPF  Tissue Procurement Facility 
 
TPL  Translational Pathology Laboratory 
 
ZDV  zidovudine 
 
 
 
1 
 
 
 
 
Chapter I: Background-Pharmacologic Opportunities for HIV Prevention
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Summary 
 
Innovations in antiretroviral treatment strategies have resulted in treated, HIV-infected 
patients having similar life expectancies as their uninfected counterparts.  Yet, the number of 
individuals capable of HIV transmission is increasing: for every person initiating antiretroviral (ARV) 
treatment, four more become infected with HIV.  The limited progress with microbicides and 
vaccines for HIV prevention reinforce the need for a concentrated exploration of the utility of 
antiretrovirals.  Preliminary animal studies with topical and systemic antiretrovirals show promise.  
However, current clinical trials were designed without a comprehensive understanding of 
antiretroviral pharmacokinetic-pharmacodynamic relationships in HIV prevention.  This review 
focuses on current strategies for prevention of HIV infection,  and how the tools of pharmacology can 
be a valuable resource for determining pharmacodynamic targets, providing interspecies scaling of 
exposures, identifying the optimal drugs/drug combinations, doses, and dosing regimens, and 
designing efficient clinical trials.   
 
Introduction 
 
 Over the past 10 years, innovations in antiretroviral treatment strategies have resulted in 
treated, HIV-infected patients having similar life expectancies as their uninfected counterparts [1].  
                                                             
1  This article is updated from an article previously published.  The original citation is as follows: 
Nicol MR, Kashuba ADM. Pharmacologic Opportunities for HIV Prevention. Clin Pharmacol Ther. 
2010 Nov;88(5):598-609. 
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Yet the number of individuals capable of HIV transmission is increasing.   According to the 
UNAIDS, the number of newly infected individuals worldwide in 2012 was approximately 2.3 
million [2]. Since the early 1990s, transmission rates have been relatively stable in the United States 
[3]. This is due, in part, to increased efforts in HIV screening, placing patients into care, and 
behavioral interventions [4].  However, countries which lack access to resources have not had similar 
success.  For example, between 2001 and 2008 in the Middle East and North Africa, the number of 
newly infected individuals increased by 17% and the number of adult and child deaths due to AIDS 
increased by 80% [5].  The World Health Organization estimates that in resource limited settings, for 
every person initiating antiretroviral (ARV) treatment, four more become infected with HIV [6].  
Since current treatment interventions will not likely curb the HIV epidemic, other prevention efforts 
are desperately needed.   
As illustrated in Figure 1, interventions for HIV prevention can be divided into four main 
strategies based on the time course of exposure.  In an individual who has yet to be exposed to HIV, 
behavioral and structural interventions may be effective [4]. In an exposed individual at the time of 
coital exposure, a vaccine that provides neutralizing antibodies or a pre-exposure prophylaxis (PrEP) 
intervention with topical microbicides/antiretrovirals, or systemic antiretrovirals may be effective.  In 
an exposed individual shortly after the time of exposure, a vaccine or a post-exposure prophylaxis 
(PEP) intervention with antiretrovirals may be effective.  Once infected, an individual may be 
rendered less infectious if placed on potent combination antiretroviral therapy [7, 8].  
Figure 1: Opportunities for prevention 
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The efficacy for each of the aforementioned interventions depends on the type and timing of 
the intervention.  Structural barriers such as male circumcision and condom use, along with other 
behavioral interventions, have shown 50-80% efficacy in clinical trials [9].  However, consistent 
implementation of these practices remains challenging, particularly due to social and cultural 
conditions that can preclude women from being empowered to utilize them [10].  Recent advances in 
vaccine development are encouraging [11], but worldwide implementation of an effective vaccine is 
years away.  Therefore, the potential of pharmacologic interventions to curtail the HIV epidemic 
quickly is significant.    
These strategies include microbicides and traditional antiretroviral drugs used systemically or 
topically.  Typically, microbicides act in the vaginal lumen to either destroy the virus before it can 
traverse mucosal surfaces, or prevent viral attachment to mucosal surfaces.  This is in contrast to 
antiretrovirals which are distributed into tissues following oral or topical application, and act at the 
mononuclear cellular level to prevent viral entry or replication. This article provides a brief review of 
these pharmacologic opportunities and their roles in the exposure continuum (Figure 1).  We also 
summarize current obstacles facing the clinical pharmacology of HIV prevention, and possible 
opportunities to overcome them.  
 
Current Approaches to Pre-Exposure Prophylaxis of HIV Infection 
 
 PrEP involves taking protective measures prior to an encounter that could lead to HIV 
infection.  An effective PrEP intervention will be invaluable to sex workers, HIV-negative partners of 
HIV-seropositive individuals, and others who are at a high risk of being exposed to HIV.  Both 
topical and systemic approaches to PrEP have been proposed.  Although four topical microbicide 
compounds have been evaluated for efficacy, none have demonstrated protection in randomized 
placebo-controlled clinical studies [12]. The first microbicide evaluated (Col-1492; a vaginal gel 
containing nonoxynol-9) unexpectedly demonstrated higher seroconversion rates (16%) than placebo 
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(12%) in a Phase III study involving 892 female sex workers in four countries [13]. Four nonspecific 
microbicides (Cellulose Sulfate, Carraguard, Buffer Gel, Pro 2000)  have failed to demonstrate 
efficacy in clinical trials [12].  VivaGel ® (SPL7013 3%; a membrane binding inhibitor) was found in 
a Phase I study to be well tolerated but adherence was reduced in the active arm compared to placebo 
and no further studies are currently planned [14].  
With the disappointing results of microbicide trials, topical formulations of antiretrovirals are 
actively being investigated.  Nucleoside/tide analogue (N(t)RTIs) and nonnucleoside analogue 
(NNRTI) reverse transcriptase inhibitors are of greatest interest due to their pre-integration activity, 
long (intracellular) half-life, safety profile, and success in preventing infection in animal models [15, 
16].  Some leading candidates as of 2010 are summarized below.  
 Tenofovir (TFV) is a nucleotide reverse transcriptase inhibitor that has advanced the farthest 
in PrEP clinical trials.  It has been FDA approved as Viread ® for HIV treatment since 2001 as the 
salt form tenofovir disoproxil fumarate (TDF), and is often used with the NRTI, Emtriva ® 
emtricitabine (FTC) as the fixed dose combination Truvada ®.  CAPRISA 004 was a Phase II safety 
and efficacy study looking at coital-dependent use of 1% TFV gel in 900 high-risk South African 
women [17].  Results of this randomized, double-blinded trial which followed the women for 30 
months provided both encouraging and informative data in regards to the future of pharmacology for 
prevention.  When applied vaginally within 12 hours before and within 12 hours after sex, the gel 
demonstrated a 39% reduction in HIV infections in the study population with 60 seroconversions in 
the placebo group (n=444) compared to 38 infections in the treatment group (n=445).  Importantly, 
the ability of the gel to protect against HIV infection closely followed the pharmacology.  In the 
group of women who seroconverted, 45% had detectable concentrations in the cervicovaginal fluid 
(CVF) (samples drawn average of 4.5 days after use) and a median concentration of 1 ng/mL.  This is 
in contrast to the group of women who remained protected from HIV of whom 96% had detectable 
plasma levels and the median concentration was 520 ng/mL.   Overall, blood plasma concentrations 
of women following vaginal administration of the gel was low, generally less than 1 ng/mL.   
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In contrast to the success of CAPRISA 004, in 2011 a Phase II study in African women 
which included an arm to evaluate daily use of 1% TFV gel, halted enrollment after external review 
by the Data Safety Monitoring Board determined futility [18].  The reasons for the failure to find a 
drug effect in this study are still being explored.  FACTS001 was launched in October and is a Phase 
III regulatory study which plans to enroll 2900 women to confirm the findings of CAPRISA 004 
regarding BAT24 dosing (www.facts-consortium.co.za).    
   The efficacy of vaginally applied TFV 1% gel has also been investigated in a macaque model 
of repeated low-dose exposure to a chimeric simian –human immunodeficiency virus (SHIVSF162P3 10  
50% tissue culture infectious doses or 1.5 x 10
6
 copies RNA per exposure]) [19].   Three milliliters of 
TFV 1% gel, TFV 1% + FTC 5% combination gel or placebo gel was administered vaginally 30 
minutes before viral challenge to groups of six macaques.  All animals in the TFV or TFV+FTC gel 
groups (6/6) remained protected from infection after 20 weekly viral challenges, whereas only 1/6 
animals in the placebo group remained uninfected (p<0.001).   The average plasma TVF 
concentration from these protected animals 30 minutes after dosing was 16 ng/mL for TFV gel, and 
39 ng/mL for TFV+FTC gel. Comparatively, preliminary pharmacokinetic data in humans following 
a four gram intravaginal dose of 1% TFV gel demonstrates that blood plasma concentrations above 5 
ng/mL are seldom achieved [20].   
Using male rhesus macaques, Cranage et al demonstrated that rectal application of three mL 
of TFV 1% gel  up to two hours before exposure to simian immunodeficiency virus (SIVmac251/32H, 20 
median rectal infectious doses) prevented infection in 6/9 animals, whereas only 1/4 animals in the 
placebo group remained uninfected [21].  Analysis of plasma concentrations 15 minutes after dosing 
suggested that protection was associated with higher TFV exposures; the lowest plasma TFV 
concentration conferring protection was 120 ng/mL.  Assuming the average male rhesus monkey 
weighs 8 kg to a human’s 70 kg, in order to achieve the same mg/kg dose, nearly 30 mL of gel would 
need to be used in humans to achieve similar plasma levels.   
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Tenofovir has also been shown safe and efficacious in cervical and colorectal tissue explants.  
In a polarized cervical explant culture (where only the epithelial layer is exposed to the air interface), 
the application of a 1mg/mL TFV gel reduced p24 antigen concentrations from an HIVBaL inoculation 
by 10-fold, compared to untreated explants [22].  Following a one hour drug incubation, colorectal 
tissue demonstrated 100% protection from infection (two hour exposure to 30X the tissue culture ID50 
(TCID50) HIVBaL) at concentrations of 10 and 100 μg/mL and >90 % inhibition at concentrations of 
0.1 and 1 μg/mL [23]. In colorectal biopsies collected from HIV-negative volunteers before and after 
rectal dosing with vaginally formulated 1% TFV gel, a reduction in p24 antigen was observed that 
was found to be correlated (r
2
 =0.23; p=0.002) with measured intracellular tenofovir diphosphate 
(TFVdp) concentrations [24].  However, a significant increase in the adverse events reported after 
seven days of gel use determined that the vaginally-formulated TFV gel was not appropriate for rectal 
use.   
UC781 is a nonnucleoside reverse transcriptase inhibitor with an intracellular half-life of 5.5 
days [25].    This long half-life confers protection against HIV infection in explant culture models up 
to six days after initial drug exposure [26].  In colorectal explants, complete protection from  HIVBaL  
infection was seen at UC781 concentrations ranging from 10-100 μM [23].  A Phase I study showed 
no significant adverse events after single or seven days of 0.1% or 0.25% UC781 gel use and also 
demonstrated efficacy in ex vivo biopsy challenge [27].   In cervical explant tissue, 100 μM UC781 
was able to confer complete protection from a two hour exposure to HIVBaL.  At concentrations as 
low as 1 nM,  greater than 99% protection was seen [26].   Using 20 pig-tailed macaques, Patton et al 
concluded that UC781 0.1% and 1% gel formulations were safe after four daily doses of rectal (2.5 
mL) or vaginal (1.5 mL) applications based on in-vitro toxicity assays, colposcopy examination, 
vaginal pH, rectal lavage examinations, rectal pH, and rectal micro flora. [28]  Even upon repeated 
dosing, UC781 was not detected in the animals’ plasma, suggesting minimal systemic absorption.  Up 
to six hours following administration of 1% gel, vaginal lavage samples contained UC781 
concentrations above the IC50, but by 24 hours they were undetectable. However, CONRAD, the IND 
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sponsor for UC781 halted the development of UC781 as a microbicide and as of 2014, no additional 
clinical studies are planned.   
Dapivirine (TMC120) is a 2
nd
 generation nonnucleoside reverse transcriptase inhibitor, which 
maintains efficacy against many NNRTI-resistant strains of HIV [29].  While dapivirine’s poor 
bioavailability precludes its utility for oral dosing, its potential to achieve high local concentrations in 
a topical formulation may prove advantageous.  In a cervical explant model, lack of detectable 
proviral DNA with dapivirine exposure  0.001 μM demonstrated its potential efficacy in prevention 
of HIV acquisition [30].  At concentrations of 1-10μM, dapivirine demonstrated a protective effect 
against HIV-1 infection for up to 6 days after drug exposure.  Pharmacokinetic evaluations performed 
after seven days of vaginally-administered [
14
C]dapivirine 0.009% gel (0.5 mL per day in rabbits and 
1 mL per day in macaques)
  
demonstrated low to undetectable plasma concentrations, with cervical 
and vaginal tissue concentrations being greater than the in vitro EC90 (0.9 ng/mL) up to 48 hours after 
dosing  [31, 32].  Histopathologic analysis of tissues from both species demonstrates that most drug 
remains on the mucosal surface, within the keratinized layer of the epithelium, or in compromised 
areas of tissue, and rarely extends into the submucosa.  Since compromised areas (lesions, ulcers, etc) 
are often portals for HIV entry, this phenomenon could be clinically important.   In two clinical 
studies, 2.5 mL dapivirine gel concentrations of 0.001, 0.002, 0.005, and 0.02% were administered 
twice daily for 42 days in healthy, HIV-negative women.[33]  Adherence was >90% based on 
applicator count and, although sample timing in relation to gel application was not reported,  mean 
(SD) blood plasma concentrations on day 42 were 17.9 (15.2), 42.4 (29.0), 76.7 (58.3), and 427 (215) 
pg/mL, respectively.  Dapivirine has also been developed into a vaginal ring delivery system, whose 
controlled drug release system and longer dwell time may have an adherence advantage for HIV 
prophylaxis.  In a Phase 1 study, two different intravaginal ring (IVR) delivery systems (matrix and 
reservoir) containing 25mg of dapivirine were evaluated for safety and pharmacokinetic exposure 
[32]. The release of drug varied greatly between the two rings.  In the reservoir IVR, only about 600 
μg was released over a 28 day period compared to 10.5 mg released from the matrix IVR.  While the 
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matrix IVR produced plasma concentrations 50-fold that of the reservoir IVR (Cmax 1194 vs. 51.87 
pg/mL), both rings produced vaginal fluid concentrations above dapivirine’s EC50 of 0.3 ng/mL for 
the entire 28 days of the study and for at least 5 days following removal (Cmax 7.5-14.37 μg/g for 
reservoir and 850-1900 μg/g for matrix IVR).  As of 2014, two Phase III studies (ASPIRE and The 
Ring Study) are currently underway to evaluate efficacy of a 25 mg DPV ring inserted once monthly 
in African women[34, 35].   
 Although topical formulations of ARVs allow high local exposure while limiting systemic 
exposure, restrictions to their use may include a difficult application technique, adherence, user and 
partner acceptance, local irritation, and multiple applications for one encounter if multiple mucosal 
surfaces require protection.  Systemic dosing of ARVs provides an alternate approach for protection 
and may overcome some of these challenges.  Finding a pill that a woman can take in a coitally-
independent manner can circumvent disclosure to their partners and assist with empowerment.   
Currently, the target drug exposure required to prevent HIV infection at mucosal surfaces is 
unknown.  Therefore, the present assumption is that higher drug exposures are better for conferring 
protection.  However, ARVs differ greatly in their ability to penetrate mucosal tissues or secretions 
[36-39].  Generally, highly protein-bound compounds do not gain access to these secondary 
compartments due to their affinity for plasma proteins such as albumin and a1-acid glycoprotein.  
Drugs such as the protease inhibitors, which are 95-99% bound to plasma proteins, achieve female 
genital tract concentrations < 50% that of blood plasma [38].  In contrast, most N(t)RTIs have a low 
degree of protein-binding (<0.7-49%) and achieve concentrations 2- to 6-fold higher than in blood 
plasma [38].  However, protein binding is not the only predictor of ARV exposure.  For example, 
maraviroc, a cellular entry inhibitor that demonstrates 85% plasma protein binding, has high 
penetration into CVF and vaginal tissue.  After seven days of 300 mg twice daily dosing, the AUCs of 
CVF and vaginal tissue are 2.7 and 1.9 times higher than blood plasma [37].  Raltegravir, an integrase 
inhibitor which is 83% protein bound in plasma, has also been shown to penetrate well in the genital 
tract: CVF concentrations after multiple dosing are approximately equal to blood plasma [39].  
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Currently there are no published data regarding intrasubject pharmacokinetic variability in the female 
genital tract; no one has sampled the same individuals under steady state conditions over multiple 
days.   However, the intersubject variability of drug exposure in the female genital tract is generally 
greater than in blood plasma (the coefficients of variation range from approximately 50-200% in CVF 
and 2-100% in blood plasma). 
An additional consideration of antiretroviral pharmacokinetics and pharmacodynamics at 
mucosal surfaces is their protein binding within the mucosal secretions.  CVF concentrations of 
albumin and a1-acid glycoprotein are both <1% of their concentration in plasma [40].  Although the 
protein binding of drugs in genital secretions has not been extensively evaluated, maraviroc has 
recently shown 10-fold less protein binding in CVF than blood plasma (7.5% vs 75%) [37]. This 
phenomenon must be considered in pharmacokinetic-pharmacodynamic analysis of antiretroviral 
prevention strategies.   
Penetration of drugs into rectal tissues also has implications for HIV transmission.  Exposures 
(AUC12 hour) of maraviroc are ~30 times higher in rectal tissues than blood plasma [41].  Some drugs, 
such as the nucleoside/tide analogues require cellular uptake and phosphorylation in order to be active 
against the RT enzyme.  Intracellular and extracellular concentrations of tenofovir and emtricitabine 
have been recently evaluated in blood plasma as well as cervical, vaginal, and rectal tissues after a 
single dose [42].  Sampling was performed from 24 hours to 14 days post-dose.  TFV exposures (as 
measured by AUCDay 1-14) were 5.8, 0.6, and 34 times higher in cervical, vaginal and rectal tissues, 
respectively.  FTC exposures were 41, 7, and 4.4 times higher in cervical, vaginal and rectal tissues, 
respectively. Intracellular concentrations of TFVdp were detected in all tissues for at least seven days.   
FTCtp (emtricitabine triphosphate) was only detected in tissues for two days post-dosing, despite 
PBMC concentrations persisting for 10 days.  These initial tissue data suggest that these ARVs may 
be promising candidates for HIV prevention.  However, more comprehensive pharmacokinetic data 
such as these are required to guide drug development.  
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 Several systemically-dosed ARVs have been tested for PrEP efficacy in nonhuman primates 
and humanized mice.  Oral dosing of CMPD167, a CCR5 inhibitor, was able to prevent infection 
from vaginal exposures to SHIV162P3 in 50% (10/20) of macaques when drug was continued for 10 
days following exposure and in 25% of macaques (1/4) if drug was given only for four days prior to 
exposure [43].   Subbarao et al demonstrated that, with weekly rectal exposure to low dose SHIV (3.8 
x 10
5
 viral particles per exposure) , oral daily (n=4) or weekly (n=4) doses of 22 mg/kg TDF  can 
delay time to infection by 4.5-5.5 weeks and provide a 60% decrease in the per-exposure probability 
of infection [44].  In this model, viral inoculation was performed two hours after tenofovir 
administration: this was based on PK sampling in a single macaque in which a concentration of 633 
ng/mL was observed at two hours post-dose. Single blood plasma sampling in these macaques at two 
hours post dose revealed lower TFV exposures in 80% (4/5) of the macaques that were infected (10-
137 ng/mL) compared to those that were protected (mean 2000 ng/mL).  In 2008, Garcia-Lerma et al 
evaluated five different routes, combinations, and/or schedules of TFV and FTC in a rectal, low dose 
SHIV (7.5 x 10
5
 viral particles per exposure) repeat-exposure macaque model [45].  Oral doses were 
selected as a result of preliminary PK dose ranging analyses in 11 animals (5 for TDF and 6 for FTC) 
demonstrating similar AUCs to humans at doses of TDF 20-24mg/kg and FTC 20mg/kg (AUC for 
TFV were 3.2-3.4 μg * h/mL and within human range of 1.03-3.56 μg * h/mL; AUC for FTC was 
13.2 μg * h/mL in macaques and ~10 μg * h/mL in humans[38]).  In this investigation, complete 
protection from HIV infection was achieved with daily subcutaneous dosing of TVF 22 mg/kg and 
FTC 20 mg/kg.   Other daily regimens (subcutaneous FTC 20 mg/kg alone or oral TDF 22mg/kg + 
FTC 20 mg/kg) achieved only partial protection (33% and 67% protected, respectively).   
Daily intraperitoneal (IP) doses of TDF+FTC (5.2 + 3.5mg) was also protective in a 
humanized BLT mouse model.  All mice (5/5) given FTC+TDF daily beginning two days before, and 
continuing for seven days after, vaginal inoculation with approximately 9 x 10
4
 tissue culture 
infectious units (TCIU) of HIV-1JRCSF remained infection free, compared to only 1/8 in the control 
group [46].  This regimen was also tested against rectal and intravenous transmission of HIV.  
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Following daily IP injections for three days, animals were exposed to HIV-1 JR-CSF in the rectal 
mucosa or by intravenous injection while continuing to receive daily TDF+FTC for an additional four 
days [47]  Using this regimen, no infections were noted with rectal challenge (n=9) and only one was 
infected with intravenous challenge (n=9).  Similar to macaques, pharmacologic data using these 
doses in mice are lacking.  Using weight-based scaling these mice received IP doses of ~30 mg/kg, 
which is likely to exceed the ~ 4 mg/kg being used in current PrEP clinical trials.   
 
Table 1: Summary of completed clinical trials involving pharmacotherapy for prevention 
Trial Prevention 
Area 
Exposure Intervention Results Sample Size Reference 
Caprisa 
004 
Phase 2; 
PrEP  
vaginal Topical 
tenofovir gel  
Results 
published 
2010 
HIV 
incidence 
reduced 
by 39%  
900 women Abdool Karim 
Q, et al. 
Science. Sep 
3;329(5996):11
68-74. 
CDC 
4323 
Phase 2; 
PrEP  
penile or 
rectal 
Once daily 
oral TDF  
Results 
published  
2011. 
No 
difference 
in risk 
behavior.  
No major 
safety 
concerns. 
400 MSM Liu, A.Y., et al. 
2011. PLoS 
One 6:e23688. 
iPrEx Phase 3;  
PrEP  
penile or 
rectal 
Once daily 
oral 
TDF/FTC  
Results 
published 
2010.  
HIV 
incidence 
reduced 
by 44%. 
2,499 MSM Grant, R.M., et 
al. 2010. N 
Engl J Med 
363:2587-2599. 
 
CDC 
4370 
(Bangko
k Study) 
Phase 
2/3; PrEP  
parenteral Once daily 
oral TDF  
Results 
published 
2013. HIV 
incidence 
reduced 
by 49%. 
2,400 IV 
drug users 
Choopanya, K., 
et al. 2013. 
Lancet 
381:2083-2090. 
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CDC 
4940 
(TDF2) 
Phase 2; 
PrEP  
penile or 
vaginal 
Once daily 
oral 
TDF/FTC  
Results 
published 
2012. HIV 
incidence 
reduced 
by 62%  
1,200 
heterosexual 
men and 
women 
Thigpen, M.C., 
et al. 2012. N 
Engl J Med 
367:423-434. 
Partners 
PrEP 
Phase 3; 
PrEP  
penile or 
vaginal 
Once daily 
oral TDF or 
TDF/FTC  
Results 
published 
2012. HIV 
incidence 
reduced 
by 67% in 
the TDF 
alone arm 
and 75% 
in the 
TDF/FTC 
arm 
4,700 sero-
discordant 
couples 
Baeten, J.M., et 
al. 2012. N 
Engl J Med 
367:399-410. 
FEM-
PrEP 
Phase 3; 
PrEP in 
women 
vaginal Once daily 
oral 
TDF/FTC  
Stopped 
early for 
futility in 
2011.   
3,900 
women 
Van Damme, 
L., et al. 2012. 
N Engl J Med 
367:411-422. 
Voice 
(MTN 
003) 
Phase 
2;PrEP  
vaginal Once daily 
oral TDF 
and 
TDF/FTC 
and topical 
TDF 
Stopped 
early for 
futility 
(oral TDF 
and 
topical 
TFV in 
2011, 
TDF/FTC 
in 2012) 
 
5,000 
women 
http://www.mtn
stopshiv.org/no
de/70 
Marrazo, J., et 
al. 2013. In 
20th 
Conference on 
Retroviruses 
and 
Opportunistic 
Infections. 
Atlanta, GA. 
Paper #26LB. 
IAVI 
E001 
and 
E002 
Phase 
1/2;  
iPrEP in 
sero-
discordan
t couples 
vaginal, 
rectal, or 
penile 
Once daily 
TDF/FTC; 
intermittent 
TDF/FTC  
Published 
in 2013.  
Adherence 
monitored 
through 
MEMs 
was >90% 
for fixed 
oral and 
intermitte
nt but only 
45% for 
post-coital 
dosing.  
72 sero-
discordant 
couples 
Kibengo, 
F.M.,.et al. 
2013. PLoS 
One 8:e74314. 
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HPTN 
052 
Phase 3; 
treatment 
for 
preventio
n 
vaginal or 
rectal 
Delayed or 
immediate 
initiation of 
ARV 
therapy 
Published 
in 2011. 
Immediate 
initiation 
reduced 
transmissi
on by 96% 
1,750 sero-
discordant 
couples 
Cohen, M.S.,et 
al. 2011. N 
Engl J Med 
365:493-505. 
 
Despite the sparse human pharmacokinetic data and the pharmacologic limitations of the 
animal data, a number of clinical studies were initiated in multiple at-risk populations with standard 
dosing of tenofovir with or without emtricitabine.  Table 1 summarizes the results of these PrEP 
investigations.   The promising results from these trials led to the 2012 FDA approval for pre-
exposure prophylaxis as an added indication for Truvada (TDF+FTC) [11]. Although many of these 
studies investigated daily dosing, this regimen may not be practical for all individuals.  Daily dosing 
may result in decreased adherence rates (prophylaxis fatigue) and unnecessary systemic toxicity.  
Adherence appears to be higher when individuals perceive themselves at high risk of HIV acquisition 
[48, 49]. Therefore, intermittent PrEP (iPrEP), using coitally-dependent or independent dosing, is also 
being investigated.   
There are several ARVs with a pharmacokinetic profile that is favorable for iPrEP.  The 
pharmacokinetic profiles of maraviroc, TFV, and FTC have been discussed in detail above.   
Maraviroc has a long residence time in the genital tract, remaining above the protein-free IC50 in 
cervicovaginal fluid for at least 72 hours after a dose [37].  TFV and FTC also have extended 
pharmacokinetic profiles in mucosal surfaces after a single dose [36, 38].  An analysis of blood and 
rectal cells in macaques following oral TDF+FTC (20 + 22 mg/kg) revealed long intracellular half-
lives for TFVdp (78-170 hours) and FTCtp (15-49 hours) [50].   Interestingly, despite the presence of 
TFVdp in rectal mononuclear cells at two hours post-dose, FTCtp was not detected until 24 hours 
post-dose.  The reason for this finding is still under investigation. 
Using these drugs, iPrEP has shown positive results in some animal investigations.  For 
example, all macaques (6/6) treated with subcutaneous TFV+FTC (22/20 mg/kg) two hours before 
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and 24 hours after repeated low dose SHIV rectal exposures were protected from infection over 14 
weeks [45].  A recent investigation has demonstrated maximum  protection from 14 weekly SHIV 
exposures when a 22 hour subcutaneous pre-exposure dose is followed by a two hour post-exposure 
dose (Hazard Ratio (HR) 16.7) [50].  This protection decreases when the pre-exposure dose is 
extended to three and seven days prior to infection (HR 15.4 and 9.3) or if the post-exposure dose is 
delayed by 22 or 26 hours post-infection (HR 4.1 and 4.)   
 Before a clinical trial for iPrEP can be performed, thorough extracellular and intracellular 
pharmacokinetic analysis must be performed with these agents to allow optimal interspecies scaling 
from humanized mice, to macaques to humans.  Although it’s not known if the PK-PD relationship 
with antiretrovirals and HIV prevention is similar between these species, it would be useful to assure 
at least similar ARV exposures.  HPTN 066, a multisite Phase I study evaluated intracellular and 
extracellular pharmacokinetics of four different treatment regimens in HIV-negative men and women 
(Arm 1: 300mg TDF/ 200mg FTC weekly; Arm 2: 300 mg TDF/ 200 mg FTC twice weekly; Arm 3: 
600 mg TDF/400 mg FTC twice weekly; Arm 4 300 mg TDF/ 200 mg FTC daily) [51].  Sampling of 
plasma, rectal, seminal, and vaginal fluid, cells, and tissues suggest that intracellular phosphorylated 
moieties may not be dose proportional across different dosing regimens and inter-donor variability in 
these tissue compartments ranges from 33-63%.   Additional studies with sensitive analytical 
techniques are needed to fill the large gap in the knowledge of intracellular kinetics of these 
medications at multiple mucosal surfaces, and will help identify the time period for which specific 
dosing strategies confer protection.   
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Current Approaches to Post-Exposure Prophylaxis 
 
Post-exposure prophylaxis (PEP) involves prevention of HIV infection after a known or 
suspected exposure in a health care worker (occupational PEP), or a risky behavioral encounter (non-
occupational PEP; nPEP).  Guidelines and recommendations for occupational and non-occupational 
PEP come from small 
studies, case reports, 
and animal data.  
Adequately powered 
interventional clinical 
trials are cost 
prohibitive due to low 
HIV infection rates 
and the need for an 
active control arm.  
Current CDC 
guidelines for 
occupational post exposure prophylaxis use an algorithm based on type of exposure and the infection 
status of the source [52].  Guidelines emphasize that medications should be started as soon as possible 
following exposure and, due largely to data from animals, four weeks of therapy are recommended 
[53].  As of 2013, it is recommended that at least three antiretrovirals be used for PEP.  Due to its 
generally high tolerability, the preferred regimen consists of the integrase inhibitor raltegravir in 
combination with Truvada (TFV/FTC).    
One case-control study investigating seroconversions of healthcare workers following 
needlestick injury demonstrated that, after controlling for other factors (eg. deep injury, visible blood 
on the needle  terminal illness of the source) the use of ZDV reduced the risk of infection by 81% 
Figure 2: Timeline of mucosal infection 
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(adjusted OR: 0.21 p=0.002) [54].  This provides important proof-of-concept for utilizing 
antiretrovirals in a post-exposure prophylaxis setting.   
Nonoccupational exposures include those that involve the male and female genital tracts, the 
rectal mucosa, and exposure from IV-drug use.  Historically, the use of nPEP has been less consistent 
than with occupational PEP, as the benefit of its routine use has been debated.  One major concern is 
behavioral disinhibition.  The potential for increased risky behaviors with increased availability of 
nPEP has been both supported and refuted in observational studies [36].   However, studies and case 
reports have supported the feasibility of nPEP [36], and in 2005, the CDC issued recommendations 
for its use (http://www.cdc.gov/hiv/resources/guidelines/index.htm). For similar reasons as PEP, an 
adequately powered interventional study for nPEP is unlikely to be performed.  Since there is no 
evidence that one particular group of drugs is more effective than others, selection is based on patient 
specific issues and prescriber experience.  Preferred regimens include two nucleoside analogues (3TC 
or FTC with ZDV or TDF) with  
lopinavir/ritonavir or efavirenz. 
Critical to nPEP is the timing with which prophylaxis is initiated.  Based on the timeline of 
mucosal infection developed from animal and in-vitro models (Figure 2) a 24 hour window of 
protection may be optimal for intervention.  The CDC recommendation of 28 days of treatment 
initiated within 72 hours of exposure is supported by animal studies.  Maximum protection from 
infection in macaques given high-dose subcutaneous TFV (30 mg/kg/day) is obtained when treatment 
is initiated within 24 hours of exposure and continued for 28 days [53].  Delaying treatment by 48 or 
72 hours after exposure and continuing treatment for 28 days was < 20% effective at protection.   If 
treatment was started within 24 hours but stopped after 10 days, treatment was only 50% effective.  If 
treatment was started within 24 hours and stopped after three days, treatment was completely 
ineffective.  
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Current Approaches to Treatment of the Index Case 
 
The model for sustaining an epidemic has been applied to HIV infection [55].  The 
requirements to sustain an epidemic are summarized in the mathematical equation R₀=β*Δ*C.   R₀ is 
defined as the number of secondary individuals infected by a single infected person.   β is the 
transmission probability per exposure (including the size/concentration of the inoculum), Δ is the 
length of time an individual remains infected, and C is the rate at which the infected individual 
acquires new partners.  According to this model, R₀ must be >1 for the HIV epidemic to be 
maintained.  In the absence of a cure for HIV, there is little that can affect Δ. While behavioral 
interventions and education have impacted C to a degree, β remains the main target that can be 
manipulated to control the HIV epidemic.   Chakraborty et al developed a model of sexual 
transmission in which a logarithmic increase in the probability of male-to-female HIV transmission 
occurs with increasing seminal HIV RNA concentrations and numbers of receptors in cervical tissue 
[56].  These mathematical formulas illustrate the potential public health benefit in suppressing HIV 
transmission through treatment of HIV infection.   Although local suppression of viral replication is 
paramount to reducing infectivity [7], there is no known HIV RNA threshold below which a person 
can be rendered noninfectious.  Observational and prospective studies have suggested this is a blood 
HIV-RNA concentration below 3500 copies/mL [7].  However, similar data for the genital tract are 
lacking, largely due to limitations in sample collection and insufficiently sensitive HIV RNA 
detection methods.  Assays able to detect low viral copy numbers require large sample volumes 
beyond what is often feasible to collect for genital secretions.   
Observational studies have demonstrated the ability of ART to reduce HIV transmission.   An 
Ugandan study demonstrated that initiation of antiretroviral therapy (drugs not specified) with 
counseling could reduce risk of transmission by as much as 98% over two years [57].  A six year 
study in Rwanda and Zambia following 2993 serodiscordant couples observed only four new 
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infections in the partners of those receiving ART, and 171 infections in couples that were not treated 
(OR: 0.87, 95% CI: 0.79 - 0.96) [58]. 
Mathematical models have also been developed to predict the benefit of ARV therapy on 
reducing transmission [7].  These models vary in their predictions based on assumptions regarding the 
number needed to be treated, the infectivity of the HIV positive individuals, and the ability of ARVs 
to suppress HIV RNA.  While some of these models suggest that widespread use of preventative ART 
would curb the epidemic, others indicate that due to sexual disinhibition and increase in HIV 
resistance, any benefit would be negated [7].  Acutely infected individuals have high viral shedding 
from the genital tract often before HIV RNA is detected in blood.  Since these individuals may be 
responsible for a significant proportion of new HIV infections, targeting this cohort for early testing 
and treatment may make an important contribution to public health.   
The choice of ARVs for “sterilization” of the genital tract is currently unknown.  Drug 
exposure in the female genital tract has been reviewed above (see section “Current Approaches to 
Pre-Exposure Prophylaxis of HIV Infection“).  Similar to the female genital tract, antiretrovirals 
display differential penetration into the male genital tract [36, 41, 59-62]. Nucleoside analogues 
(abacavir: ABC, ZDV, TDF, and 3TC) achieve seminal exposures ranging from 150-600% that of 
blood plasma [36]. Following oral administration of TDF, intracellular seminal mononuclear TVF-DP 
concentrations are at least 8 times higher than in PBMCs [59].  However, this increased extracellular-
intracellular concentration relationship in semen does not hold for ZDV or 3TC.  Despite 4-6 fold 
higher seminal plasma concentrations, intracellular seminal mononuclear cell concentrations of ZDV-
TP are 40% of PBMCs, and seminal mononuclear cell concentrations of 3TC-TP are approximately 
equal to PBMCs [62].  As in the female genital tract, there are no data regarding intrasubject 
pharmacokinetic variability in the male genital tract.  However, intersubject variability in drug 
exposure is generally greater in the male genital tract (the coefficients of variation range from 
approximately 100-300%) than in blood plasma.  These data illustrate the importance of quantifying 
intracellular drug exposure to develop accurate PK-PD models of HIV prevention.   
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The pharmacokinetics of newer classes of antiretrovirals in semen has recently been 
evaluated.  Maraviroc AUC in semen is 40% lower than blood plasma.  However, similar to findings 
in the female genital tract, low protein binding in semen results in free drug concentrations 28-fold 
higher than the protein-free IC90 [41].  Raltegravir concentrates 3-6 times higher in semen than blood 
plasma [60], although the protein binding in seminal plasma has not been determined.   A summary of 
antiretroviral exposure in relevant mucosal fluids and tissues is presented in Table 2.  
An important consideration in antiretroviral choices for HIV prevention is genital tract 
compartmentalization.  Genotypic differences in HIV isolated from blood plasma and the male and 
female genital tract have been found, and is evidence for viral compartmentalization [63, 64].  These 
resistance patterns coincide with observed antiretroviral drug exposure in genital secretions.  For 
example, protease inhibitors have the poorest penetration into the genital tract.  This may explain the 
presence of protease-resistant viral isolates found in seminal plasma and vaginal fluid [36].  Likewise, 
an increased number of mutations conferring NNRTI resistance have been detected in the genital tract 
of treatment experienced women:  <1% of efavirenz (an NNRTI) blood plasma exposure is achieved 
in cervicovaginal fluid [38].   Although it has not been adequately tested, it is assumed that 
antiretrovirals with a higher exposure to the genital tract will be more effective at reducing viral loads 
in the genital compartments.  Understanding drug penetration into the genital tract will allow for 
educated choices for therapy to “sterilize” this compartment [8].   
In January of 2008, an international debate followed the release of a consensus statement by 
Swiss HIV experts declaring that an HIV-infected person on effective antiretroviral therapy (defined 
as suppressed viremia for  6 months) with no other sexually transmitted infections, may be 
considered noninfectious.  The statement sparked much concern over the implications on behavioral 
practices of HIV-infected individuals.  A model-based analysis of transmission risk per exposure type 
demonstrated that while the risk of transmission in the setting of effective treatment was decreased, it 
was not nonexistent and risky behaviors should be discouraged [65].   HPTN 052 was the first 
prospective trial evaluating the use of ARVs in reducing HIV transmission [66].  This Phase III, two–
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arm, international study will compare infection rates between two different treatment strategies in 
serodiscordant couples in which the infected partner began ART (with a recommended regimen of 
3TC+ZDV + efavirenz or atazanavir) either immediately, or when he/she had two consecutive CD4+ 
cell counts below 250 mm
3
 or develops an AIDS defining illness. The findings of this study found an 
astounding 96% reduction in HIV transmission, as well as fewer clinical events (HR 0.59) in the 
immediate treatment arm.  Due to the large implications these findings have on HIV treatment and 
prevention, Science magazine named this finding the “2011 breakthrough of the year” [67]. 
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Table 2 Exposures of Antiretrovirals in Relevant Tissues Compared to Blood Plasma. 
Comparisons are tissue/BP paired samples unless otherwise noted. NRTI=Nucleotide reverse 
transcriptase inhibitor, PI= Protease inhibitor, NNRTI=Non-nucleotide reverse transcriptase inhibitor, 
EI=Entry inhibitor, II=Integrase inhibitor 
                                                             
2 Seminal mononuclear cells compared to PBMCs 
3 AUC CVF, SP, or tissue: AUC BP ratio 
4
 cervical 
5AUC tissue1-14 days: AUC BP1-14 day 
6 vaginal 
 Drug Female Genital Tract 
Single Dose (steady-state) 
Male Genital Tract 
Single Dose (steady-state) 
Rectal Tissue 
Single Dose (steady-state) 
  CVF Tissue Seminal Plasma Intracellular
2 
Tissue 
N
R
T
IS
 
Tenofovir 1.35(0.75)
3 5.84,5/ 0.66,5 4.4(5.1) 9.4(17.5) 335 
Abacavir 0.21(0.08)
3   (1.5)3   
Lamivudine        2.41(4.11)
3        (6.7)       1.0  
Zidovudine 3.71(2.35)
3  (2.3) 0.36  
Didanosine 0.06(0.21)
3 
    
Emtricitabine 1.11(3.95)
3 424,5/ 76,6   4.35 
Stavudine 0.04(0.05)
3  (3.5)    
P
Is
 
Lopinavir 
with RTV 
0.17(0.08)3  (0.05) 
 
  
Atazanavir 
with RTV 
0.16(0.18)3  (0.1)   
Ritonavir 0.18(0.26)
3  (0.03)3    
Indinavir 
with RTV 
(4.6)  (1.9)3   
Darunavir 
with RTV 
(1.5)3  (0.12)    
Amprenavir 
 
(0.5) 
 with RTV
 
 (0.2) 
without RTV 
  
Nelfinavir   (0.08)
3   
Saquinavir 
with RTV 
  (0.03)3   
N
N
R
T
IS
 Efavirenz 
0.005(0.004)3  (0.03)   
Nevirapine (0.8)
  (0.6)   
Delavirdine (0.4)
     
Etravirine (1.3)
3     
E
Is
 Maraviroc 1.9(2.7)
3 1.93 0.6(0.6)3  9(28)3 
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Developmental Obstacles in HIV Prevention Studies 
 
 All current completed clinical trials for HIV prevention have evaluated TDF alone or in 
combination with FTC.  These were chosen based on safety, availability, and preliminary nonhuman 
primate data.   Since preclinical pharmacology was not prospectively or concomitantly performed for 
the effective macaque subcutaneous doses ranging from 22-30 mg/kg, standard labeled treatment 
dosing strategies were pursued for the clinical studies.  This approach has a number of limitations in 
HIV prevention research, and more data are required to make rational choices for drugs, doses, and 
dosing strategies. 
Quantifying the pharmacokinetics of antiretrovirals in mucosal tissues is complex.  Blood 
plasma concentrations do not always correlate with genital or rectal concentrations, and accumulation 
ratios vary between and within therapeutic classes [36, 38, 41].  The mechanisms behind these 
differences have yet to be fully elucidated.  In the male genital tract, the primary influence appears to 
be protein binding.  However, as illustrated in Figure 3 this is not the case for the female genital tract.  
Figure 3 Relationship of total genital tract exposure to blood plasma protein binding 3TC: 
lamivudine; ABC: abacavir; APV: amprenavir; ATV: atazanavir; AZT: zidovudine; D4T: stavudine; 
DDI:didanosine; DLV: delavirdine; EFV: efavirenz; FTC: emtricitabine; TNF: tenofovir; IDV: 
indinavir; LPV: lopinavir; MVC: maraviroc; NVP: nevirapine; RTV: ritonavir; SQV: saquinavir 
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Further investigations on the physicochemical properties of antiretrovirals that confer increased 
mucosal penetration are required.  
 Although the majority of antiretrovirals act intracellularly, only the nucleoside/tide analogue 
reverse transcriptase inhibitors require further phosphorylation in order to exert antiviral activity.   
Since an extracellular-intracellular disconnect between ZDV, 3TC, and TFV has been found between 
semen and blood [59, 62], additional studies quantifying intracellular moieties in the female genital 
tract will be important for identifying appropriate concentration targets for HIV prevention.  
Quantification of the intersubject variability in subpopulations of mononuclear cells susceptible to 
HIV infection may also provide insight into the probability of protection in a targeted population.  
Finally, additional insight into what portions of the female genital tract are most susceptible to HIV 
infection (vagina vs cervix vs uterus), or which portion can be a pharmacologic and virologic 
surrogate for the others, is required.    Advanced physiologic-based modeling may be able to assist in 
this effort.   
Developing a reliable animal model for prevention studies has been challenging.  Human 
immunodeficiency virus infection is a species-specific disease which limits animal model flexibility.  
For decades, research has been limited to macaque models, due to the permissibility of SIV: a virus 
similar, but not identical, to HIV.  SIV’s distinct co-receptor usage can confound results of prevention 
studies [68].  SIVmac and SIVmc most closely resemble HIV-1 in progression of plasma RNA and CD4 
T cell response [8].  The chimeric SHIV, while containing a portion of the HIV-1 genome, does not 
mimic the progression of infection as closely as SIV.  Some models utilize progesterone therapy to 
thin the epithelial layer of the vaginal tract, increase the probability of infection, and increase the 
likelihood of documenting an antiretroviral effect.  However, the impact this intervention has on 
antiretroviral concentrations or efficacy in these tissues is unknown. Finally, exposure models also 
differ.  The low-dose repeat exposure model was developed to mimic the human condition. The single 
high-dose exposure model represents the “worst case scenario.”   However, one investigation using 
oral TDF (22 mg/kg) for PrEP found less protection with the low-dose exposure model (40%) than 
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with the high dose model (75%) [69].  The variability between these models is a strong consideration 
when assessing outcomes.   
Interspecies scaling of antiretroviral exposures between macaques and humans has been 
difficult due to the limited amount of pharmacokinetic information generated in these studies.  The 
only systemic antiretroviral regimens that have demonstrated  full protection against rectal, vaginal, 
and oral exposure to SHIV in macaques is daily or intermittent subcutaneous administration of 22 
mg/kg TFV or 22 mg/kg TFV+ 20 mg/kg FTC [15, 45].  Although no Cmax or AUC value was 
reported for subcutaneous TFV, the Cmax of the selected human-equivalent oral dose (633 ng/mL) [44] 
was approximately twice as high as the observed Cmax in humans [38].  Local exposure of 
antiretrovirals in mucosal tissues following topical administration remains to be measured 
comprehensively in animal models.  Given the smaller genital and rectal cavities of macaques, it is 
possible that animals in the preclinical trials discussed above received supratherapeutic dosing.   
The humanized mouse model has recently been developed to overcome some of the logistical 
challenges with macaques.  The first humanized mouse was from a SCID (severe combined 
immunodeficiency) variant.  The mutation in the prkdc gene leading to loss of function in mature T 
and B lymphocytes allows these mice to be infected with foreign tissue without rejection [16].  Since 
only the implanted tissues can be infected with HIV, this has limited applications for HIV prevention 
research.  The SCID-hu PBL model was developed by IP injection of human peripheral blood 
lymphocytes.  Although populations of human B and T cells can be recovered, the repertoire is 
limited and transient, with no renewal capacity.  These mice have been used to study viral 
pathogenesis and screen vaccine candidates.  However, the limited numbers of human cells in 
mucosal tissues make them poor candidates for prevention research.  In the SCID-hu Thy/Liv model, 
human thymus and liver are grafted into the SCID mouse, with subsequent production of human 
mononuclear cells (including CD4+ cells).  However, this model is not susceptible to mucosal 
transmission of HIV, as the T cells appear to be mostly confined to the thymic area.  More recent 
models such as the Rag2
-/-
 IL2Rγc-/- mouse, the NOD/SCID- IL2Rγc-/- , and the NOD/SCID BLT 
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mouse generally have more extensive humanization of mucosal tissues.  Rag2
-/-
 IL2Rγc-/- mice are 
developed by intrahepatic placement of human CD34+ hematopoetic stem cells which then 
differentiate into human B, T, and dendritic cells. These mice are susceptible to HIV following 
systemic, vaginal, and rectal exposure.  Additionally, appropriate viral suppression and CD4+ T cell 
recovery can be achieved upon administration of antiretroviral therapy [70].  The NOD/SCID- 
IL2Rγc-/- mice are formed upon introduction of CD34+ hematopoetic stem cells, either 
intrahepatically or intravenously.  This model is currently undergoing investigations as to their 
susceptibility to mucosal transmission of HIV.  In the NOD/SCID BLT mouse, human fetal liver and 
human fetal thymus are implanted under the kidney capsule of the NOD/SCID mouse with 
subsequent transplantation of human fetal liver CD34+ hematopoetic stem cells.  This model has 
shown a robust humanization of the rectal and female genital tracts and susceptibility to both vaginal 
and rectal HIV transmission [16].  However, no pharmacokinetic investigations in this model have 
been performed. 
An alternative, or complementary, approach to a preclinical animal model for HIV prevention 
strategies is the tissue explant culture model.  This technique has been previously used with human 
thymus tissue and more recently applied to rectal, vaginal, and cervical tissues: common sites of 
exposure in HIV transmission [71].  This promising ex vivo approach allows human tissue from 
healthy volunteers to be used in the study of HIV transmission, in addition to antiretroviral safety, 
efficacy, and pharmacology.  Insights into successful prevention strategies may be obtained by 
varying drug doses, viral isolates and titers in this model.  This technique has been utilized to evaluate 
several candidate microbicides [23, 26, 30], as well as tenofovir [22, 24].    
  
Future Role of Clinical Pharmacology to Bridge the Gaps 
 
 As more predictive preclinical models are developed for prevention, the tools of 
pharmacology will become a valuable resource for determining PD targets, providing interspecies 
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scaling of exposures, identifying the optimal drugs/drug combinations, doses, and dosing regimens, 
and designing efficient clinical trials.   
Characterization of the pharmacokinetics occurring at mucosal surfaces prone to infection 
(rectal, vaginal, cervical) has provided valuable information on which antiretrovirals should be 
pursued in prevention trials.  Those drugs that accumulate in  tissues (eg TFV, FTC, 3TC, maraviroc) 
as well as those that achieve concentrations above their respective IC90 (eg raltegravir, atazanavir, 
darunavir) are candidates for further investigation. However, the specific pharmacokinetic behavior of 
these drugs in tissues remains unknown, including residence times, cellular uptake, and intracellular 
phosphorylation.  While it is known that certain physiochemical properties such as protein binding, 
lipophilicity, and molecule size have an impact on penetration into genital tract secretions, there 
remain undefined mechanisms of uptake, particularly for the female genital tract.  Even without a 
complete mechanistic understanding of drug movement between these compartments, 
pharmacokinetic modeling may still allow for accurate estimation of concentrations in the genital 
tract.    
 Identifying the 
concentration of 
antiretroviral(s) needed at the 
site of exposure to prevent HIV 
infection is critical to this field.  
Preclinical models have shown 
that antiretrovirals can protect 
against HIV infection.  
However, in the absence of 
rigorous pharmacokinetic data, 
it is difficult to determine how these results can be extrapolated to humans.  More deliberate, well 
designed sampling strategies in preclinical models can provide a great deal of information with only 
Figure 4: What should be measured for accurate PK-PD 
evaluations? *Only N(t)RTIs require phosphorylation for 
activation ART-P-P-P =tri-phosphorylated metabolite; fub= 
fraction of drug that is unbound from protein 
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minimal increase in cost and effort.   The tissue explant culture model may also assist in defining PK-
PD relationships in cervical, vaginal, and rectal mucosal tissues.  Physiological based modeling may 
then assist in selecting the most appropriate drugs or combinations, doses, and dose strategies to move 
forward in clinical investigations.   
Once drug targets for prevention are identified, determining the appropriate surrogate 
sampling schemes to generate data in large groups of individuals will be required.  Figure 4 represents 
the compartments from which pharmacokinetic data can be obtained.  It is possible that only 
intracellular ARV concentrations from a specific cellular subset in tissues predict efficacy.  However, 
to expediently perform larger population PK-PD modeling analysis from registration clinical trials, 
surrogates of this exposure will need to be developed.  However, optimal use of these surrogates 
requires accurate information on when the interventions are used.  Without proper dose-timing 
information, any drug exposure measure will have little value as a tool for adherence.     
Likewise, when comparing local exposures in the mucosal tissues to blood plasma 
concentrations, single paired concentrations will not yield as comprehensive an understanding of drug 
exposure as AUC measures.  In order to calculate an AUC however, either extensive intra-individual 
sampling is needed, or pharmacokinetic models with population pharmacokinetic approaches are 
required.  Therefore, many of the clinical trials conducted thus far have not prospectively 
incorporated this degree of pharmacokinetic sampling.  Future studies which include a thoughtful 
approach to obtaining pharmacokinetic data will provide additional insight into the pharmacologic 
relationships between dose, plasma concentrations, mucosal concentrations, and efficacy.   
Finally, an important consideration in analyzing clinical trial data is the confounder of 
adherence to therapy.  In the case of prevention research, reliance is placed on the individual subjects 
to ensure adherence.  To adequately interpret clinical trial outcomes, investigators require a thorough 
understanding of the number of subjects in the active treatment arm not taking their medications, and 
the number of subjects in the placebo arm being exposed to drug (eg due to drug pooling/sharing).    
Having too many of these subjects in each group has the potential to confound the results and negate 
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the time and resources invested in the clinical trial.  Real-time pharmacokinetic sampling with 
subsequent adherence interventions could be built into these investigations for pharmacologic quality 
assurance.   
Conclusion 
 
The recent failures with microbicide and vaccine candidates for HIV prevention necessitate a 
focus on topical and systemic antiretroviral therapy.  Implementation of an acceptable and efficacious 
antiretroviral prevention strategy will dramatically impact the global HIV epidemic and significantly 
reduce the burden of disease.  Both topical and systemic animal model data are promising.  From 
these data, a number of prevention studies were created to investigate a limited range of 
antiretrovirals in a variety of populations and geographic settings (as of 2010, nearly 20,000 
individuals were enrolled in PrEP trials).  As these clinical trials were not designed to provide 
definitive information to correlate drug exposure with HIV protection, many pharmacologic 
opportunities still exist.  The target antiretroviral exposure for prevention of infection in animals or 
tissues is unknown, as is the effect of combining antiretrovirals from different drug classes.  New 
analytical capabilities and novel sampling strategies allow cellular pharmacokinetics and dynamics to 
be more diligently investigated and to identify surrogate markers for protection.  Assessing 
intracellular and mucosal tissue dose proportionality will allow the development of predictive PK-PD 
models to investigate strategies for intermittent PrEP that are most likely to succeed.   Standardization 
of real-time drug adherence/exposure measures in clinical studies will ensure interpretable results 
once studies are complete.   Clinical pharmacology tools, techniques, and expertise are essential to 
advancing the field of HIV prevention, and will continue to play a significant role until the HIV 
epidemic can be contained. 
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Specific Aims 
 
AIM 1: Quantify gene and protein expression, variability, and localization of drug transporters 
ABCB1 (MDR1), ABCC2 (MRP2), ABCC4 (MRP4), SLC22A6 (OAT1), SLC22A8 (OAT3), and 
SLC01B1 (OATP1B1) in vaginal, cervical, and colorectal tissues.  Drug transporters expressed on 
relevant cells in mucosal tissues have the potential to impact the efficacy of antiretrovirals.  To date, 
there has been little exploration of transporter distribution in these tissues.  If identified as a 
significant predictor of tissue drug exposure, screening for transporter affinity could increase the 
efficiency in identifying next generation compounds for HIV prevention. Discussed in Chapter II  
AIM 2: Develop an ex vivo tissue model that can be used to identify the concentration of TFV 
and MVC in vulnerable mucosal tissue that will provide complete protection against HIV.  
2a: Measure variability of immune cell populations, localization and viability of vaginal, cervical, 
and rectal tissue.  Unlike cell-based assays, the explant model is not able to control for the number of 
target cells present in each culture, leading to high variability in infection response.  Quantification of 
specific immune cells in each explant prior to infection, can define a baseline to which infection 
response can be normalized.  Discussed in Chapter III  
2b: Determine sensitivity of alternative methods to detect early HIV tissue infection.  The widely 
used measurement of p24 in the culture supernatant in tissue explant experiments is not able to 
distinguish between inoculum virus and newly infected cells, and the resultant data are highly 
variable. More sensitive methods are needed to accurately identify and measure the low frequency of 
infected cells early in one infection. Discussed in Chapter III  
2c: Utilize the tissue explant model to determine efficacy of MVC and TFV in cervical, vaginal, and 
rectal tissues. To understand optimal dosing of these drugs for HIV prevention, the protective efficacy 
of TFV and MVC both independently and in combination must be determined.  Cervical, vaginal, and 
rectal tissues will be used to develop Emax (maximum efficacy) models of HIV protection, and 
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determine whether the combination of TFV and MVC has additive or synergistic protection against 
HIV.  Discussed in Chapter IV   
AIM 3: Validate the findings from the tissue explant model in AIM 2 in a healthy volunteer 
study with ex-vivo HIV challenges.  Coupled with mucosal exposure data generated in our lab, the 
dose response model generated in Aim 2a will be used to perform PK/PD modeling that will identify 
the most promising intermittent oral dosing regimen to protect tissues from HIV infection.  This 
regimen will be administered to healthy female volunteers, with subsequent tissue biopsy harvest for 
drug concentration analysis and ex-vivo HIV challenge to verify protection.  If successful, this will 
provide a new Proof of Concept model for drug development. Discussed in Chapter V  
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Chapter II:  Expression of Six Drug Transporters in Vaginal, Cervical, and 
Colorectal Tissues: Implications for Drug Disposition in HIV Prevention
7
 
 
Summary 
 
Effective antiretroviral (ARV)-based HIV prevention strategies require optimizing drug 
exposure in mucosal tissues; yet factors influencing mucosal tissue disposition remain unknown. We 
hypothesized that drug transporter expression in vaginal, cervical, and colorectal tissues is a 
contributing factor and selected three efflux (ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and 
three uptake (SLC22A6/OAT1, SLC22A8/OAT3, SLCO1B1/OATP1B1) transporters to further 
investigate based on their affinity for two ARVs central to prevention (tenofovir, maraviroc).  Tissue 
was collected from 99 donors.  mRNA and protein expression were quantified using qPCR and 
immunohistochemistry (IHC).  All of the tissues expressed efflux transporters at the mRNA level. 
IHC localized them to the epithelium and/or submucosa.  Multivariable analysis adjusted for age, 
smoking, and co-medications revealed significant (p<0.05) differences in efflux transporter mRNA 
between tissue types (vaginal ABCB1 3.9 fold > colorectal; vaginal ABCC2 2.9 fold>colorectal; 
colorectal ABCC4 2.0 fold>cervical).  In contrast, uptake transporter mRNA was expressed in <25% 
of tissues. OAT1 protein was detected in no female genital tissue samples and in 100% of colorectal 
tissues, but only in rare epithelial cells.  These data support clinical findings of higher maraviroc and 
tenofovir concentrations in rectal tissue compared to vaginal or cervical tissue after oral dosing.  
                                                             
7 This chapter was taken from an article previously published.  The original citation is as follows: 
Nicol MR, Fedoriw Y, Mathews M, Prince HMA, Patterson KB, Geller E, Mollan K, Mathews S, 
Kroetz DL, Kashuba ADM. Expression of Six Drug Transporters in Vaginal, Cervical, and Colorectal 
Tissues: Implications for Drug Disposition in HIV Prevention. J Clin Pharmacol 2014 May; 
54(5):574-583. 
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Quantifying mucosal transporter expression and localization can facilitate antiretroviral selection to 
target these tissues.     
 
Introduction 
 
Even in the era of highly active antiretroviral therapy, the HIV epidemic remains a significant 
global burden [72].  Current treatment strategies alone will not curb the epidemic and additional 
options are needed to supplement the current prevention strategies of condoms, circumcision, and safe 
sex counseling.  Antiretrovirals administered topically or orally as pre-exposure prophylaxis (PrEP) 
are being investigated for their ability to protect individuals at high risk of acquiring HIV [73].  To 
date, the results of these trials have been mixed and demonstrate that mucosal antiretroviral 
pharmacology, in addition to medication adherence, are important predictors of PrEP success[74].   
The sites of sexual transmission of HIV are the mucosal surfaces of the female genital tract 
and the colorectum.  Yet penetration of antiretrovirals (ARVs) into female genital and colorectal 
tissue has been demonstrated to be variable and difficult to predict [37, 38, 42, 75, 76]  For example, 
following a single dose, maraviroc concentrates two-fold in female genital tract tissue compared to 
blood plasma [37] but nine-fold in colorectal tissue [41]. Tenofovir achieves equivalent 
concentrations in female genital tract tissue compared to blood plasma, but accumulates 100-fold 
higher in colorectal tissue [38, 42]. Physiochemical properties such as protein binding, molecular 
weight, and lipophilicity alone do not account for this variability [75].  Understanding and predicting 
which ARVs have favorable characteristics for high mucosal tissue penetration is necessary for 
streamlined development of the next generation of prevention compounds.   
Membrane drug transporters significantly impact intestinal absorption, uptake into 
hepatocytes, efflux into biliary canaliculi, penetration through the blood-brain barrier, and 
intracellular drug accumulation [77, 78].  Nearly all antiretrovirals have been documented to be 
substrates for, or affect the activity of, efflux and/or uptake transporters [79]. Drug transporters are 
expressed on other epithelial tissues in the body such as the upper gastrointestinal tract, hepatocytes, 
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the blood-brain barrier, endothelial cells, lung, and blood-testes barrier [78-80].  In many of these 
tissues, interindividual variability in drug transporter protein expression is high.  For example, 
expression of the uptake transporter MDR1 varies 3-6 fold in the intestine and up to 55-fold in the 
liver [81]. Likewise, expression of uptake carriers such as OATP1B1 and OCT1 can vary in hepatic 
tissues 20-80 fold [81].  For many drug transporters in human liver tissues, the correlation between 
message and protein expression is weak [82].  In lymphocytes, protein expression of MDR1 was 
inversely correlated with intracellular accumulation of MDR1 substrates including HIV protease 
inhibitors [83], indicating protein expression may serve as a surrogate for drug transporter activity. 
Therefore, differences in mucosal exposure to antiretrovirals may be explained, at least in part, by 
variable drug transporter activity.  To date, the knowledge of transporter expression in lower female 
genital and colorectal tissues is limited to evaluations in small sample sizes with techniques that are 
minimally quantitative [80, 84-86]. 
Maraviroc and tenofovir are two lead candidates for pre-exposure prophylaxis [73].  For this 
focused investigation, we explored the expression of transporters known to affect the disposition of 
these two compounds, including three transporters from the ATP-binding cassette (ABC) family 
responsible for drug efflux from cells, and three transporters from the solute carrier (SLC) family that 
facilitate drug uptake into cells. MPR2, MRP4, OAT1, and OAT3 have been implicated in tenofovir 
disposition [87-90] while MDR1 and OATP1B1 affect maraviroc [91-93].   We determined gene 
expression, protein localization, and estimated intersubject variability in ninety-eight mucosal tissues.  
Materials and Methods 
Tissue Procurement 
 
Vaginal, cervical, and colorectal tissue samples, each from a unique donor, were procured 
from surgical waste specimens and from cadaver tissues from July 2009-January 2013.  Surgical 
waste tissues were obtained through the UNC Tissue Procurement Facility (TPF) under two UNC 
IRB approved studies (#09-0921 and #12-0368).  Written informed consent was obtained from all 
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participants. Demographic information including age, sex, race, surgical indication, smoking status, 
co-medications, and menopause status was collected via retrospective chart review. Prior to release 
from tissue procurement facility, all specimens were examined by a pathologist to ensure there were 
no abnormal pathologies.  When tissue was collected from rectal carcinoma cases, all tissue used was 
>3 cm from tumor.  Cadaver tissues were obtained from the National Disease Research Interchange 
(NDRI).  Per NDRI protocol (http://ndriresource.org), all cadaveric donors signed a witnessed 
consent form prior to death.  Tissues were procured within 3-10 hours post-mortem and shipped on 
ice overnight to our laboratory for processing.   All tissue was collected under applicable regulations 
and guidelines regarding informed consent, protection of human subjects and donor confidentiality.   
After harvest, all tissue was immediately placed on ice in Iscove’s Modified Dulbecco’s 
Medium until received into the laboratory.  Ninety percent of samples were received within six hours 
of harvest and no difference in mRNA expression was observed for those samples that were received 
after six hours (data not shown).  For mRNA expression analysis, tissues were snap frozen in liquid 
nitrogen and stored at -80°C or preserved in RNALater ® (Qiagen, Hilden, Germany).  When 
possible, a portion of the specimen was also fixed in formalin to be used for immunohistochemical 
protein expression analysis.     
mRNA Expression  
 
Total RNA was extracted from 30 mg snap frozen or RNALater preserved tissues using the 
RNeasy Fibrous Tissue Kit (Qiagen).  Tissues were homogenized in lysis buffer using Precellys 
Mixed Beads Homogenization Kit (Bectin Technologies, Villeurbanne, France) and underwent a 10 
minute digestion in Proteinase K prior to RNA isolation and purification.  RNA was quantified and 
tested for purity using a NanoDrop® UV Spectrometer (Thermo-Fisher Waltham, MA).  RNA 
integrity was tested on a subset of samples using the Agilent Bioanalzyer 2100 (Agilent 
Technologies, Santa Clara,CA).  First strand cDNA synthesis was performed from total RNA using 
Superscript® Vilo™ cDNA Synthesis kit (Life Technologies,Grand Island, NY)  mRNA expression 
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was quantified using quantitative PCR (qPCR) with TaqMan® Gene Expression Assays  (ABCB1; 
Hs00184500_m1, ABCC2; Hs00166123_m1, ABCC4; Hs00988717_m1, SLC22A6; 
Hs00537914_m1, SLC22A8; Hs00188599, SLCO1B1; Hs00272374) on an ABI 7300 Real-Time 
PCR System (Life Technologies). Liver and kidney from healthy donors (First Choice®, Life 
Technologies, Grand Island, NY) were used as comparator organs. Expression was normalized to the 
expression of the endogenous control gene beta-actin (ACTB) (Hs99999903_m1) using the 2
-ΔCt
 
method [94].  Earlier investigations demonstrated that among five candidate endogenous control 
genes selected, the ACTB gene, while still being expressed consistently >Ct 35, had the least 
variability in expression between female genital and colorectal tissues (see Table 3).    
To further investigate the role of physiologic factors in transporter expression, the gene 
expression of the efflux transporters in vaginal and cervical tissue was compared between 
premenopausal and postmenopausal women.    
 
Table 3: Expression and variability in mRNA expression of five endogenous control genes. 
Candidates were chosen based on literature search on endogenous control genes commonly used in 
female genital and colorectal tissues.  In a preliminary analysis, mRNA was compared between three 
vaginal, one cervical, and one colorectal tissue.  ACTB was chosen to be used in the study for gene 
normalization because it had the lowest standard deviation among the genes studied and was 
consistently expressed at a Ct >30.   
Gene name Life Technologies Assay ID Average Ct  Standard 
Deviation 
Beta-actin (ACTB) Hs99999903_m1 26.75 2.159 
TATA box binding protein (TBP) Hs99999910_m1 33.14 2.297 
Peptidylprolyl isomerase (PPIA) Hs99999904_m1 24.19 2.432 
18s Ribosomal RNA (18s) Hs99999901_s1 11.24 2.382 
Glyceraldeyhyde-3-phosphate 
dehydrogenase (GAPDH) 
Hs99999905_m1 26.89 2.245 
 
Protein Expression 
 
            Tissues no greater than 5 mm thickness were formalin-fixed, embedded in paraffin molds, cut 
into 5 µm sections, and mounted on glass slides.  The slides were deparaffinized in xylene and 
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hydrated in a graded ethanol series. Slides were then stained using standard immunohistochemical 
techniques with primary antibodies for MDR1, clone JSB-1 (catalogue # MAB4120, Millipore, 
Billerica, MA; 1:400 dilution), MRP2 clone M2III-5 (catalogue #MC267, Kamiya, Seattle, WA; 1:50 
dilution), MRP4 clone 1B2 (catalogue #H00010257-M03 Novus Biologicals, Littleton, CO; 1:1500 
dilution), and OAT1 (catalogue #AB118346, Abcam, Cambridge, MA; 1:600 dilution) followed by 
staining with the secondary antibody (Leica Biosystems, ready-to-use Bond secondary antibody kit, 
approximately 10 minutes).  For detection, DAB (3,3’-diaminobenzidine) was used as a substrate-
chromogen (approximately 8 minutes).  As reliable antibodies were not found for OAT3 or 
OATP1B1, immunohistochemical evaluations were not performed for these transporters.  All stains 
were performed using the Leica Bond automated tissue stainer (Leica Biosystems Wetzlar, Germany).   
     For positive and negative controls, normal human liver tissue was used for MDR1, normal human 
kidney tissue for MRP2 and OAT1, and normal human prostate for MRP4.  Negative stains were 
performed using the secondary antibody only. To determine assay consistency, we initially stained 
two sections at least 30 µm apart from each of nine cervical, eight colorectal, and ten vaginal donors.  
Since no intraindividual variability was noted the remainder of the samples were stained in singlet.    
Tissues stained with the secondary antibody alone were used as negative controls.  Samples were 
evaluated for localization staining intensity as well as localization of expression.  
Statistical Analysis 
 
Association between continuous variables was evaluated with Spearman rank correlation.  
mRNA expression was compared between tissues types with  an exact Kruskal-Wallis test, and when 
statistically significant (p<0.05), pairwise multiple comparisons were performed with Dunn’s method.  
Tissue effect upon gene expression was further evaluated with a general linear model (GLM) adjusted 
for age (years), smoking status (yes/no), inducer co-medication (yes/no), and hormone therapy 
(yes/no). Additional sensitivity analyses adjusted for race (Caucasian/African American), when 
known, in addition to the above covariates.  mRNA expression was natural-log transformed  to satisfy 
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the GLM normality assumption.  Pairwise tissue comparisons are presented as covariate-adjusted 
geometric mean ratios, and were evaluated with the Tukey-Kramer multiple comparison method. 
Exact Wilcoxon rank-sum tests were used to explore the effect of menopause upon gene expression 
within vaginal and cervical tissue. 
All analyses were conducted two-sided at a 0.05 significance level.  Statistical analyses were 
performed with SAS 9.2 (SAS Institute Inc. Cary, NC) and SigmaPlot 11.0 (Systat Software Inc. San 
Jose, CA).   
Results 
 
A total of 99 tissues, each from a unique donor, were procured and analyzed in this study. 
Demographic information for tissue donors is summarized in Table 4.   Expression of each transporter 
gene is reported as the ratio to ACTB expression as outlined in the methods.   
ABC Efflux Transporters: 
 
mRNA expression was measured in 40 vaginal, 30 cervical, and 21 colorectal tissue 
specimens. ABCB1, ABCC2, and ABCC4 were consistently expressed in all tissues analyzed.  Figure 
5 summarizes the expression results. mRNA expression of transporters were correlated (ABCB1 vs. 
ABCC2 r=0.73 p<0.001; ABCB1 vs. ABCC4 r=0.74 0. p<0.001; ABCC2 vs. ABCC4 r=0.66 
p<0.001).  The variability in raw Ct values for reference gene ACTB was 4.3, 9.4, and 4.8% for 
vaginal, cervical, and colorectal tissues respectively and overall variability was 6.5%.  Preliminary 
analysis in 18 samples (5 vaginal, 6 cervical, 5 rectal) showed that RNA integrity (determined by the 
Agilent Bioanalyzer) was not significantly correlated with mRNA normalized expression (r=0.22, 
p=0.3) indicating that our results were not influenced by RNA degradation. See Appendix for 
additional statistics from sensitivity analyses.   
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Table 4 Demographics of tissue donors used in transporter analysis. Demographic information 
regarding donors of tissue specimens is reported.  One rectal surgical sample did not have any 
demographic information available.    
Demographic 
Parameters 
 Vagina Cervix Rectum 
  n=47 n=31 n=21 
Age median (range)  58 (36-84) 54 (39-83) 57 (25-92) 
Males n (%)  N/A N/A 9 (43) 
Females n (%)  47 (100) 31 (100) 11 (52) 
Race n (%) Caucasian 39 (83) 19 (61) 18 (86) 
 African American  4 (9) 7 (23) 1 (5) 
 Asian 0 (0) 1 (3) 1 (5) 
 Native American 1 (2) 0 (0) 0 (0) 
 Mixed 0 (0) 1 (3) 0 (0) 
 Unknown 3 (6) 3 (10) 1 (5) 
Surgical Donor n 
(%) 
 46 (98) 31 (100) 14 (67) 
Primary Surgical 
Indication 
Vaginal or rectal 
prolapse/rectocele 
38/4 3/0 0/1 
 Stress urinary incontinence 3   
 Diverticulum 1   
 Pelvic or adnexal mass  12  
 Endometrial cancer or uterine 
fibroids 
 10  
 History of breast cancer or 
BRCA positive 
 3  
 Abnormal pathologies  3  
 Rectal carcinoma   12 
Cadaver Donor n 
(%) 
 1 (2) 0 7 (33) 
Cause of death Cerebrovascular 
accident/subarachnoid 
hemorrhage 
1/0  1/1 
 Cardiopulmonary 
arrest/myocardial infarction 
  2/1 
 Amyotrophic lateral sclerosis   1 
 Anoxic encephalopathy   1 
Smoker n (%)  8 (17) 7 (23) 11 (52) 
Co-medications n 
(%) 
Inducers
8
 21 (45) 19 (61) 8 (38) 
                                                             
8 Inducers included phenytoin, simvastatin, atorvastatin, nifedipine, omeprazole, carbamazepine, 
lamotrigine and topiramate.   
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 Hormones 
9
 14 (30) 4 (13) 0 (0) 
Menopause n (%)
10     
 Postmenopausal 25 (53) 16(52) 5 (24) 
 Pre or peri-menopausal 14 (30) 12 (39) 1 (5) 
Included in mRNA
11
 
analysis n (%) 
 40 (85) 30 (97) 21 (100) 
Included in IHC 
analysis 
 n (%)
12
 
 30 (64) 27 (87) 11 (52) 
For protein expression, sections from 30 vaginal, 27 cervical, and 11 colorectal specimens 
from surgical donors were evaluable for immunohistochemical interpretation.  Representative images 
are displayed in Figure 6.  Images of positive and negative control stains are showed in Figure 7. 
Images at a lower magnification are included in Figure 8. 
 
ABCB1/MDR1 
 
Median (Interquartile range (IQR)) expression ratios (to ACTB) for ABCB1 were 0.0402 
(0.0178-0.0582), 0.0236 (0.0101-0.0524), and 0.0073 (0.0053-0.0208) for vaginal, cervical, and 
colorectal tissue, respectively.  One colorectal sample did not have sufficient sample volume to 
include in the analysis.  ABCB1 expression was 3-16% of comparator liver tissue and 1-5% of 
comparator kidney tissue.  ABCB1 expression was different between the three tissue types (p 
<0.001), and was significantly higher in vaginal compared to colorectal tissues (p <0.05).   
                                                             
9 Hormones included estrogen replacement therapy administered orally or vaginally as well as oral or 
long-active contraceptive therapy.   
10 Percentages are reported as percent of total donors from each tissue. 
11 The majority of tissues were evaluated for both protein and RNA expression.  However, some 
samples (vagina n=6; cervix n=1) did not yield enough RNA to perform qRT-PCR 
12
 Some samples (vagina n=16, cervix n=4, colorectum  n=10) did not have tissue available for 
immunohistochemistry.   
 
40 
 
ABCB1/MDR1
Vagina Cervix ColorectumR
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
 (
fo
ld
 o
f 
A
C
T
B
) 
0.0
0.1
0.2
0.3
0.4
n=21
n=30n=40 n=20
ABCC2/MRP2
Vagina Cervix Colorectum
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
 (
fo
ld
 o
f 
A
C
T
B
 )
0.000
0.002
0.004
0.006
0.008
n=40 n=30 n=21
ABCC4/MRP4
Vagina Cervix Colorectum
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
 (
fo
ld
 o
f 
A
C
T
B
)
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
n=40 n=30
*
*
*
 In a multivariable analysis, 
differences in ABCB1 expression between the 
tissue types remained significant after 
adjusting for age, smoking status, and co-
medications (tissue effect, p<0.001).   In the 
adjusted analysis, vaginal ABCB1 expression 
was 3.9 fold greater than colorectal ABCB1 
expression (p<0.001).  Results further 
adjusted for race were also significant 
(p<0.001).  When tissues from cadaver donors 
were excluded, similar results were observed 
(See Appendix).  
Epithelial staining for MDR1 was 
observed in all vaginal, cervical, and 
colorectal tissues (Figure 6).  Although there 
were no quantifiable differences in epithelial 
staining between tissue types, the squamous 
mucosa of the vaginal tissue and ectocervix 
showed qualitatively more intense and diffuse 
staining than in both the glandular mucosa of 
the endocervix and colorectal tissue.  In these 
latter tissues, expression was largely limited 
to the luminal surface of the epithelium. 
Many submucosal lymphocytes in all tissue 
types also stained positive. Lymphoid 
follicles, when present, showed strong positive staining for MDR1 
Figure 5 mRNA expression of three ABC 
transporters in vaginal, cervical, and 
colorectal tissues. mRNA was detected by qRT-
PCR and levels were normalized to ACTB Ct 
values using the 2
-ΔCt
 method.  Box plots 
represent the 50
th
 percentile (line), 25
th
 and 75
th
 
percentile (box), 10
th
 and 90
th
 percentile (error 
bars), and outliers (circles).  Tissues were 
compared using an exact Kruskal-Wallis test and 
pairwise comparisons were made using the 
Dunn’s method *p <0.05 
41 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Immunohistochemical staining of vaginal, cervical, and colorectal tissues.  Black 
arrows identify expression of efflux transporters expressed in the epithelial layers.  Submucosal 
lymphocytes and/or monocytes are highlighted by the yellow arrows.  The red arrow identifies 
a rare positive columnar epithelial cell.  Images of OAT1 expression in vaginal and cervical 
tissue, and MDR1 in vaginal tissue were taken at an original objective magnification of 20X, 
and all others at an original magnification of 60X.   
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Figure 7 Positive and Negative Controls for Transporter Immunohistochemistry.  Positive 
(Column A and B) and negative (Column C) controls.  Original objective magnification 20X 
(Column A and C) and 60X (Column B).  Negative control images were stained with secondary 
antibody only. 
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ABCC2/MRP2 
 
Median (IQR) expression values for ABCC2 were 0.0014 (0.0008-0.0025), 0.0009 (0.0004-
0.0016), and 0.0003 (0.0001-0.0011) for vaginal, cervical, and colorectal tissues, respectively.  This 
expression was 1-3% of the comparator liver tissue and <1% of the comparator kidney tissue.  
ABCC2 expression was different between the three tissue types (p <0.001) and was significantly 
higher in vaginal compared to colorectal tissues (p<0.05).  In a multivariable analysis, differences in 
ABCC2 expression between the tissue types remained significant after adjusting for age, smoking 
status and co-medications (tissue effect, p<0.01).  In the adjusted analyses, vaginal ABCC2 
expression was 2.9-fold greater than colorectal ABCC2 expression (p<0.001).  The tissue effect 
remained significant when further adjusted for race (p<0.01) and when cadaver tissues were excluded 
(see Appendix).  
Diffuse staining was observed in the epithelia of all tissues types without any notable 
difference between tissue types.  Similar to MDR1, positive staining was observed in submucosal 
lymphocytes and in lymphoid follicles of vaginal, cervical, and colorectal tissues. 
ABCC4/MRP4 
 
Median (IQR) expression values for ABCC4 were 0.0193 (0.0131-0.0291), 0.0097 (0.0061-
0.0226), and 0.0237 (0.0122-0.0368) for vaginal, cervical, and colorectal tissues, respectively.  This 
expression is 120-310% of the comparator liver and 6-14% of the comparator kidney.  ABCC4 
expression was different between the three tissue types (p<0.05) with expression significantly higher 
in colorectal versus cervical tissues (p<0.05).  In a multivariable sensitivity analysis, the differences 
in ABCC4 expression remained significant after adjusting for age, smoking status, and co-
medications (tissue effect, p<0.05).  In the adjusted analysis, colorectal ABCC4 expression was 2.0-
fold greater than cervical ABCC4 expression (p<0.05).  The tissue effect did not reach significance 
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when further adjusted for race (p=0.18).  When tissues from cadaver donors were excluded, similar 
results were observed (see Appendix). 
Epithelial staining was observed in all tissue types, with the most intense staining identified 
in endocervical glandular mucosa, faint diffuse staining in vaginal squamous epithelium, and very 
faint focal 
staining in 
colorectal 
columnar 
epithelium.   
While a 
subset of 
submucosal 
lymphocytes 
and 
monocytes 
were also 
positive in 
all three 
tissue types, the highest expression was observed in colorectal samples where staining was primarily 
localized to the luminal surface of the epithelium. Primary follicles in the colorectal tissue showed no 
definitive staining, although germinal centers of secondary follicles, present for evaluation in two 
samples, were moderately positive for MRP4 expression.   
 
 
 
 
Figure 8 Lower Magnification Images (original 
objective magnification 20 or 40X. 
45 
 
SLC Uptake Transporters: 
 
The SLC transporters were expressed in less than 25% of all mucosal tissues.  These results 
are summarized in Table 5.  Detecting one SLC gene did not increase the likelihood of detecting 
another SLC gene from the same sample.  For example, there were three cervical samples with 
quantifiable SLC22A6 mRNA expression and three cervical samples with quantifiable SLC22A8 
mRNA expression:  only one of these samples had quantifiable levels of both genes.  No tissue 
samples had all three SLC genes quantifiable.  
 
Table 5 Proportion of samples for each transporter with quantifiable mRNA expression.  The 
range of expression values (normalized to ACTB expression using 2
-ΔCt
) when detected is included in 
parenthesis.  
 
 
Tissue OAT1 
SLC22A6 
OAT3 
SLC22A8 
OATP1B1 
SLC01B1 
 
 
% Quantifiable 
(range) 
% Quantifiable 
(range) 
% Quantifiable 
(range) 
Vagina (n=40) 0 
(0) 
5 
(3.4 x 10-5 – 
 4.5 x 10-5) 
10 
(6.0 x 10-6 -  
1.3 x 10-4) 
Cervix (n=30) 10 
(2.2 x 10-5 – 
1.6 x 10-4) 
10 
(1.8 x 10-6 - 
7.4 x 10-5) 
27 
(9.4 x 10-6 –  
1.6 x 10-4) 
Rectum (n=21) 9.5 
(8.5 x 10-6 -  
6.4 x 10-4) 
9.5 
(2.3 x 10-6 – 
 6.0 x 10-6) 
9.5 
(1.5 x 10-6 – 
2.8  x 10-6 ) 
 
SLC22A6/OAT1 
 
SLC22A6 was quantifiable in only 5% of samples and of those samples, expression was 
<0.1% of the kidney comparator tissue.   
Similarly, no protein expression was observed in vaginal or cervical (Figure 6) samples by 
immunmohistochemistry.  However, all colorectal samples had scattered cells within the epithelium 
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that showed intense staining. Morphologically, these cells most likely represent true colorectal 
epithelial cells rather than intraepithelial lymphocytes, monocytes, or plasma cells. These cells 
comprise <1 per 500 epithelial cells at a frequency of <0.5 per 600X high power field. 
SLC22A8/OAT3 and SLCO1B1/OATP1B1 
 
SLC22A8 was quantifiable in 8% of all samples and expression was <0.01% of the kidney 
comparator. SLCO1B1 was quantifiable in 14% of all samples and was <0.1% of expression in the 
liver comparator. As described in methods, immunohistochemical evaluations were not performed for 
these two transporters. 
Role of Menopause Status in Efflux Transporter mRNA Expression 
  
In vaginal tissue, mRNA expression was compared between 22 postmenopausal and 13 
premenopausal women.   Median ABCB1 expression was decreased by 17% in postmenopausal 
compared to premenopausal samples (p<0.05).   ABCB1 expression within vaginal tissue also 
negatively correlated with age (r=-0.426, p<0.01).  Median vaginal tissue expression of ABCC2 and 
ABCC4 were reduced in postmenopausal women by 11% and 28% respectively, but these did not 
reach statistical significance (p=0.26 and p=0.12).  Within cervical tissue, mRNA expression was 
compared between 16 postmenopausal and 11 premenopausal women. There was no observed 
difference in cervical expression of ABCB1, ABCC2 or ABCC4.  Because there was only one 
premenopausal donor in the colorectal group, no analysis was done with this tissue type.   
Discussion 
 
To our knowledge, these data represent the most robust evaluation of drug transporter 
quantification and localization in female genital and colorectal tissues to date.  Based on affinity for 
maraviroc and tenofovir, two candidates for HIV prevention that show different distribution patterns 
in female genital tract and colorectal tissue, we chose three efflux transporters from the ABC family 
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(ABCB1/MDR1/P-glycoprotein, ABCC2/MRP2, and ABCC4/MRP4) and three uptake transporters 
from the SLC family (SLC22A6/OAT1, SLC22A8/OAT3, and SLCO1B1/OATP1B1).  We found 
that efflux transporters MDR1, MRP2, and MRP4 are consistently expressed in both female genital 
and colorectal tissues, but to different extents and with unique cellular localizations. At the mRNA 
level, vaginal tissue has the highest expression of ABCB1 and ABCC2 while ABCC4 is most highly 
expressed in colorectal tissues. Uptake transporters SLC22A6, SLC22A8, and SLCO1B1 are 
expressed in a minority of 
samples at the mRNA level, 
and colorectal epithelial cells 
express very low levels of 
OAT1.  
The differential 
tissue expression profiles for 
each transporter observed in 
our study may assist with 
understanding how drugs are 
distributed to, and 
accumulate within, mucosal 
tissues (Figure 9).  For drugs 
being considered for use in 
PrEP (such as a fixed dose combination tablet of two nucleoside/tide reverse transcriptase inhibitors 
emtricitabine and tenofovir disoproxil fumarate (FTC/TDF), and the CCR5 antagonist maraviroc) 
mucosal penetration is of great interest.  A healthy volunteer study measuring vaginal, cervical, and 
colorectal penetration following a single oral dose of FTC/TDF found tenofovir and tenofovir 
diphosphate exposures 100-fold higher in colorectal tissue than in female genital tract tissue [42]. 
Both in vitro and clinical data have demonstrated that tenofovir is a substrate for the efflux transporter 
Figure 9: Hypothesized influence of drug transporters on 
drug exposure in colorectal and vaginal tissues.  The 
differential expression between colorectal and vaginal 
epiethelial tissues for each transporter relevant to a specific 
substrate's drug distribution is summarized. (A) Tenofovir is a 
substrate for MRP2, MRP4, and OAT1.  (B) Maraviroc is an 
MDR1 substrate.  The black circles represent the respective 
drug molecules.  The relative in vivo exposures observed 
(colorectal/vaginal) following an oral dose is summarized in the 
boxes to the left of the schematic. 
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MRP4[87].   The immunohistochemical data for MRP4 displayed a distinct staining profile in the 
colorectal tissues with intense staining observed in the submucosal lymphocytes and faint staining 
observed in the epithelial layers.  Less expression of efflux transporter specifically in the epithelial 
layer may imply less overall efflux from the tissue (Figure 9A). Tenofovir has also been implicated as 
an MRP2 substrate although its role in cellular disposition is less clear [88].  Both mRNA and protein 
expression suggest MRP2 expression is greater in vaginal compared to colorectal epithelium.  Similar 
to MRP4, less expression of MRP2 in colorectal epithelium may contribute to less efflux of tenofovir 
from the tissue (Figure 9A).  Tenofovir has also been shown in vitro to be a substrate for the uptake 
transporter OAT1 and to a lesser extent OAT3 [89, 90].  OAT1 expressing cells were not found in 
any of the vaginal or cervical tissues evaluated for protein.  However, each of the colorectal tissues 
examined had isolated cells in the epithelium that clearly expressed the OAT1 uptake transporter.  
The overall abundance of these OAT1 expressing cells was low, although higher expression in 
colorectal versus female genital tissues may contribute to the greater accumulation of tenofovir in 
colorectal tissues[42] (Figure 9A) Additionally, tenofovir bioavailability is 25%[95], therefore 
colorectal luminal concentrations are likely high and would facilitate tissue uptake despite low 
transporter expression.    
Currently in early phase studies for PrEP, maraviroc is a known substrate of MDR1[91, 92].
 
Higher expression of the efflux transporter MDR1 in vaginal versus colorectal tissues is consistent 
with clinical findings that maraviroc accumulation is greater in colorectal tissues [41] than in the 
female genital tract (Figure 9B) [37].
  
Maraviroc has also been implicated as a substrate for 
OATP1B1[93], however this transporter was not found to be expressed in either female genital or 
colorectal tissues.   
Although mRNA expression does not always correlate with protein expression [82, 96], the 
use of immunohistochemical evaluations supported our mRNA expression results in these tissues.  
MRP4 and OAT1 antibodies for immunohistochemistry had reliable performance and low inter-batch 
variation.  MDR1 and MRP2 antibodies were more challenging to validate and maintain.  The poor 
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quality of available antibodies limited our ability to perform quantitative analysis of protein 
expression.  However, consistent staining of MDR1, MRP2, and MRP4 in all tissues and sparse 
staining of OAT1 in colorectal tissue supported the mRNA measures of pan-detectable ABC 
transporters and sparsely detectable SLC transporters. MDR1 and MRP2 staining was mostly 
localized to the epithelium with some staining in submucosal monocytes and lymphocytes.  Since the 
squamous epithelium of vaginal and ectocervical tissue has many more layers of epithelial cells than 
the single columnar layer of the colorectal tract, this may explain why the mRNA expression for these 
transporters was higher in vaginal than colorectal tissues. Conversely, MRP4 was only modestly 
detected in the epithelium in all tissues but was most remarkable in the submucosal lymphocytes and 
monocytes in the colorectum.  Since the colorectum is highly colonized with these submucosal 
immune cells and lymphoid follicles [97], this may explain the significantly higher ABCC4 mRNA 
expression in colorectal compared to cervical tissues. 
While expression in the intestinal tract has been previously explored for certain transporters, 
the emphasis has been on their role in drug absorption with most studies focusing on the small 
intestine [80, 98, 99].  Our data in 99 individuals has been confirmed with recent published reports. 
Hilgendorf et al. reported that ABCB1/ABCC4 mRNA expression in colon was similar to expression 
in liver, kidney, and jejunum [99].  Nishimura et al. found undetectable mRNA expression of 
SLC22A6 and SLC22A8, low mRNA expression of ABCC2, moderate expression of ABCB1, and 
high expression of ABCC4 in colonic tissues [80].  De Rosa et al. found a similar trend for mRNA 
expression [86].    
In the female genital tract of 12 individuals, a recent study by Zhou et al. used conventional 
PCR to evaluate mRNA expression of 22 drug transporters and 19 metabolizing enzymes [85].   This 
study found that MRP4 mRNA was highly expressed, MDR1 modestly expressed, and MRP2 and 
OAT1 were undetectable. This investigation only documented the presence or absence of mRNA and 
did not provide information on interindividual variability, protein expression, or protein localization.   
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Many factors contribute to the regulation of transporter expression including genotypic 
polymorphisms, inflammation, and xenobiotics [100-103].  A role for sex steroid regulation in drug 
transporter expression has been proposed based on significant differences in endometrial MDR1 
expression across the menstrual cycle [104].  These findings have been supported by in vitro data in 
various cell lines [105, 106].
  
Within vaginal tissue, we saw a 17% decrease in the expression of 
ABCB1 in post-menopausal women suggesting that estrogen may play a role in the in vivo regulation 
of this gene.  Since post-menopausal women are also at risk for HIV acquisition [107], future studies 
are needed to elucidate the effect of estrogen status on mucosal drug exposure in post-menopausal 
women.   Expression between transporters was modestly correlated, suggesting at least some degree 
of co-regulation in gene expression.  Despite these correlations, differences were observed between 
transporters in the rank order of tissue expression (i.e. vaginal>cervical>colorectal for ABCB1 and 
ABCC2; colorectal>vaginal>cervical for ABCC4) which is noteworthy.  
There are limitations to this investigation.  From this analysis, the functionality of these 
transporters could not be determined.   Also, our study was not performed in “healthy volunteers” but 
rather surgical and cadaver donors. The surgical procedures performed were primarily for structural 
reasons (vaginal/rectal prolapse, 60%) and there are no data on the effect these may have on 
transporter expression. Additionally, our results were similar when cadaver tissues were excluded.  
Finally, although there are over 400 membrane transporters annotated in the human genome [78], 
because of the limited sample available from each donor, only six targeted membrane transporters 
were evaluated in this analysis   Given the importance of mucosal tissue transporter localization for 
PrEP, we chose to use immunohistochemistry to evaluate protein expression.  Now that localization 
of these transporters is better understood, quantifying protein concentrations using quantitative 
targeted proteomics may provide more information on the correlations between mRNA and protein 
concentrations in the future [108].   
In conclusion, in support of the development of PrEP agents, this investigation quantified the 
interindividual and intertissue variability of mRNA expression for six membrane drug transporters 
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important to tenofovir and maraviroc disposition, and determined protein expression and localization 
in vaginal, cervical, and colorectal tissues. We found higher expression of the efflux transporters 
MDR1 and MRP2 and lower expression of OAT1 in the female genital tract compared to colorectal 
tissues.  Although MRP4 expression was higher in colorectal tissues at the mRNA level, protein 
expression in colorectal epithelium was minimal.  This may explain why the MDR1 substrate 
maraviroc, and MRP2/4 and OAT1 substrate tenofovir achieve higher concentrations in colorectal 
tissues compared to vaginal or cervical tissue.    Identifying which transporters play key roles in 
controlling drug distribution into female genital and/or colorectal tissues will streamline the candidate 
selection process for compounds requiring high mucosal exposure.  Data generated from 
investigations such as this one can also be applied beneficially to therapeutic areas such as sexually 
transmitted diseases, gynecological disorders, and gastrointestinal diseases. 
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Chapter III: A Human Tissue Explant Model as a Preclinical Tool to Evaluate 
HIV Pre-Exposure Prophylaxis Candidates 
 
Summary 
 
Despite utilization of potent combination antiretroviral (ARV) therapy, the incidence of HIV 
in the United States has not declined over the past 15 years. Several clinical trials have recently 
demonstrated that daily dosing of ARVs can modestly protect vulnerable mucosal surfaces (vaginal, 
cervical, and rectal tissue) against infection, although protection ranges from 0% to 73%.  This lack of 
consistent and potent efficacy is due to the absence of a preclinical model to inform and optimize an 
efficacious regimen prior to clinical trials.  Here we describe an ex vivo human tissue culture model 
that we suggest can be used as a preclinical model to identify target concentrations of ARVs required 
for efficacy in prevention.  The model was developed with human surgical explant tissues.  A high 
variability of HIV target cell populations was observed using immunohistochemistry and their 
distribution within mucosal tissue described.  Using LC/MS-MS, antiretrovirals were found to rapidly 
distribute throughout explant tissues and formation of active metabolites was highly variable. The 
dynamic changes in tissue architecture, as well as a dramatic reduction in immune cell expression, 
and endogenous nucleotides were described over the first week in culture.  Finally, a novel RNA 
assay was developed that can determine infection within three days of viral exposure and can be used 
to access antiretroviral efficacy for HIV prevention in an efficient fashion.  This optimized explant 
culture system can be used in future studies to define target concentrations of antiretrovirals in 
mucosal tissue that are needed for complete protection against HIV infection and will assist in a 
streamlined drug development for HIV prevention.   
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Introduction 
 
Interventions that prevent the sexual transmission of HIV will be critical to curbing the global 
HIV epidemic.  By the end of 2011 there an estimated 34 million people worldwide were living with 
HIV/AIDS [72].  With a new 2-3 million individuals infected every year [72], it is clear that 
additional preventive measures are needed. Condoms and male circumcision have been the main 
components in the prevention arsenal to date [109].  When used appropriately, these interventions can 
be highly effective at reducing the risk of HIV sexual transmission [9, 110].  Despite extensive 
prevention education and outreach programs however, research studies show that people are unable or 
unwilling to use these interventions consistently [10].  Microbicide and vaccine research is ongoing 
but thus far no candidate has made it past Phase III clinical trials.  More recently, the use of 
antiretroviral (ARV) therapy given as pre-exposure prophylaxis (PrEP) either systemically or 
topically has been proposed as a means to protect individuals at a high risk of HIV exposure.   
 Several clinical trials have tested the efficacy of antiretrovirals, either orally or topically 
administered for HIV prevention and the results have been disparate [73]. The same dosage regimens 
that are used in treatment were implemented in these trials.  Without knowing how drug distributes 
into mucosal tissues, or the concentrations required for protection, development of a completely 
protective drug regimen has moved slowly.  With more comprehensive knowledge of drug exposures 
at the site of infection (mucosal tissues) following oral dosing, and a characterization of the drug 
exposure-protective response relationship in these tissues, dosing regimens can be strategically 
designed to maximize the likelihood of achieving 100% protection.     
The human tissue explant model has potential to be a valuable tool to predict efficacy of oral 
regimens for prevention.  The tissue explant model is a technique that has been previously used to 
study early transmission events in HIV as well as evaluate microbicides [27, 111].  The explant model 
is an appealing tool to evaluate dose-response relationships in relevant tissues since tissue can be 
procured from healthy volunteers.  Before accurate clinical predictions can be made however, more 
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needs to be understood about what is occurring at the cellular level in these ex-vivo tissues.  
Unfortunately, current publications using the explant model report a high variability making 
predictions regarding ARV efficacy unreliable [27].  Some of this variability may be accounted for by 
a robust characterization of some key components of the explant model.  In this chapter, an in depth 
characterization is presented on the disposition of antiretrovirals in the ex-vivo explant system by 
defining tissue uptake, activation, and elimination properties.  A quantitative picture of the immune 
populations in explant tissue is also described that will inform on the role these cells play in 
susceptibility to infection and likewise the needs for protection.  Lastly, methods to quantify infection 
in the model are compared. 
Materials and Methods 
Tissue Procurement 
 
Vaginal, cervical, and colorectal tissue samples were procured from surgical waste specimens 
and from cadaver tissues.  Surgical waste tissues were obtained through the UNC Tissue Procurement 
Facility (TPF) under two UNC IRB approved studies (#09-0921 and #12-0368).  Written informed 
consent was obtained from all participants. Cadaver tissues were obtained from the National Disease 
Research Interchange (NDRI).   All tissue was collected under applicable regulations and guidelines 
regarding informed consent, protection of human subjects and donor confidentiality.  After harvest, 
all tissue was immediately placed on ice in Iscove’s Modified Dulbecco’s Medium until received into 
the laboratory.   
Immunohistochemistry and Immune Cell Quantification 
 
Tissue explants were fixed in formalin for ≥24 hours and then placed in cassettes with 70% 
ethanol.  A tissue processor dehydrated and infiltrated tissue with paraffin overnight.  The next day, 
tissue was embedded into a paraffin mold and cut into 5 µm sections that were mounted on glass 
slides.  Slides underwent deparaffinization using xylene and graded alcohols followed by subsequent 
55 
 
staining with anitbodies performed by the Leica bond automatic stainer.  Hematoxylin and eosin 
(H&E) staining was performed first to 1) assess quality of tissue samples and 2) ensure the tissue was 
oriented correctly during processing.   Once reviewed, staining was performed for the immune cell 
markers CD4 (Leica, Clone 4B12), CD3 (Leica, Clone LN10), CD68 (Leica, Clone 514H12), CD1a 
(Leica, Clone MTB1), and CCR5 (Abcam, ab65850).  For infected explants, staining was performed 
with an antibody for p24 (Dako, clone Kal-1).  All tissue processing and immunohistochemical 
staining was performed by the University of North Carolina Translational Pathology Laboratory.   
Immune cell quantitation for CD3+, CD4+, and CD68+ cells was performed by manual cell 
counting. High powered fields (hpf) at 600X (original objective magnification 60X) were selected 
such that the mucosal-submucosal junction in vaginal and cervical tissue was centered in the 
microscopic field and contained approximately 50% epithelium and 50% submucosa in samples at 
time 0, and rectal tissue included whole visual fields of mucosa and lamina propria.  The average 
quantity of positively stained cells per representative hpfs (minimum two views counted per samples) 
was calculated for each sample.   
CCR5 mRNA was quantified with real-time PCR (Ab 7300 Real Time PCR Syste, Life 
Technologies) using the Taqman Gene Expression Assay Hs00152917 (Life Technologies).  RNA 
was extracted using the RNeasy Fibrous Tissue Kit (Qiagen).  RNA was converted to cDNA using 
Superscript Vilo cDNA Synthesis Kit (Life Technologies).  Expression was normalized to ACTB 
expression (Taqman Gene Expression Assay ID Hs99999903, Life Technologies) using the 2
-ΔCt
 
method [94]   .  
Ex-vivo Explant Cultures 
 
Explants were prepared and cultured similar to methods previously described [71, 111]   
Once tissue specimens were received, they were immediately rinsed in culture medium consisting of 
Iscove’s Modified Dubecco’s Medium (Gibco), 10% fetal bovine serum (Gibco), 240 units/mL 
nystatin (Sigma), 100 units/mL penicillin-100 ug/mL streptomycin (Gibco), and MEM Vitamin 
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Solution (Sigma).  Specimens were examined and excess muscularis tissue cut away so that only the 
epithelium and the immediate underlying submucosa remained.   Explants were then prepared using a 
3mm
 
biopsy punch (Miltex). 
Following drug or viral incubations (see below), explants were then transferred to 12-well 
tissue culture plates where, explants were placed on pre-soaked gelfoam (Gelfoam ®, Pfizer) rafts 
with 0.5 mL medium/well.  
MTT Viability Assay  
 
Tissue viability was assessed quantitatively using the methylthiazolydiphenyl-tetrazolium 
bromide (MTT) (Sigma) assay similar to methods described by Greenhead et al[111].  Explants from 
11 donors were incubated in 200 uL of 250 ug/mL MTT for 3 hours in a 96-well tissue culture plate.  
The explants were then submerged in methanol overnight to extract the formazan metabolite of MTT. 
The concentration of formazan was measured using optical density (Dynex Opsys plate reader) at 560 
nm and normalized for dry weight of the explant.   
Antiretroviral Drug Disposition 
 
To assess the rate and extent of drug uptake into tissues from media, explants were incubated 
in 0.5 mL of 1-100 µg/mL of tenofovir (TFV) or maraviroc (MVC) in a 48 well tissue culture plate 
for 3-72 hours. Tissues were snap frozen in liquid nitrogen and stored at -80 °C after 3, 6, 12, 16, 24, 
and 48 hours of incubation.  To assess the rate of drug elimination from tissues, after 24-48 hours of drug 
incubation, tissues were transferred to a pre-soaked gelfoam raft with 0.5 mL drug-free media in a 12-
well tissue culture plate.  Tissues were then harvested and snap frozen at 3, 6, 12, 24, 48, 72, and 96 
hours.  MVC, TFV, and tenofovir diphosphate (TFVdp) tissue concentrations were quantified based 
on previously published LC-MS/MS methods [41, 42]. Samples with a peak below the assay’s 
quantifiable limit were reported as 1/2 the lower limit of quantification (LLOQ) (determined by each 
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explant weight).  For statistical analysis, samples with no peak were reported as 1/10
th
 the LLOQ.  
Re-equilibration half-lives were calculated using Phoenix software (Cetera™).  
Protein binding of MVC in culture medium was determined similar to methods described in 
Brown et al [41]. MVC was spiked into culture media at 100 ng/mL and incubated in rapid 
equilibrium dialysis chambers (Rapid Equilibrium Dialysis System, Thermo Scientific) for 17 hours 
at 37° at 300rpm followed by protein precipitation with acetonitrile.  MVC concentrations were then 
analyzed as above by LC/MS/MS.  Plasma from a patient on MVC collected two hours post-dose was 
also included as a positive control.   
dATP and dCTP concentrations were measured by LC-MS/MS. The analytical range for both 
dATP and dCTP was 0.020 - 20.0 ng/mL homogenate.  Inter- and intra-day variability was <15%, and 
precision was within 10%.   
Viral Propagation and Explant Infections 
 
To evaluate infection in explant tissues, we exposed explants to a high titer (10
5-7
 TCID50) of 
HIV-1 JRcsf/hPBMC.  HIV-1 JRcsf was chosen as it is both R5 and T-cell tropic [112, 113], 
characteristics of viruses responsible for >90% of the sexual transmission of HIV infection [114].     
HIV-1 JRcsf (NIH AIDS Repository Program) was propagated in fresh human peripheral 
blood mononuclear cells (PBMC) following 24 hour phytohemagglutinin (PHA) stimulation[115] 
Virus was harvested on days five and seven post-infection.  Tissue culture infectious dose 50% 
(TCID50) titers of the harvests were determined in TZM-bl cells [116, 117] using a luciferase reporter 
assay Bright Glo ™ (Promega) and calculated using the Reed and Muench method [118]. 
Immunohistochemistry to Measure Intracellular p24  
   
 Immunohistochemistry was used to evaluate infection status of explants following exposure 
to 10
5
-10
6 
TCID50 HIV-1JR-CSF/hPBMC.  Explants were harvested three to six days post-inoculation, 
fixed in formalin, embedded in paraffin, sectioned (one to four sections per tissue) and stained with 
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p24 antibody (Dako, clone Ka1-1) using immunohistochemical techniques (see above).  To evaluate 
the number of sections needed to determine infection status, frozen vaginal (n=1) and cervical (n=1) 
tissues from HIV-infected donors were obtained from the National Disease Research Interchange.  
These frozen tissues were fixed in formalin, and with the assistance of the Translational Pathology 
Laboratory, the explants were paraffin-embedded (two pars per donor), sectioned (eight sections per 
par), and stained as described above using immunohistochemical techniques. 
Real-time PCR to Measure Proviral DNA  
 
Nevirapine-Challenge 
To determine if infected explants could produce a proviral DNA signal that was consistently 
higher than background, the non-nucleotide reverse transcriptase inhibitor (NNRTI) nevirapine 
(NVP) was used as a negative control.  Vaginal explants from two donors were infected with 5x10
5
 
TCID50 for three hours.  One half of the explants were incubated in NVP 270 ng/mL (25X IC50) while 
the remainder were incubated in drug-free grown medium.  After the three hour viral exposure, 
explants were briefly rinsed and transferred to pre-soaked gelfoam rafts.  NVP-treated samples were 
transferred to wells that contained a 270 ng/mL NVP.  Explants were harvested daily over 24-72 
hours post-inoculation.   
 
DNase of Viral Stock 
To remove possible background contamination from DNA present in the viral stock, an 
aliquot of viral stock was treated with DNase I enzyme (Promega).  One unit of enzyme was added 
per 10 uL viral stock and incubated for 1 hour at 37 °C.  The DNased sample then underwent 
extraction using the Viral RNA kit as above.  The number of gag copies DNA/uL viral stock was 
compared to a control aliquot of virus that had been treated with water instead of enzyme.  To test 
infectivity of the DNase-treated viral stock, cervical tissue (n=1 donor) was exposed for three hours 
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with DNase-treated and “mock”-treated viral stock.  Explants were harvested at 24 and 48 hours post-
inoculation. 
 
Proviral DNA Quantification 
 DNA was extracted from tissues using the QiaAmp DNA Mini Kit (Qiagen).  Primers and a 
fluorescent-labeled Taqman probe were designed to detect the HIV-gag sequence in a real-time PCR 
assay. Forward primer 5’- ACA TCA AGC CAT GCA AAT-3’; reverse primer 5’ TCT GGC CTG 
CTG GTG CAA TAG G-3’; probe-5’-FAM-CTA TCC CAT TCT GCA GCT TCC TCA TTG ATG-
TAMRA-3’.  To serve as a standard curve for quantitative calibration, log dilutions of 8E5/LAV 
cells[119], which each contain one copy of HIV proviral genome[120], were run in parallel with 
every PCR run.    
  
Spliced Viral RNA Assay 
 
Tissue explants (n=25 vaginal donors; n=7 cervical donors) were infected by incubation with 
10
7
 TCID50 /well HIV-1 JR-CSF/hPBMC in a 48 well tissue culture plate for 3 hours.    Explants were 
then rinsed in culture medium and transferred to gelfoam rafts in a 12-well tissue culture plate.  
Explants were harvested daily over 24-72 hours post-inoculation.  RNA was extracted using the 
Qiagen RNeasy Fibrous Tissue Kit.  RNA was converted to cDNA using Superscript Vilo cDNA 
Synthesis Kit (Invitrogen).  RNA was quantified using the NanoDrop™ 2000 (ThermoScientific).  A 
real-time PCR assay was designed to specifically detect copies of spliced RNA in the HIV-1 JR-CSF 
genome expressed in abundance at early stages of the HIV transcription life cycle.  The forward and 
reverse primers were designed to sit on each side of the Tat/Rev (D4-A7) splice site with the probe 
spanning the splice site.  Forward primer 5’ CCT CAA GAC AGT CAG ACT CAT CAA G- 3’; 
Reverse primer 5’ CTG CGG GTC CCC TCG TT-3’; probe- 5’/FAM/TAC CAA AGC AAC CCT 
C/MGB/-3’.  A log dilution of a cloned plasmid of this splice variant was used for a standard 
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quantification curve and the number of viral spliced RNA copies per tissue weight (mg) was 
determined for each explant.  
 
Statistical Analysis 
 
 Unless otherwise noted, data is presented as median and range, due to the lack of normally 
distributed data and high interdonor variability observed.    Correlations between continuous variables 
were made using the Spearman Rank Correlation.  Mann-Whitney Rank Sum test was used to 
compare CD3 and CD4 cell populations between tissues that were susceptible and resistant to HIV 
infection.  Except where noted, no differences were observed between cervical, vaginal, and 
colorectal tissues so data is reported as composite.  
Figure 10:  HIV target cells and relevant immune cells are expressed in explant tissue 
sources. Representative images of immunohistochemical stains.  Images are taken at original 
objective magnification of 20x for cervix and vaginal tissues and at 10x for colorectal tissues. 
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Results 
Expression and Variability of HIV Target and Immune Cells in Explant Tissues 
 
To explore factors influencing susceptibility to infection, HIV target and immune cells were 
quantified.  Cells expressing CD3 (marker for T cells), CD4 (marker for T helper cells), CCR5 
(chemokine receptor, used by R5 tropic HIV strains to enter CD4+ T cells), CD68 (marker for 
monocytes and macrophages), and CD1a (marker for antigen presenting cells, responsible for 
trafficking of HIV across 
mucosal epithelium [121]) 
were detected in the epithelia 
and submucosa of vaginal, 
cervical, and colorectal explant 
tissues.  Representative images 
of immunohistochemical stains 
are shown in Figure 10. Using 
manual cell counting, 
expression of CD3, CD4, and 
CD68 expressing cells were 
quantified in tissues from 13 
cervical, 12 vaginal, and 4 
colorectal donors (Figure 11).  
Variability between donors 
was >40% for all cell types, 
with highest variability in cervical tissues and lowest variability in rectal tissues.  CD3 and CD4 
expression were modestly and positively correlated (r
 
=0.60 p<0.001).  There was no correlation 
between CD68 expression and either CD3 (r
 
=0.22 p=0.4) or CD4 (r
 
=0.10 p=0.7) expression. CCR5 
Figure 11: Explant tissue composition is variable. 
Quantification of HIV target cells using immunohistochemistry 
shows that interdonor variability is high.  Cervical and vaginal 
specimens were counted at 600X so that the field through the 
microscope contained 50% epithelium and 50% submucosa. A 
600X field of view was roughly equal to 0.1mm
 2
 area of 
mucosal tissue.  For rectal specimens, cells were counted at 
600X and so that the epithelium and lamina propria were 
included.  The bars represent median/IQR. 
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staining indicated expression in all tissues, and CCR5 mRNA expression normalized to βactin in 
seven vaginal tissues demonstrated high inter-donor variability (+/- 116%).  CD1a was consistently 
expressed in the squamous epithelium of vaginal and ectocervical tissues with little expression in the 
columnar epithelium of colorectal tissues.  No cell counting was performed due to the typical 
confounding by dendritic processes protruding through multiple sections of fixed tissue.   
Changes in Architecture, Immune Cell Composition, and Viability over Time  
 
Over the first seven days in culture, sloughing of the epithelial layer, along with a loss of 
cellular architecture, was noted in all tissues (Figure 12).  However cellular viability measured by the 
MTT assay remained above 90% from day zero to day seven in culture (Figure 13).     
Figure 12: Sloughing of the epithelial layer and tissue architecture changes demonstrated by 
hematoxylin and eosin staining in vaginal explants that were collected prior to (left), 3 days 
in culture (middle), and 6 days in culture (right).  Total cell populations have decreased with 
loss of nuclear, basophilic staining and the multiple layers of the squamous epithelium have 
degraded.   
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Figure 13 illustrates changes in CD3, CD4, CCR5, and dATP, dCTP expression over time.  
By four days, CD3 and CD4 expression (by IHC) declined to 16 and 5% of baseline, respectively.  
seven days findings were similar to day four.    CCR5 mRNA expression (normalized to βactin) also 
declined over time to 25 and 18% of baseline on day four and seven, respectively.  We could not 
definitively determine whether cell loss was due to death or migration of cells out of the tissue.  
However, investigations placing 0.4 µM filter paper between the explant and the gelfoam raft to trap 
migratory cells did not suggest appreciable migration in this system.  Finally, endogenous nucleotides 
dATP and dCTP were quantified in explants from three donors after zero, one, two, and three days in 
culture. After one day in culture, an 89% reduction in dATP concentrations and a 70% reduction in 
dCTP concentrations were observed.  
 
 
Figure 13 Rapid changes occur in explant tissue over time in culture. All values were 
normalized to an explant from the same tissue donor at Day 0 (100%).  Symbols represent the 
median values and error bars represent the Interquartile Range for MTT viability, CCR5 gene 
expression, CD3 IHC cell counts, and CD4 IHC cell counts; error bars represent range for dATP 
Days in culture
0 2 4 6 8
%
 b
a
s
e
li
n
e
0
20
40
60
80
100
120
140
MTT viability (n=11)
CCR5 gene expression (n=5)
CD3-IHC (n=6)
CD4-IHC (n=5)
dATP(n=3) 
dCTP (n=3) 
64 
 
Time (hours)
0 12 24 36 48 60 72 84 96 108 120 132 144 156
C
o
n
c
e
n
tr
a
ti
o
n
 (
%
 m
e
d
ia
)
1
10
100
TFV
MVC
Time (hours)
0 24 48 72 96 120 144 168
T
F
V
-d
p
 f
m
o
l/
m
g
100
1000
10000
Uptake, Elimination, and Metabolism of Antiretroviral Drugs in Explant Tissues 
 
 The disposition of antiretrovirals was examined from tissues incubated ex vivo with the drugs 
of interest.  Explants incubated in 0.1-100 ug/mL TFV achieved median tissue concentrations that 
were 82 (range 65-98) % of media concentrations.  TFV equilibrium between medium and tissue was 
reached within three hours 
(first assessment time) and 
remained stable up to 48 
hours in culture (Figure 14).  
To simulate samples obtained 
from clinical study 
participants, tissues were 
rinsed and placed in drug-free 
media.  A rapid loss of drug 
from the tissue was observed 
until a new concentration 
equilibrium between tissue 
and media was achieved 
(Figure 14) at 2.5% of initial 
incubation concentrations.  
This calculated half-life was 
3.3 hours.  
Tissue 
concentrations of TFVdp 
were also measured, as this is 
the active intracellular metabolite of TFV, and is responsible for antiviral activity.  The median molar 
Figure 14 Antiretrovirals are rapidly taken up by tissue and 
rapidly eliminated.  Antiretroviral concentrations in tissue are 
reported as the percent initial concentration of the media tissues were 
incubated in assuming a tissue density of 1 g/mL.  Symbols represent 
median values and vertical lines represent range.  Tissues incubated 
in MVC (2-4 explants per time point from a total of 10 donors) were 
rinsed at 24 hours (dashed arrow and transferred to a drug-free 
culture plate.  Tissues incubated in TFV (2-6 explants per time point 
from total of 9 donors) were rinsed at 48 hours (solid arrow). Inset: 
Formation and elimination of TFVdp from explant tissue.  Explants 
from two vaginal donors were used to evaluate the rate of TFVdp 
formation over 48 hours of incubation in 100 ug/mL TFV.  Explants 
from a separate three donors were used to evaluate the rate that 
TFVdp was eliminated from tissues.  Explants were incubated in 100 
ug/mL TFV for 24-48 hours, rinsed in culture media, and transferred 
to gelfoam raft.  At 48 hours the tissues were removed from TFV 
incubation (black arrow). Symbols represent median values and error 
bars represent range. 
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conversion to TFVdp was 0.29% (range <0.01-2.01, n=28 explants) of TFV concentrations.  TFVdp 
concentrations were correlated with parent TFV concentrations (r=0.51, p=0.004) although there was 
high variability in its formation between tissue donors.  This variability could be explained, in part, by 
cellular viability, as the amount of TFVdp present in tissues correlated with a tissue viability score 
based on the reduction of the tetrazolium dye MTT to formazan (r=0.51, p=0.04).  Formation of 
TFVdp peaked at 48 hours, and had a monophasic elimination half-life of 20h (Figure 14 inset). 
Explants were also incubated in 1-100 ug/mL MVC.  Explants achieved median 
concentrations 91% (range 85-111%) of media concentrations (Figure 14).  Tissue and medium 
equilibrium was reached within six hours and remained stable for 24 hours.  Following removal from 
drug-containing medium, a rapid loss of drug from the tissue was observed until a new concentration 
equilibrium between tissue and media was achieved at  3.3% of initial incubation concentrations.  The 
half-life elimination for MVC was 2.8 hours (Figure 14). 
 In media containing 10% FBS, MVC was found to be 29% protein bound.  MVC was found 
to be 70% bound in plasma from a patient 2 hours post-dose, similar to what has been previously 
Figure 15 Explant tissues can be infected with a clinically relevant strain HIV-1JR-CSF/hPBMC . 
A-C) Infected mucosal cells expressing p24 antigen.  Original objective magnification is 40X. Brown 
cells are positive for p24 expression.  A) vaginal tissue collected six days post-infection; B) cervical 
tissue seven days post-infection; C) colorectal tissue two days post-infection 
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reported[92]. Plasma protein binding for tenofovir is <0.7% [95] and was therefore not assessed in 
culture medium.    
Identification and Quantification of HIV Infection in Explant Culture  
 
Measuring p24 using immunohistochemistry  
In explants exposed to HIV-1 ex vivo, immunohistochemistry detected individual p24 
positive cells in cervical, vaginal, and colorectal tissues (Figure 15 A-C), verifying infection had 
occurred.  These positive cells occurred as early as 24 hours post-inoculation, were observed 
infrequently, and were seen as singly infected cells. To determine the consistency across sections 
from the same explant, four sections were prepared from each of eight exposed explants; two explants 
were p24 positive in three of four sections, one explant in two of four, and five explants had no p24 
positive cells in any of four sections. In sections of tissue from HIV positive donors, positive cells 
were detected in six of eight sections of both pars from the vaginal tissue and in three of eight 
sections from the cervical tissue pars.   
 
Measuring proviral DNA using real-time PCR  
 In explants from one of two vaginal donors, NVP-treatment reduced the proviral DNA signal 
at 48 hours by 80% compared to the untreated control (no difference at 24 hours).  In the remaining 
donor, there was no difference between NVP-treated and untreated over 72 hours post-inoculation.  
DNase-treatment of viral stock with 20 units of DNase reduced background DNA by 22-fold, 
however no proviral signal was produced in explants that had been infected with the DNase-treated 
virus, suggesting that the process of DNase-treatment also reduced infectivity. 
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Table 6: Demographic information for vaginal explant donors used in spliced RNA assay time 
course.  
Age 
 median 
(range) 
N=25 68 (38-80) 
Race 
(n) 
Caucasian  15 
African 
American 
5 
American Indian 2 
Asian 1 
Mixed/Other 2 
Menopause 
Status 
(n) 
Pre 5 
Post 19 
unk 1 
 
 
Measuring spliced RNA using real-time PCR 
A method was developed to measure a spliced viral RNA containing the major splice that 
removes the Rev response element (RRE; the D4-A7 splice found in vpr, tat, rev and nef RNAs).  
Time course experiments were completed in explant tissues from vaginal and cervical donors.  The 
demographic information from the vaginal donors is summarized in Table 6 (no demographic 
information available for the cervical donors).  By quantifying this spliced viral RNA using real-time 
PCR, a viral peak (defined as >50% baseline) was observed in explants from 21 out of 25 (84%) 
vaginal donors and 6 out of 7 (84%) cervical donors (Figure 16).    The viral growth curves of 
explants from the remaining five donors never achieved spliced viral RNA >50% baseline, suggesting 
these tissues did not become productively infected.  Of those infected, 89% had reached >50% 
baseline by 24 hours and 96% by 48 hours. In vaginal tissues, 57% of those tissues infected peaked at 
24 hours, 29% at 48 hours, and 14% at 72 hours.  In contrast, 17% of cervical tissues peaked at 24 
hours, 33% at 48 hours, and 50% and 72 hours.  In explants where the conditions were tested in 
duplicate or triplicate (n=15 donors), the median intra-donor variability of spliced viral RNA at any 
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harvesting time point was 23%, suggesting experiments in singlet are sufficient to characterize the 
infection.    
There was no difference (p=0.2) in median count of CD3 cells in tissues susceptible to HIV 
infection (44 cells/hpf) and those resistant (56 cells/hpf).  Likewise there was no difference (p=0.5) in 
CD4 cell counts (median =18 cells/hpf for both groups).   
Discussion 
 
A method to evaluate the efficacy of pre-exposure prophylaxis candidates is needed for the 
development of PrEP candidates.   Human tissue explants may offer one method for direct assessment 
of the relationship between antiretroviral tissue concentrations and protection from HIV infection.   
Here we describe the explant model in terms of cellular populations, viability, drug activation, and 
Figure 16  Spliced viral RNA and replication in explant tissue.  Left) Vaginal tissues or Right) 
qcervical tissues were infected on Day 0 with 10
7
 TCID50/ well HIV-1JR-CSF/hPBMC.  Baseline samples 
(Day 0) were harvested immediately following the end of the 3 hour viral incubation.  Copy number of 
spliced RNA was determined using real-time PCR after reverse transcription and the fold change from 
baseline is reported (median/IQR).  Squares represent experiments where the fold change from baseline 
was >50% by Day 3 and these were the tissues that were determined to be infected with HIV.  Circles 
represent experiments where the fold change was never >50% by Day 3 and these tissues were 
determined to be uninfected.   
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drug distribution.  We also describe a novel method to quantify spliced viral RNA in tissue, providing 
an increased sensitivity to detect early rounds of HIV infection. 
One inherent limitation with the explant model is the high level of variability seen in 
infection response. This variability is evident both within and across lab groups [27, 122].  With this 
high variability in the susceptibility of the tissue to infection, it is difficult to elucidate drug effect.  
Because tissue used in the explant model comes from multiple donors, the tissue is likely in various 
states of immune activation, which subsequently leads to various levels of susceptibility to infection.  
One approach to understanding this variability is to develop a better appreciation of the HIV target 
cell populations in the explants at the time of HIV exposure. The high interindividual variability 
observed in the tissue samples from various donors may explant some of the variability that is seen in 
infectivity.    Based on our results from immunohistochemistry, we estimate between 40-230 CD4+ 
cells/mm
2 
vaginal mucosa.  Although we did not observe a correlation between CD3+ or CD4+  cell 
frequency and susceptibility to infection, this six-fold range could impact infection rate, as previous 
studies have suggested that the frequency and distribution of target cells in genital mucosa correlates 
with HIV acquisition[123-125].  Different cellular activation levels and cell types in mucosal tissues 
can also impact infectivity [126].  For example, α4β7 has been identified as a key target for mucosal 
HIV transmission [127].  It has also been proposed that HIV susceptibility is associated with the 
proportion of CD4+ cells that express Th-17[128].  Future studies are required to elucidate the role of 
immune cell quantity and phenotype in explant infectivity.   
We show here, for the first time, that endogenous nucleotides rapidly decline in explant tissue 
within the first day of culture.  Nucleotide analogues such as TFV are effective at inhibiting reverse 
transcription by competing with endogenous nucleotides for incorporation into the proviral DNA 
chain.  It has recently been suggested that high concentrations of endogenous nucleotides may have 
antagonistic effects on TFVdp and result in lack of TFV efficacy [129].  Therefore, it is possible that 
pharmacodynamic effect of certain agents could be overestimated (e.g. NRTIs could be measured as 
more potent than what would be found in vivo) if there are fewer endogenous nucleotides to compete 
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for viral RNA reverse transcription, particularly in long-lived explant systems.  A better 
understanding of endogenous nucleotide concentrations in human mucosal tissues is required to 
determine whether these nucleotides should be supplemented into the culture system to better mimic 
in vivo conditions. 
A number of early phase clinical studies are utilize a biopsy-challenge version of the explant 
model ([24, 27] clinical trials.gov NCT01505114) which involves ex vivo viral exposure of biopsies 
obtained from healthy volunteers dosed with antiretrovirals.  With this study design, drug penetration 
into mucosal tissue must be accounted for, as well as drug retention in the tissue upon removal from 
the body.  Given that explant methods typically transport tissue to the laboratory in medium over 0.5-
1 hour, and then incubate tissue with virus for two to three hours, our finding that >50% of drug has 
washed away within three hours means that relevant concentrations of parent drug may only be 
present for a fraction of the time the tissue is exposed to virus.  Although TFVdp was retained longer 
(t1/2 =20h), this elimination is still faster than the reported in vivo elimination in vaginal tissue (t1/2= 50 
hours) [130]. We also observed high inter-donor variability in the conversion of TFV to TFVdp, 
suggesting that variability in response may be related to variable concentrations of active drug in 
explant tissue.    
MVC is bound to human plasma proteins at ~76% and shows moderate affinity for human 
albumin and alpha-1 acid glycoprotein [92].  Here we showed only 20% protein binding of MVC in 
culture media containing 10% FBS.  Since it is only unbound drug that is able to elicit 
pharmacodynamic effect, adjustments should be made when interpreting the EC50.  While protein 
binding within vaginal tissue is not known, protein binding in cervicovaginal fluid collected from 
women after seven days of MVC therapy was 7.6% [37].   
For our infection studies, we chose HIV-1JR-CSF rather than HIVBaL to perform viral challenges 
in our explant model.  HIVBaL is an R5 macrophage tropic strain [131] commonly used for tissue 
explant challenge [24, 27, 111, 132, 133].  However, data from human and macaque studies suggest 
the earliest infected cells in HIV mucosal transmission are CCR5+/CD4+ activated T cells,[127, 134] 
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and analysis of acutely infected humans indicate the initially replicating virus in these individuals is 
R5 T-cell tropic, and not macrophage-tropic.[135] In order to mimic in vivo infection, we chose HIV-
1JR-CSF, a virus that is R5 and T-cell tropic, but not macrophage-tropic.[112, 113]  Additionally, since 
HIV-1JR-CSF is also used in humanized mouse models, use of the same viral strain could allow for 
better translation and data interpretation between species.[46, 47]   
With this work, we introduce a new method to quantify HIV replication in mucosal tissues.  
Although viral protein (p24) released into culture supernatant is often measured to quantify HIV 
infection in the explant model, there are a number of difficulties in defining infection with this 
method, including a low signal, a high background, variable response, and multiple proposed cutoffs 
for efficacy [122, 132, 136].  We evaluated a number of alternatives in developing our model.  Tissue 
staining of intracellular p24 using immunohistochemistry allowed visualization of infected cells 
within one to six days of infection. However, infection was observed as a rare event with a low 
frequency of infected cells/explant. This frequency was not unexpected, as it is similar to the staining 
observed in lymph nodes and vaginal mucosa of HIV infected patients [137, 138].  However, to 
confirm infection had occurred, this method required the analysis of multiple tissue sections, which 
was labor intensive and time consuming. Although we developed a real-time PCR assay able to detect 
~1 copy proviral DNA/mg tissue, it was not able to discriminate between ARV-treated and untreated 
tissues within the first few days of infection due to background DNA in the viral stock.  DNase-
treatment of viral stock substantially reduced the DNA background; however, it also rendered the 
virus non-infectious.  We then designed a real-time PCR assay to detect the copy number of spliced 
HIV mRNA missing the RRE (encoding Vpr, Tat, Rev, or Nef).  This D4-A7 splice occurs early in 
the HIV life cycle [139] and the resultant mRNA is expressed in relative abundance in each actively 
infected cell [140].  With this assay, we could detect a robust infection within the first three days 
post-viral challenge in >80% of explant donors.  This rate of infection is consistent with other 
reports[132].  Although not powered to detect any differences between tissue types, these preliminary 
data suggest differences in replication patterns between vaginal and cervical tissues.  Although the 
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same percentage of tissues became infected, replication in vaginal tissues tended to peak within the 
first 48 hours post-inoculation, while cervical tissues had a greater likelihood of increasing replication 
at 72 hours.  These data are consistent with other observations that observed greater p24 production in 
ectocervical explants than in vaginal explants over 21 days in culture [132].  
Our model has many advantages, with some limitations similar to other explant models.  Our 
model represents a “worst-case scenario” for HIV infection.  The use of a nonpolarized explant 
system allows tissue to be vulnerable to viral infection from all sides, with the epithelial layer no 
longer providing protection to submucosal immune cells.  Our design was intentional, in order to 
mimic compromised mucosal tissue.  However, it is possible that the model overestimates the amount 
of antiretroviral required for protection in-vivo.  Further comparisons of this model with in vivo data 
are needed.  A higher titer of viral inoculum than is typical in explant systems with HIV BaL[24, 111] 
or in humanized mouse models is utilized [46]. This titer was chosen to maximize the probability of 
an infectious event.  Antiretroviral potency has been shown to be dependent on multiplicity of 
infection [141] and our goal is to evaluate the concentration that would protect against all potential 
exposures.   
In summary, we have demonstrated that by using a R5, T-cell tropic HIV virus and a novel 
RNA assay, coupled with a complete understanding of mucosal tissue pharmacokinetics, our 
streamlined explant model can be used to identify target concentrations of antiretrovirals protective 
against HIV acquisition.  These data can then be synergistically combined with pharmacokinetic data 
from Phase 1 studies to model scheduled or coitally-dependent dosing strategies that will be 
maximally protective against HIV challenge.   
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Chapter IV: Concentration-Response Relationship of Tenofovir and Maraviroc 
in Human Explant Tissue 
 
Summary 
 
 The modest success of recent HIV pre-exposure prophylaxis (PrEP) trials illustrates the need 
to optimize drug doses and dosing frequency in clinical studies.  A method to identify target 
concentrations of antiretrovirals that protect vulnerable mucosal tissues against HIV infection is 
needed for designing these regimens. Here we generated concentration-response profiles for two 
antiretrovirals being used or being considered for use in PrEP, tenofovir and maraviroc.   Fresh 
vaginal tissue was collected from women undergoing surgical repair for vaginal prolapse. Explants 
were incubated for 24 hours in 0.1-1000 ug/mL tenofovir (n=5 donors; 14 explants) or 0.1-500 ug/mL 
maraviroc (n=5 donors; 13 explants) prior to a three hour incubation with 10
7
 TCID50 HIV-1 JR-
CSF/hPBMC.  Spliced RNA was measured in explants at 24, 48, and 72 hours post-inoculation and 
adjusted for tissue weight. Efficacy was also assessed in a TZM-bl cell monolayer using a luciferase 
reporter assay. For tenofovir-treated explants, the AUC24-72h was used to quantify infection and an 
Emax model identified an EC50 of 716 fmol/mg tenofovir diphosphate, a value similar to what has been 
imputed from clinical trials to be required for efficacy.  For maraviroc-treated explants, an EC50 of 9.7 
ug/mL was identified at 24 hours post-inoculation.  No efficacy was observed in maraviroc-treated 
explants beyond 24 hour time points. Tenofovir and maraviroc efficacy in vaginal explants was 
overestimated in a TZM-bl model which identified EC50’s of 61 fmol/mg for tenofovir diphosphate 
and 0.006 ug/mL for maraviroc.   
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Introduction 
 
As discussed in previous chapters, antiretrovirals given locally or systemically are being 
evaluated for prevention of HIV.  The first study to demonstrate prevention efficacy was CAPRISA 
004, in which coitally-dependent administration of 1% tenofovir (TFV) gel reduced HIV acquisition 
in women by 39% [17].  Clinical trials have also evaluated daily oral tenofovir disoproxil fumarate 
(TDF) taken alone or in combination with emtricitabine (FTC) in men who have sex with men 
(MSM)/transgender women (iPrEX), and heterosexual men and women(Partners PrEP/TDF2), and 
injecting drug users (Bangkok Tenofovir Study) [48, 142-144].  The results were promising but 
variable (44-73% efficacy), yet nevertheless provided proof-of-concept that oral antiretrovirals can 
protect against HIV transmission. These studies led to the FDA giving Truvada®, a fixed dose 
TDF+FTC combination pill commonly used in HIV treatment, an indication for use as a prophylactic 
agent in uninfected individuals [11]. However, two additional studies conducted exclusively in 
women (FemPrEP, using daily oral TDF+FTC, and VOICE, using either TFV gel, TDF, or oral 
TDF+FTC) were either stopped early for futility or were unable to demonstrate a significant 
protective effect [49, 145].  Inconsistent adherence [74, 146], combined with different mucosal tissue 
drug penetration patterns [42], help explain these differences in clinical trial efficacy.   
Based on these clinical trial data, it’s clear that successful drug dosing strategies in 
chemoprevention must be designed to achieve adequate drug exposure in the population under study.  
Yet a significant challenge is a lack of identified target concentrations that are protective against HIV 
infection.  Regulatory agencies recommend optimizing dosing strategies for clinical trials with 
pharmacometric approaches once the concentration-response relationship at the site of infection (e.g. 
mucosal tissues) is quantified [147].  Therefore, a model system that can accurately predict in vivo 
correlations for chemoprophylaxis could significantly advance the chemoprevention field. 
The human tissue explant system in which cervical, vaginal, or colorectal tissue from HIV 
negative donors are exposed to virus in an ex vivo culture system, has potential as a preclinical tool to 
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quantify chemoprevention efficacy.  We used the model described in Chapter III to identify target 
concentrations for TFV and TFVdp that were protective against viral vaginal challenge and compared 
our predictions with cell and clinical trial data.  The model was then used to evaluate MVC in cells 
and vaginal tissues as a potential agent for PrEP.  The target concentrations, once validated, may be 
used to assist with dosing strategies for future clinical trials.    
Methods 
Tissue Procurement 
 
Vaginal tissue samples were procured from surgical waste specimens obtained through the 
UNC Tissue Procurement Facility (TPF) under UNC IRB approved study #12-0368.  Written 
informed consent was obtained from all participants.  All tissue was collected under applicable 
regulations and guidelines regarding informed consent, protection of human subjects and donor 
confidentiality.  After harvest, all tissue was immediately placed on ice in Iscove’s Modified 
Dulbecco’s Medium until received into the laboratory. 
Concentration-Response Relationship in Vaginal Explant Tissue 
 
  To examine the ability of antiretrovirals to interrupt HIV infection, vaginal explants were 
pretreated in a 48-well tissue culture plate for 24 hours with 0.5 mL TFV (0.1-1000 ug/mL) or MVC 
(0.1-500 ug/ml).  Explants from five donors were used to complete each dose response curve.  Based 
on the size of tissue specimens and the number of explants produced from each specimen, two donors 
were incubated in 0.1, 1, 10, and 100 ug/mL TFV, one donor in 1, 10, and 100 ug/mL, one donor in 
100 and 1000 ug/mL, and one donor in 100 ug/mL only.  For MVC- treatment, one donor was 
incubated in 0.1, 1, 10 and 100 ug/mL, two donors in 1, 10 and 100 ug/mL, and two donors in 100 
and 500 ug/mL.  Additional explants were incubated in drug-free medium and used as donor-specific 
positive controls.   Following the 24 hour pre-incubation in TFV, one explant from each concentration 
was used to measure TFVdp tissue concentration as previously described [42].  Remaining explants 
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were then incubated with 10
7 
TCID50/well HIV-1 JR-CSF/hPBMC.  At the end of the three hour 
incubation, one explant from each donor was harvested to measure background spliced viral RNA.  
Remaining explants were rinsed and transferred to gelfoam rafts presoaked with drug-containing 
medium in a 12-well tissue culture plate.  Explants were harvested daily for three days and measured 
for spliced RNA as described in Chapter III.  The copy number was normalized for explant weight.  
Concentration-Response in TZM-bl Cells 
 
 TZM-bl cells (NIH AIDS Repository[116, 117, 148]) were incubated in 96-well plate with 
dilutions of TFV ranging from 10
-4
-10
3
 ug/mL, or maraviroc 10
-5
-10
2
 ug/mL for 24 hours prior to a 48 
hour incubation with 10
3 
TCID50  HIV-1JR-CSF/hPBMC.  Cells were lysed and infection quantified 
using a luciferase reporter assay (Promega).   Intracellular TFVdp was measured in TZM-bl cells 
using published LC-MS/MS methods[149] and normalized for weight of cells.  A conversion factor 
of 42,208 cells/mg was determined by weighing a cell pellet with a known amount of cells.  
Experiments were performed in triplicate. 
 To assess whether MVC and TFV display an additive or synergistic effect on viral inhibition 
when used in combination, TZM cells were incubated in combinations containing the EC50 of each 
drug when used alone; EC25 concentrations were also combined.  Following 24 hour drug incubations, 
cells were incubated with 10
3 
TCID50  HIV-1JR-CSF/hPBMC.  Cells were lysed and infection quantified 
using a luciferase reporter assay (Promega).  Experiments were performed in triplicate.  
Data analysis 
  
EC50 concentrations were defined using the 4 parameter Emax model y = min + (max-min)/(1 + 
(x/EC50)^(-Hillslope)).  For all models in tissue, max was fixed to 100 and remaining three parameters 
were estimated. For TFV and TFVdp models in TZM-bl cells all four parameters were estimated.  For 
MVC in TZM-bl cells, the min was fixed to zero and the remaining three parameters were estimated.  
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The EC50 ± standard error for each model is reported. Analyses were performed with Sigma Plot 11.0 
(Systat Software Inc).  
Results 
 
TFV Efficacy in Vaginal Explants Determined by TFVdp Concentrations  
 
Viral inhibition by TFV was determined by the percent decrease in the weight normalized 
AUC24-72h of spliced RNA of treated explants compared to untreated controls.  An Emax model was fit 
to describe the relationship between TFV concentrations and HIV inhibition in vaginal explant 
tissues.  The predicted EC50 for this model was 97±8 ug/mL (Sum of Squared Error (SSE) 9788) 
(Figure 17A). An Emax model utilizing intracellular TFVdp concentrations was also fit (Figure 17B).  
The estimated EC50 was 716 ± 448 fmol/mg (SSE 8896).  In a sensitivity analysis whereby data were 
Figure 17 Inhibition of HIV is correlated with tissue concentrations of TFVdp in human 
vaginal explant tissue.  Vaginal explants (black) (n=5 donors) were incubated in 0.1-1000 ug/mL 
TFV for 24 hour prior to a 3 hour viral exposure to 10
7
 TCID50/ well HIV-1JR-CSF/PBMC.  Drug 
concentrations were measured at the time of viral exposure. Percent inhibition was determined by 
comparing the weight-normalized spliced RNA AUC24-72h of the TFV-treated tissues to the untreated, 
donor-matched positive controls.  TZM-bl cells (n=3) were incubated in TFV 0.01-1000 ug/mL for 
24h prior to viral exposure.  Percent inhibition was determined by comparing the relative light units 
(RLU) to positive control (untreated cells) in a luciferase reporter assay.  Left) Percent inhibition 
versus the concentration of TFV in medium.  Right) Percent inhibition vs TFVdp measured in tissue 
explants.  Circles represent the raw data while the lines represent the predictions from the best fit Emax 
models.   
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normalized to ng RNA rather than tissue weight, a similar TFVdp EC50 of 914 fmol/mg was 
produced, confirming that the results were not confounded by variability in tissue composition or 
RNA extraction  
To compare these explant tissue results to a typical cell monolayer system, we evaluated 
antiretroviral efficacy in a TZM-bl cell line using a luciferase reporter assay.  When the dose response 
of tenofovir was tested in TZM-bl cells, the predicted EC50 was 0.9 ± 0.02 ug/mL for TFV and 61 ± 
18 fmol/mg for TFVdp (Figure 17).  These results are approximately 10-100 fold lower than the 
explant tissue data generated.   
MVC Efficacy in Vaginal Explants is Short Lived 
 
Viral inhibition in 
MVC-treated vaginal explants 
was not sustained over three 
days in culture and any 
concentration-response 
relationship was best defined 
by examination of the explants 
harvested at 24 hours.  At 24 
hours post-infection, the Emax 
model (SSE 9769) 
determined an EC50 of 9.7 ± 
65 ug/mL MVC (Figure 18).  
No relationship between 
concentration and viral 
inhibition was observed when 
Figure 18 Maraviroc inhibits HIV infection in vaginal explants 
for 24 hours. Vaginal explants (black) (n=5 donors) were 
incubated in 0.1-500 ug/mL MVC for 24 hour prior to a 3 hour 
viral exposure to 10
7
 TCID50/ well HIV-1JR-CSF/PBMC.  Percent 
inhibition was determined by comparing the weight-normalized 
spliced RNA copies/mg of the MVC-treated tissues to the 
untreated, donor-matched positive controls in explants collected 
24h post-infection.  TZM-bl cells (n=3) were incubated in MVC 
0.0001-100 ug/mL for 24 hour prior to viral exposure.  Percent 
inhibition was determined by comparing the relative light units 
(RLU) to positive control (untreated cells) in a luciferase reporter 
assay.  Circles represent the raw data while the lines represent the 
predictions from the best fit Emax models.    
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AUC24-72h  of the MVC treated explant tissues were compared to untreated controls and no Emax model 
produced a good fit.  In TZM-bl cells, an EC50 of 0.006 ± 0.002 ug/mL was determined.   
Additive Efficacy of Tenofovir and Maraviroc in Cell Culture 
 
 When MVC and TFV EC25 concentrations in TZM-bl cells were used in combination, a 54% 
inhibition was observed.  When a combination of EC50 concentrations was used, an 88% inhibition 
was achieved, suggesting that MVC and TFV have additive efficacy against HIV-1 infection in TZM-
bl cells.   
Prediction of Efficacy from Oral Tenofovir Disoproxil Fumarate and Maraviroc 
 
 By applying the Emax models developed in vaginal tissues and TZM-bl cells, the expected 
efficacy from different oral dosages can be estimated.  Table 7 shows the model predictions for 50%, 
100%, and 200% FDA-approved treatment dosages of MVC and TDF using tissue concentration data 
from a previously performed pharmacokinetic study [150]. 
Table 7 Emax model predictions of oral MVC and TDF efficacy at 50, 100 and 200% 
dosing.  Expected concentrations of MVC and TFVdp in female genital tissues at 24 hours following 
respective dosages were input into the Emax models developed for TZM-bl cells and explant models to 
predict the expected % efficacy at each dose.  The expected effect of the combination of MVC and 
TFVdp was calculated assuming additive properties between the two compounds.   
 
Dosing 
Explant Emax Model 
(% efficacy) 
TZM-bl Emax Model 
(% efficacy) 
Maraviroc 
50% 10.04 81.84 
100% 11.49 87.11 
200% 13.85 92.30 
    
Tenofovir dp 
50% 0.016 2.19 
100% 0.019 2.46 
200% 0.076 7.25 
    
Combination 
50% 10.06 84.03 
100% 11.51 89.57 
200% 13.92 99.55 
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Discussion 
 
A lack of data relating antiretroviral tissue concentrations to mucosal tissue protection has 
challenged the design and interpretation of HIV chemoprophylaxis clinical trials.  Improving the 
understanding of the relationship between local pharmacokinetics and pharmacodynamics enhances 
the drug development process [147].  This could be particularly true in the case of chemoprevention 
where plasma concentrations result in significantly different cervical, vaginal and colorectal mucosal 
tissue concentrations [75].   We believe this model provides a clinically relevant framework for drug 
development.    
The relationship between TFV exposure and HIV protection was best described by using 
TFVdp concentrations directly, as shown by the reduction in SSE of the model fits.  This is likely due 
to the inter-donor variability in the conversion of TFV to TFVdp (Chapter III).  This model defined a 
TFVdp tissue concentration of ~700 fmol/mg as 50% protective against HIV infection, which is 
similar to data generated from clinical trials.  In CAPRISA 004, a study in South African women 
using coitally-dependent 1% TFV gel that provided ~50% protection against HIV acquisition, women 
with vaginal lumen concentrations of >1000 ng/mL of TFV were more likely to be protected from 
infection than women with <1000 ng/mL [151].   Results from previous pharmacokinetic 
investigations [152, 153] demonstrate that ~500 fmol/mg TFVdp is present in vaginal tissue when 
TFV luminal concentrations are ~1000 ng/mL.  A phase I study evaluating the safety, tolerability, and 
efficacy of oral and rectally-applied tenofovir gel demonstrated TFVdp concentrations of ≥1000 
fmol/mg were needed in colorectal explants to reduce p24 antigen expression by >50% [24].  These 
comparisons suggest that a clinically relevant mucosal tissue exposure-response relationship was 
defined in this explant system.   
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We also found that high concentrations of MVC were able to initially inhibit viral replication 
in a concentration-dependent manner, but the inhibition was lost after 24 hours.  While MVC has not 
yet been tested for efficacy as a PrEP agent in clinical trials, in a macaque rectal SHIV-challenge 
model, a lack of protective effect was observed despite high MVC concentrations in rectal tissue 
[154].  After two viral challenges, 3/6 macaques in the treatment group were infected compared to 3/4 
macaques in the control group; however, after five viral challenges, there was no  overall difference 
in infection rates between treatment (5/6 macaques) and placebo (3/4 macaques) groups, suggesting 
MVC treatment may have delayed the time to infection..   In both the explant and macaque models, 
concentrations of MVC are well above the concentrations in plasma following typical treatment doses 
and are above the concentrations required to inhibit viral replication in vitro [92].  The mechanisms 
by which HIV is able to overcome MVC inhibition in the explant system require further exploration.  
The occurrence of cell-associated transmission may offer one explanation for this observation.  
Studies in macaques and in humans have shown that Langerhans cells, which do not express CCR5, 
participate in early uptake of HIV-1 in a phagocytic manner [155, 156]. Myeloid dendritic and 
Langerhans’ cells in female genital mucosa have also been shown to take up HIV and transmit in 
trans to CD4+ T cells [156, 157].  Therefore it is possible that HIV is able to circumvent CCR5 
inhibition by temporarily “hiding” in dendritic and Langerhans cells; virus can then be transferred in 
trans to the CD4+ T cells where integration and replication can occur. Additionally, CCR5 
conformations have been shown to be dynamic [141] and HIV-1 has been shown to be less 
discriminatory in binding to various CCR5 conformations than other CCR5 ligands and inhibitors 
[137]. Therefore, the pattern of temporal efficacy of MVC we described may also be related to 
changes in CCR5 conformation in explant tissue over time and differing affinities between MVC and 
gp120 on the viral envelope for their unique respective CCR5 binding sites.   
A number of cellular monolayers are utilized as standard methods for determining inhibitory 
or effective concentrations of antiretrovirals [158-162]. Since the tissue explant method had not been 
compared to these standard virologic approaches previously, we compared the results from our tissue 
82 
 
culture method to the results from a TZM-bl cell monolayer, a HeLa derived cell line that stably 
expresses CD4 and CCR5 and possess integrated copies of the luciferase gene under control of the 
HIV-1 promoter [148]. Even when normalizing for cellular TFVdp, TZM-bl cells under-predicted the 
TFV EC50 by 10-fold.  Likewise, the difference in MVC potency in TZM-bl cells and vaginal tissue 
was >1000-fold and, suggesting that pharmacodynamic data from cell lines may not be an adequate 
surrogate for mucosal tissue.  A similar 15-fold  reduction in TFV potency has been observed in the 
presence of cell-associated virus compared to cell-free virus alone [163], providing further support for 
the possible role of in trans cell to cell spread in female genital tissues.  Other possible mechanisms 
for the difference in potency could be related to differences between TZM-bl cells in cell activation, 
protein binding, or drug transport.  
Lastly, the Emax models for both cells and tissue were used to prospectively estimate the 
efficacy that would be expected in vivo 24 hours following oral administration of MVC or TDF.  To 
date, no robust comparison between cell and explant data have been performed and the best model to 
predict clinical efficacy has yet to be defined.  Similar to what has been shown previously, our in 
vitro data suggests additive properties exist between MVC and TFV [50].  Therefore the TZM-bl cell 
model would predict that 200% oral dosages would provide near complete protection in vivo.  In 
contrast, the vaginal explant model would predict only 14% protection from HIV.  In Chapter V, 
these predictions are compared to a biopsy-challenge model where healthy volunteers are given a 
200% combination dose and 24 hours later, biopsies are collected and challenged to HIV ex vivo.   
In summary, we have applied the human tissue explant model described in Chapter III to 
create concentration-response curves for two antiretroviral agents being considered for use in PrEP.  
The explant model predicted concentrations required for efficacy that were 1-3 logs higher than 
predictions from an in vitro cell-based assay, supporting the need to measure efficacy directly in 
human tissues.  The Emax models produced from this data can be synergistically combined with tissue 
pharmacokinetic data from Phase I studies to make predictions on the efficacy outcomes of different 
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ARV prevention strategies.  Modeling strategies can be employed to identify the scheduled or 
coitally-dependent dosing strategy that will be maximally protective against HIV challenge.  
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Chapter V: Efficacy of Oral Maraviroc and Tenofovir for HIV Prevention: 
Proof of Concept Study to Evaluate Explant Model Predictions  
 
Summary 
 
 In Chapter IV, the protective concentrations for tenofovir diphosphate and maraviroc in 
vaginal explants were shown to be 10-1000 fold higher than in TZM-bl cells.  In this chapter, the 
efficacy predicted by vaginal explants and by cell monolayers is compared to efficacy of a biopsy 
challenge model in healthy volunteers following high dose oral maraviroc plus tenofovir.  Six healthy 
pre-menopausal women were administered a single dose of 600mg maraviroc + 600mg tenofovir 
disoproxil fumarate.  Two vaginal and two cervical biopsies were collected 24 hour post-dose and 
exposed ex vivo to 10
7 
TCID50/well HIV-1JR-CSF/hPBMC.   HIV protection was defined as weight-
normalized spliced RNA within one standard deviation of the background at 24 and 48 hours post-
inoculation. While TZM-bl and explant models predicted >99 and 14% efficacy respectively, in 
healthy volunteers, protection was observed in 50% (3/6) vaginal biopsies and 67% (4/6) of cervical 
biopsies, with 50% (3/6) of women having complete protection against HIV challenge.  Data from 
TZM-bl cell monolayers over predicted, and tissue explants under predicted, efficacy in a healthy 
volunteer biopsy-challenge study.  Tissue concentrations at 24 hours after single high-dose of 
maraviroc and tenofovir were moderately protective against HIV infection.  
Introduction 
 
 The mixed success of recent PrEP clinical trials (discussed in Chapter IV and in ref [73]) 
highlights the need for a surrogate in Phase I and II studies that can be used to measure efficacy.  The 
human tissue explant model may be able to provide such a surrogate but the prediction potential of 
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this model has yet to be validated.  While Chapter IV described the identification of protective 
antiretroviral concentrations by incubating vaginal explants or TZM-bl cells in various concentrations 
prior to and during HIV-exposure, an alternative model is the biopsy- challenge model.   In this 
model, healthy HIV-negative volunteers are dosed with drug and biopsies are subsequently collected 
and exposed to HIV ex vivo.    
 The biopsy-challenge model had been previously used to test topical microbicides [27]. 
MTN006 tested this method to evaluate the efficacy of 1 % tenofovir (TFV) and oral tenofovir 
disoproxil fumarate (TDF by ex vivo challenge of colorectal biopsies following drug administration 
[24].  Although the tissues showed a wide variability in susceptibility to HIV infection, a negative 
correlation between tissue concentrations of TFVdp and HIV replication was observed, suggesting 
proof of concept for this method.  To date, this biopsy-challenge model has not been used to evaluate 
the efficacy of orally administered antiretrovirals to protect female genital tissues.   
In Chapter IV, a relationship between tissue concentration of antiretrovirals in vaginal tissue 
and inhibition of viral replication was demonstrated for TFV and MVC.  To determine the prediction 
potential of the vaginal explant model, we performed a feasibility study in six healthy pre-menopausal 
women in which ex vivo HIV challenges were performed on cervical and vaginal biopsies 24 hours 
following oral dosing of maraviroc (MVC) and TDF at the 200% dose level.  The Emax models 
developed in vaginal tissue predict 14% efficacy while the Emax models in TZM-bl cells would predict 
>99% efficacy (Chapter IV) . 
Methods 
Study Design 
 
 Six healthy pre-menopausal females were enrolled between February-April 2014 at the 
University of North Carolina at Chapel Hill.  The UNC Biomedical Institutional Review Board 
approved the study (IRB #13-3940, ClinicalTrials.gov identifier NCT02039323).  Participants were 
required to have an intact cervix and uterus, test negative for STIs and be willing to refrain from 
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sexual intercourse from 72 hours prior to enrollment until follow up.  All participants were required to 
be using an acceptable form of contraception.  No other medications or herbal supplements were 
permitted from seven days prior to dosing until after completion of all study visits. 
Women were screened for eligibility while not on their menstrual cycle.  If eligible, women 
were enrolled in the study seven to fourteen days after the start of their period.  At enrollment, a pre-
dose blood draw was performed to collect donor PBMC.  Women were then administered via oral 
route 600 mg TDF + 600 mg MVC.  Women were required to fast for four hours prior and two hours 
following dosing to prevent any interference with absorption of medication.  Subjects were kept in the 
Clinical Translational Research Center (CTRC) for three hours following dosing to observe for any 
adverse events.  Women returned to the CTRC 24 hours post-dose, where two cervical and two 
vaginal biopsies were collected for ex vivo HIV challenge.  Follow-up safety visits were completed 
seven to fourteen days following collection of tissue biopsies. 
Two women not administered medication were also screened, consented under UNC IRB 
#10-2265, and provided control data.  One subject was used as an untreated control for the biopsy 
viral challenge.  Blood was collected for PBMC isolation and one cervical and one vaginal biopsy 
were collected.  The other subject was previously shown in another study (NCT 01505114) to have 
PBMCs and cervical biopsies resistant to ex vivo HIV infection (C. Dezzutti, personal 
communication).   
Peripheral Blood Mononuclear Cell Stimulation and Infection 
 
To determine whether PBMC collected prior to medication dosing could be used to assess 
donor susceptibility to HIV infection ex vivo, blood was collected in CPT tubes (BD Diagnostics) for 
PBMC isolation.  Within 4h of collection, tubes were centrifuged at 1300 g for 30 minutes with no 
brake.  The cell containing plasma was transferred to a 15 mL conical tube and the gel layer rinsed 
with phosphate-buffered saline (PBS).  The suspension was centrifuged at 350 g for 10 minutes.  
Supernatant was then discarded and cells were resuspended in red blood cell lysis buffer for 3 
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minutes.   Cell suspension was brought up in 10 mL with phosphate-buffered saline and cells were 
centrifuged at 300 g for 10 minutes.  The supernatant was discarded and the cell pellets were brought 
up to 1 mL with RPMI.  Cell count and viability were determined using the Muse® Cell Analzyer 
(Millipore).  All procedures were performed at room temperature. 
Prior to infection, cells were stimulated overnight with phytohemagglutinin (PHA).  PBMC 
(2 x 10
7
) were added to a T-75 tissue culture flask with 10 mL of growth media (GM) containing 
RPMI (Gibco), 20% FBS (HyClone), 100 units/mL penicillin/100 ug/mL streptomycin (Sigma), and 
100 units/mL IL-2 (Sigma).  PHA (Sigma) was added for a final concentration of 5 ug/mL.   
Following overnight incubation at 5% CO2 and 37°C, PHA was washed out by centrifuging the cell 
suspension at 350 g for 10 minutes and resuspending the cells with 10 mL of GM.  HIV-1JR-
CSF/hPBMCs (10
7
 TCID50) was added to each flask.  Cells were incubated with virus overnight.  The 
virus was washed out the following day by centrifuging the cell suspension at 350 g for 10 minutes, 
discarding the supernatant, and resuspending the cell pellet with 10 mL fresh GM. Cells were isolated 
on day zero and infected on day one.  Supernatant of cells was collected at days 3, 5, 7 and 10 and 
analyzed for p24 concentration using the AlphaLISA ® p24 kit (Perkin Elmer) per manufacturer 
instructions. 
Cervical and Vaginal Biopsy Ex-vivo HIV Challenge 
 
 Two cervical and two vaginal biopsies were collected from each study participant 24 hours 
post dose.  Similar to methods previously described [42], subjects were placed in the dorsal lithotomy 
position. After speculum insertion, the vaginal fornices and the entire cervix were prepped with 2% 
viscous lidocaine solution (lidocaine hydrochloride), and then were additionally anesthetized with 
topical 20% benzocaine spray (HurriCaine, Beutlich Pharmaceuticals). Vaginal tissue biopsies were 
obtained at either the left or the right vaginal fornix. Cervical biopsies were obtained at either the 3- 
or the 9-o’clock position. About 3 mm × 3 mm × 1 mm specimens were obtained at both the vaginal 
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and the cervical sites with Baby Tischler forceps (Cooper Surgical).  Biopsies were placed in separate 
cryovials and transferred on ice to the laboratory for processing.   
Within 30 minutes of collection, biopsies were placed in 48-well tissue culture plate with 
biopsy culture medium containing Iscove’s Modified Dulbecco’s Medium (Gibco), 10% FBS, 100 
units/mL penicillin/ 100 ug/mL streptomycin, 240 units/mL nystatin (Sigma), and MEM Vitamin 
Solution (Sigma).  HIV-1JR-CSF/hPBMC (10
7
 TCID50 /well) was added to each well.  Final volume of 
medium plus virus was 0.5 mL per well.  Biopsies were incubated at 5% CO2 and 37°C for three 
hours.  Biopsies were then rinsed in culture medium and transferred to gelfoam rafts in a 12-well 
tissue culture plate. One vaginal and one cervical biopsy were weighed and harvested at 24 hours and 
48 hours post inoculation.  For the untreated control, the vaginal biopsy was harvested at 24 hour and 
cervical biopsy at 48 hour.  Spliced RNA was quantified in the tissue explants as described in Chapter 
III and normalized for tissue weight.  Since over 95% of tissues susceptible to infection in Chapter III 
showed detectable replication within 48 hours, tissues were considered protected if both the 24 hour 
and 48 hour biopsies were below the pre-determined threshold of 434 copies/mg tissue.  The 
threshold value was calculated based on the background RNA signal measured in 41 mucosal 
explants (mean + 1 S.D.).   
Results 
Study Participants and Adverse Events 
 
 Six women, screened and enrolled between February –April 2014, received combination 
600mg MVC + 600 mg TDF. All subjects were Caucasian, non-Hispanic, women with a median age 
at screening of 23.5 years (range 21-40).  The median BMI was 22.8 kg/m
2
 (range 19.6-33.8).   All 
adverse events reported were Grade 1 and medication-related events included nausea (n=2), dry 
mouth (n=2), increased bowel frequency (n=1), and light-headedness (n=1).  All resolved prior to 
follow-up.  
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Oral Maraviroc and Tenofovir Protection of Cervical and Vaginal Biopsies 
 
 Results of the ex vivo HIV challenge are summarized in Figure 19.  In three subjects, both 
vaginal and cervical tissues were protected from HIV infection through 48 hours.  One subject had 
mixed efficacy with cervical tissues being protected while vaginal tissues were infected.  Both 
cervical and vaginal tissues were infected in the remaining two subjects. In the untreated control, 
infection was observed by day 2 post-inoculation.    
 
PBMC as a surrogate for donor susceptibility to HIV infection 
 
 To assess the utility of PBMC to serve as a surrogate for tissue susceptibility to HIV 
infection, we compared the susceptibility of PBMC from a donor known to have cervical tissue 
Figure 19 Protection of mucosal biopsies from HIV following oral maraviroc and oral tenofovir 
at 200% dosing.  Two vaginal and two cervical biopsies were collected form all study participants 
(S1-6) 24 hours after a 600/600 mg dose of MVC/TDF. All biopsies were challenged with a 3 hour 
viral exposure to 10
7
 TCID50/ well HIV-1JR-CSF/PBMC. Spliced RNA was measured in tissues at one 
and two days post-inoculation.  The dark dashed line represents the pre-determined infection cutoff 
of 434 copies/mg.  Open symbols represent vaginal tissues. Closed symbols represent cervical 
tissues.   
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resistant to HIV infection, to the susceptibility of PBMC from the study participants in the biopsy-
challenge study.  Prior to start of the study, three of the study participants were known to have tissue 
biopsies susceptible to HIV infection due to participation in previous studies.    Results of this 
comparison are shown in Table 8.  When PBMC were stimulated overnight prior to infection, p24 
levels of 10 ng/mL were reached by day 10 in all cases except for the donor with resistant cervical 
tissue.   
Table 8 Correlation between PBMC and tissue biopsy susceptibility to HIV infection.  PBMC 
were considered susceptible to HIV infection if p24 by Day 10 was >10 ng/mL.  In the previous 
study, cervical biopsies were considered susceptible if the cumulative p24 by Day 10 was >1000 
pg/mL.  S1-4 PBMC were collected prior to dose with 600 mg MVC+ 600 mg TDF and biopsies for 
this study were collected 24 hours post-dose.  C1 and C2 did not receive any study medication.  C1 
only donated PBMC as her tissues were previously shown to be resistant to infection. 
Subject/ 
Control 
PBMC Previous Study This study 
S1 Susceptible Cervix susceptible Cervix and Vagina susceptible 
S2 Susceptible Cervix susceptible Cervix and Vagina protected 
S3 Susceptible N/A Cervix and Vagina susceptible 
S4 Susceptible N/A Vagina susceptible 
Cervix protected 
S5 Susceptible N/A Cervix and vagina protected 
S6 Susceptible Cervix susceptible Cervix and Vagina protected 
C1 Resistant Cervix resistant N/A 
C2 Susceptible N/A Cervix susceptible 
 
Discussion 
 
This study using a biopsy-challenge model is the first to evaluate the efficacy of combination 
oral MVC and TDF for HIV prevention in women.  A direct comparison of the explant model to the 
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biopsy-challenge model has not been previously performed.  Although efficacy in the biopsy-
challenge study was higher than predicted by our explant model in Chapter IV, we demonstrate that 
complete protection of the female genital tract from ex vivo HIV-1 infection cannot be achieved with 
single dosing of 200% the doses used in treatment.   
In a biopsy-challenge study, drug penetration into mucosal tissue must be accounted for, as 
well as drug retention in the tissue upon removal from the body. We used pharmacokinetic data 
collected from a previous study [150] to estimate tissue concentrations at the time of our biopsy 
collections. In our study, all tissues were incubated in virus within 0.5h of removal from the body.  
Since we did not transport the biopsies in medium, it is expected that minimal drug was washed away 
prior to incubation.  Biopsies were incubated in virus for 3 hours and based on our evaluation of drug 
elimination in explant culture, we expect that >47% of the initial MVC (t1/2 2.8 hours) concentration is 
retained over this time period.  Intracellular TFVdp is retained longer in tissue (t1/2 20 hours), and 
>90% would be retained during the viral exposure period.    
We demonstrate that when administered at 200% of the doses used in treatment, complete 
protection of the female genital tract from HIV-1 infection cannot be achieved with single oral dosing 
of MVC and TDF.  Overall, 50% of subjects were protected from HIV infection in both cervical and 
vaginal tissues.  These data would suggest that our vaginal explant model underestimated the efficacy 
of MVC or TFV; however, this difference could be due to the small sample size in the healthy 
volunteer study.  It is also worth noting that in our previous explant challenges, only 84% of tissues 
became infected (Chapter III) and therefore it could be expected that at least 1 of the 6 women in our 
study had tissues not susceptible to ex vivo infection, although all had PBMC susceptible to infection.   
Additionally, although the concentration of TFVdp measured in FGT did now show any protection 
from HIV in the Emax models from vaginal explants, given the additive properties between MVC and 
TFV demonstrated in vitro (Chapter IV), TFVdp may have enhanced the efficacy of MVC in the 
healthy volunteer study.  Another possible explanation for the differences between the model and this 
study are the populations of women from whom the tissue was collected.  While the biopsy-challenge 
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study used biopsies collected from young, healthy, pre-menopausal women, the explant model was 
generated with surgical specimens from women whom were mostly older and postmenopausal.  In 
addition to vaginal atrophy, changes in pH, and in the vaginal microflora of postmenopausal women 
[164], the loss of estradiol regulation on inflammatory mediators has been associated with increased 
HIV replication in ectocervical explants from postmenopausal women vs premenopausal women 
[165].  Therefore it is possible that different target concentrations are required for protection in pre- 
versus postmenopausal women.     
In contrast to the explant model, TZM-bl cells (a monolayer HeLa cell line) overestimated the 
efficacy observed in the dose-challenge study.  A discussion on the discrepancy in drug effect 
between cells and explants is presented in Chapter IV.  A comparison of TFV drug efficacy between 
cell types suggests that efficacy in primary cell cultures such as PBMCs is up to 300-fold more potent 
than in HeLa cell lines [158], moving the EC50 even farther from what we have predicted in either the 
explant model or the dose-challenge study. These disparate results highlight the importance of 
identifying appropriate models to predict in vivo efficacy. While efficacy in the biopsy-challenge 
model fell somewhere in between the explant and TZM-bl model predictions, it may be prudent in 
preclinical development to use the least sensitive model to screen antiretroviral candidates, thereby 
increasing the likelihood of success in clinical development.   
In this study we did not use donor- matched positive controls by collecting biopsies prior to 
administration of study drug.  It has been shown that not all tissues explants are susceptible to HIV 
infection (Chapter III and refs [24, 132]) and evaluation of drug effect can be difficult if donor 
susceptibility is unknown.  Collection and HIV-1 challenge of pre-dose biopsies may be theoretically 
sound but is not always an ideal way to screen for susceptible candidates as it lengthens the time on 
study, increases cost, and puts increased burden on study volunteers.  However as we demonstrated, 
collecting PBMC pre-dose to determine HIV susceptibility may be a feasible alternative.  More 
evaluations are needed to confirm this method’s utility, especially in donors with tissue resistant to 
HIV infection.  
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In summary, we have provided “proof of concept” that efficacy of oral antiretrovirals for 
prevention of HIV in women can be assessed via ex vivo viral challenge with minimal risks or ethical 
constraints.  Our Emax model generated in surgical donor vaginal explants under-predicted and a model 
in TZM-bl cells over-predicted the efficacy observed in this study, but given our small sample size, 
this should be confirmed in a larger study.  These data provide support for the use of the human tissue 
explant model to be used for prospective evaluation of target tissue concentrations and provide a 
translational model (bench to bedside) for development of HIV prevention agents.   
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Chapter VI: Perspectives and Future Directions 
Clinical Pharmacology for HIV Prevention: Advances and Limitations 
 
 The specific aims of this dissertation were designed to overcome some of the obstacles to the 
success of ARV therapy for HIV PrEP.  These obstacles, discussed in Chapter I, include highly 
variable penetration with different antiretrovirals to mucosal tissue following oral dosing and lack of 
a robust preclinical tool to identify target concentrations in mucosal tissue required for protection 
from HIV infection [75].   
 In Chapter II, the first robust data describing drug transporters in female genital tissues are 
summarized.  The efflux transporters MDR1 and MRP4 are shown to be expressed in female genital 
tissues at levels comparable to liver and kidney tissues [166].  These findings have been validated 
with other expression studies [85, 86] and a cheminformatics analysis that identified the influence of 
MRP4 and MRP1 in predicting drug penetration in female genital tissues [167].  We propose that 
differential expression between the epithelium of female genital and colorectal tissues may explain 
the differential penetration into these compartments following oral dosing.  Understanding the factors 
that influence drug distribution within female genital and colorectal tissues will inform the design and 
selection of antiretrovirals to target these tissues.   
 One limitation of this work is the lack of functional data.  Due to post-translational 
modifications, mRNA and protein expression do not always correlate to efflux activity [168] and 
although we can make hypotheses and predictions regarding the drug disposition of transporter 
substrates, these predictions will need to be validated with in vivo probe studies.  Additionally, 
although we performed a robust chart review to determine any clinical co-factors or medications that 
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may influence expression, the information collected was retrospective; therefore, to fully understand 
the role of clinical factors such as menopause, co-inflammatory conditions, and co-medications on 
mucosal tissue expression, prospective studies powered to look for these differences should be 
performed.         
 In Chapter III, the characterization and improvements made to the human tissue explant 
model are discussed.  Cell populations and intracellular drug metabolism are highly variable between 
donors, highlighting the importance of measuring drug concentrations of active drug directly in tissue.  
Changes in tissue architecture and decreases in CD3 and CD4 cell populations and endogenous 
nucleotide concentrations over the first four days in culture support the use of an infection measure 
that can identify early replication in explant tissue.  Therefore, a particularly important outcome of 
this project is the development of a novel assay to measure spliced RNA that can detect infection 
within one to three days post exposure.  This development not only streamlines the efficiency of the 
explant model, but may also provide a more relevant surrogate to in vivo situations compared to the 
10-21 day explant models.  
 Identifying and quantifying viral infection in explant tissue was a particularly challenging 
obstacle in the development of the explant model.  The reasons for this were primarily two-fold.  
First, the low frequency of infected cells in a single explant required an assay that was able to identify 
infection in the presence of high background introduced by the inoculum.  This obstacle was largely 
overcome by the development of an assay to quantify a spliced RNA product that is expressed in 
relative abundance in each infected cell; however, the issue of background was not completely 
eliminated.  Defining infection in our explant model is still dependent on characterizing the 
background spliced RNA level and this will likely have to be redefined for every batch of viral 
inoculum used.  The second obstacle presented was determining what factors to normalize for 
infection.  Unlike a homogenous cell population, explant tissues vary from piece to piece in size, cell 
types, and RNA yield.  Ideally, the perfect assay would be able to normalize for the exact number of 
susceptible cells in each explant.  Poor quality antibody precluded our ability to adjust for CCR5 
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populations in our tissues.  As technology improves, other methods of accounting for susceptible cells 
in may improve the sensitivity of the model and the detection of low-level infection. 
The explant model we described was developed with vaginal and cervical surgical tissues.  
While the cervical tissue was procured from anonymous donors, nearly all vaginal donors were 
postmenopausal women undergoing surgical repair for vaginal prolapse.  Although postmenopausal 
women are a population at risk for HIV infection [107], clinical trials usually limit inclusion criteria 
to include pre-menopausal women only.  Menopause-induced changes in female genital tissues 
include vaginal atrophy, changes in pH, and changes in vaginal microflora [164].  No significant 
differences have been observed in the cell populations between pre- and postmenopausal women but 
high interindividual variability and small sample sizes may have thus far limited the ability to detect 
differences [169].   In regards to explant tissues, one study found that although ectocervical explants 
from premenopausal and postmenopausal women were infected with similar frequency,  increased 
HIV replication was detected in explants from postmenopausal women [165].  More data is required 
to understand the limitations of translating efficacy from postmenopausal explant tissues to efficacy 
in premenopausal women.     
 In Chapter IV, the explant model was used to create concentration-response curves relating 
TFV and MVC to HIV inhibition in vaginal explants.  The validity of our model was indirectly 
supported by comparable TFVdp concentrations required for protection in clinical studies [151] and 
in colorectal explants [24].  Unfortunately, efficacy of MVC in explant culture decreased over time, 
similar to efficacy of oral MVC in macaques following rectal SHIV exposure [154].  Nevertheless, 
the Emax models produced for TFV and for early MVC response can be used as a starting point to 
inform future clinical trials.   
 The concentration-response experiments in Chapter IV were performed under the assumption 
of constant drug levels.  This “steady-state” environment mimics the minimal variation in tissue 
concentrations with daily oral dosing [170] but caution should be employed when extrapolating these 
findings to predict efficacy from intermittent dosing where drug concentrations may have greater 
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fluctuations in tissue compartments.  While our experiments may inform on a minimally effective 
concentration, additional experiments are required to inform on the length of time concentrations 
must remain above that concentration.   
 Although ex vivo viral inoculation in the explant model aims to mimic in vivo transmission as 
closely as possible, there are still physiologic limitations.  In addition to the dynamic tissue changes 
described in Chapter III, the explant model is a closed system and unlike in vivo mucosal tissue, is not 
connected to the systemic circulatory or immune system.  Therefore, while recruitment of regulatory 
and immune cells has been shown to occur in female tissues following vaginal intercourse and semen 
exposure [171], explant tissues are unable to elicit such a response.  Whether this lack of recruitment 
would attenuate or enhance drug response remains to be determined. Additionally, all inoculations in 
our model were performed using cell-free virus.  However, both cell-free and cell-associated virus is 
present in semen and both have been shown to be able to infect vaginal mucosa [172].  Since 
antiretroviral efficacy may be altered in the presence of cell-associated virus [163], caution should be 
made in extrapolating the results from our model all forms of HIV transmission.  
 In Chapter V, we explored the feasibility of testing oral antiretroviral efficacy for HIV 
prevention in healthy volunteers by collecting biopsies post-dose and challenging them with virus ex 
vivo as in the model described in Chapters III.  Half of the donors in our study had female genital 
tissues protected against HIV infection.  This was a greater protective effect than what was expected 
based on the concentration-responses developed in Chapter IV.  Whether this is due to the small 
sample size in our clinical study, differences in premenopausal versus postmenopausal women, or 
unknown factors is unclear.  In clinical studies, efficacy of oral TDF in women is unclear due to 
issues with adherence [49, 145], or studies not being statistically powered separate efficacy from men 
and women [48, 143].  No Phase II or III clinical trials evaluating the efficacy of oral maraviroc in at-
risk female populations have been performed.  Therefore, the ultimate clinical utility of these ex vivo 
approaches are unknown.   Regardless, as both the explant model and the biopsy-challenge model are 
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being used to evaluate pre-exposure prophylaxis candidates, making these comparisons is critical in 
understanding how to interpret their results.    
The Future of PrEP 
 
The added indication for pre-exposure prophylaxis to Truvada in 2012 [11], as well as interim 
guidance from the CDC providing support on the use of  PrEP in clinical settings[173-175], provide 
evidence that regulatory agencies are vested in the use of ARV-based prevention strategies to curb the 
HIV epidemic.  Yet, many questions still remain unanswered regarding the optimal use of PrEP and 
how it should be tailored to specific populations.  If taken consistently, once daily Truvada is highly 
effective at preventing HIV acquisition in both MSM [142] and heterosexual discordant couples [48, 
143].  However, the failure of two late phase clinical trials to demonstrate a protective effect of daily 
Truvada when studied exclusively in women have raised some concerns about the use of PrEP for all 
populations [49, 145]. While inconsistent drug taking behavior may have played a role in differences 
in clinical trial efficacy, the difference in adherence levels between the trials in women and in MSM  
was not significantly different [74, 146].  Given different mucosal tissue drug penetration patterns to 
female genital and colorectal tissues following oral dosing [42], it may be that the level of adherence 
to oral therapy required for efficacy is dependent on the route of HIV exposure (e.g. heterosexual vs 
anal receptive intercourse).   
The low adherence to once daily oral therapy that was observed in many of these clinical 
studies raises concerns over the real world utility of daily PrEP therapy.  Intermittent dosing, where 
drug is applied within a certain window before and/or after known HIV exposure, is one alternative.  
Topical administration of ARV(s) may provide some advantages in this strategy given the quickly 
achieved high drug concentrations at local sites [151].  Another option to improve adherence is the 
use of long acting formulations.  There are a number of products and formulations currently being 
pursued for use in prevention.  These are reviewed elsewhere [73, 176], but include formulations of 
tenofovir, dapivirine, maraviroc, or rilpivirine given as gels, rings, films, vaginal tablets, and/or long 
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acting injectables.  Similar to the methodologies used in this dissertation, clinical pharmacology 
approaches can be used to facilitate the development of these products.  With the necessary data, 
outcomes of different dosing strategies can be predicted by integrated pharmacokinetic and 
pharmacodynamics models, similar to the method applied to predict outcomes in Chapter V.   
 
Applications beyond Prevention 
 
 Many of the principles applied in this dissertation project can be used to address clinical 
problems outside of the HIV PrEP field.  The variability in the ability of different antiretrovirals to 
penetrate into genital tissues may have implications for persistent viral shedding despite suppressive 
ART therapy [38, 177-179] which in turn could have implications for the use of treatment as 
prevention [66].  Drug penetration into other tissue compartments may also have implications in the 
ability to suppress viral replication in known viral reservoirs such as intestinal and lymphatic tissues 
[180].  Despite drug distribution to mucosal and lymphatic tissues being critical for HIV prophylaxis, 
suppression of viral shedding, and eradication of viral reservoirs, there is a paucity of data on the role 
of drug transporters and metabolizing enzymes in these compartments and their contributions to 
antiretroviral efficacy.  Our findings in Chapter II support the role of drug transporters in drug 
penetration to mucosal tissues.  Investigations should be expanded to include an understanding of 
protein expression, localization, and ultimately the function of additional drug transporters and 
metabolizing enzymes.  The factors that may influence expression and localization (e.g. inflammation 
and hormonal regulation) must also be quantified to understand how best to target viral reservoirs and 
also to understand how factors such as contraceptive medications, pregnancy, and menopause affect a 
women’s risk of HIV shedding, transmission, and/or acquisition.  
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Conclusion 
 
 In summary, the work described here has used in vitro, ex vivo, and in vivo clinical 
pharmacology approaches to add to the understanding of antiretroviral tissue pharmacology and has 
potential to significantly advance the field of HIV prevention.  Ongoing validation of these 
approaches must be performed so that the vigorous translational methods and data described here can 
serve as a model for drug development of future HIV prevention strategies.   
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APPENDIX : Transporter Gene Expression Statistical Tables 
 
ABCB1 Univariate Analyses : Correlation between age and gene expression was assessed by 
Spearman Rank Sum Test (Corr.=Spearman correlation coefficient).  Gene expression between 
groups was tested by Wilcoxon Rank Sum Test. 
 
 
  
vagina cervix rectum overall 
  Corr. 
p-
value 
Corr.  p-value Corr.  
p-
value 
Corr.  
p-
value 
age 
 
-0.42645 0.006 N/A 0.979 N/A 0.490 -0.16688 0.118 
  
Median 
(n) 
p-
value 
Median 
(n) 
p-value 
Median 
(n) 
p-
value 
Median 
(n) 
p-
value 
menopause 
pre 
0.0462 
(n=13) 
0.049 
0.0308 
(n=11) 
0.865 
0.0267 
(n=1) 
N/A 
0.0409 
(n=25) 
0.099 
post 
0.0384 
(n=22) 
0.0179 
(n=16) 
0.0059 
(n=5) 
0.0220 
(n=43) 
race 
Caucasian 
0.0402 
(n=34) 
0.532 
0.0360 
(n=20) 
0.028 
0.0070 
(n=17) 
N/A 
0.0274 
(n=72) 
0.102 
African 
American 
0.0498 
(n=2) 
0.0115 
(n=6) 
0.0076 
(n=1) 
0.0170 
(n=9) 
smoking 
smokers 
0.0252 
(n=8) 
0.029 
0.0131 
(n=7) 
0.352 
0.0070 
(n=11) 
0.837 
0.0159 
(n=26) 
0.008 
non 
smokers 
0.0455 
(n=32) 
0.0308 
(n=23) 
0.0070 
(n=9) 
0.0368 
(n=64) 
source 
cadaver 
0.0061 
(n=1) 
0.050 
All cervical tissues 
collected from 
surgical donors 
0.0076 
(n=7) 
0.641 
0.0069 
(n=8) 
0.005 
surgical 
0.0403 
(n=39) 
0.0070 
(n=14) 
0.0310 
(n=83) 
gender 
Male 
N/A N/A 
0.0146 
(n=9) 
0.401 
0.0146 
(n=9) 
0.094 
Female 
0.0062 
(n=11) 
0.0291 
(n=81) 
inducer 
yes 
0.0220 
(n=18) 
0.055 
0.0173 
(n=18) 
0.390 
0.0184 
(n=8) 
0.259 
0.0177 
(n=41) 
0.124 
no 
0.0457 
(n=22) 
0.0334 
(n=12) 
0.0059 
(n=12) 
0.0349 
(n=49) 
hormone 
yes 
0.0406 
(n=8) 
0.581 
0.0109 
(n=4) 
0.329 N/A 
0.0384 
(n=12) 
0.495 
no 
0.0390 
(n=32) 
0.0281 
(n=26) 
0.0235 
(n=78) 
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ABCC2 Univariate Analyses : Correlation between age and gene expression was assessed by 
Spearman Rank Sum Test (Corr.=Spearman correlation coefficient).  Gene expression between 
groups was tested by Wilcoxon Rank Sum Test. 
  
vaginal cervix rectum overall 
  Corr. 
p-
value 
Corr. 
p-
value 
Corr. 
p-
value 
Corr. 
p-
value 
 
age -0.0586 0.720 
 
0.948 
 
0.217 0.039 0.715 
  
Median 
(n) 
p-
value 
Median 
(n) 
p-
value 
Median 
(n) 
p-
value 
Median 
(n) 
p-
value 
menopause 
pre 
0.00164 
(n=13) 
0.264 
0.00062 
(n=11) 
0.481 
0.00012 
(n=1) 
N/A 
0.00130 
(n=25) 
0.981 
post 
0.00146 
(n=22) 
0.00089 
(n=16) 
0.00126 
(n=5) 
0.00122 
(n=43) 
race 
Caucasian 
0.0015 
(n=34) 
0.206 
0.00121 
(n=20) 
0.295 
0.00035 
(n=18) 
0.638 
0.00121 
(n=72) 
0.4901 
African 
American 
0.0028 
(n=2) 
0.00064 
(n=6) 
0.00024 
(n=1) 
0.00066 
(n=9) 
smoking 
smokers 
0.00118 
(n=8) 
0.065 
0.00062 
(n=7) 
0.264 
0.00037 
(n=11) 
0.328 
0.00063 
(n=26) 
0.015 
non 
smokers 
0.00160 
(n=32) 
0.00116 
(n=23) 
0.00024 
(n=9) 
0.00121 
(n=64) 
source 
cadaver 
0.00107 
(n=1) 
0.699 
All cervical 
tissues collected 
from surgical 
donors 
0.00026 
(n=7) 
0.853 
0.00056 
(n=8) 
0.109 
surgical 
0.00149 
(n=39) 
0.00035 
(n=14) 
0.00117 
(n=83) 
gender 
Male 
N/A N/A 
0.00029 
(n=9) 
0.651 
0.00029 
(n=9) 
0.001 
Female 
0.00034 
(n=11) 
0.00121 
(n=81) 
inducer 
yes 
0.00114 
(n=18) 
0.133 
0.00088 
(n=18) 
0.789 
0.00038 
(n=8) 
0.263 
0.00082 
(n=41) 
0.433 
no 
0.00158 
(n=22) 
0.00097 
(n=12) 
0.00027 
(n=12) 
0.00120 
(n=49) 
hormone 
yes 
0.00168 
(n=8) 
0.611 
0.00054 
(n=4) 
0.500 N/A 
0.00142 
(n=12) 
0.344 
no 
0.00140 
(n=32) 
0.00103 
(n=26) 
0.00100 
(n=78) 
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ABCC4 Univariate Analyses : Correlation between age and gene expression was assessed by 
Spearman Rank Sum Test (Corr.=Spearman correlation coefficient).  Gene expression between 
groups was tested by Wilcoxon Rank Sum Test. 
 
  
Vaginal cervix rectum overall 
  Corr. 
p-
value 
Corr. 
p-
value 
Corr. 
p-
value 
Corr. 
p-
value 
 
age -0.155 0.338 
 
0.891 
 
0.843 -0.076 0.475 
  
Median 
(n) 
p-
value 
Median 
(n) 
p-
value 
Median 
(n) 
p-
value 
Median 
(n) 
p-
value 
menopause 
pre 
0.0267 
(n=13) 
0.116 
0.0065 
(n=11) 
0.688 
0.0123 
(n=1) 
N/A 
0.0172 
(n=25) 
0.508 
post 
0.0192 
(n=22) 
0.0094 
(n=16) 
0.0087 
(n=5) 
0.0156 
(n=43) 
race 
Caucasian 
0.0193 
(n=34) 
0.318 
0.0157 
(n=20) 
0.009 
0.0237 
(n=18) 
0.736 
0.0193 
(n=72) 
0.018 
African 
American 
0.0277 
(n=2) 
0.0051 
(n=6) 
0.0157 
(n=1) 
0.0086 
(n=9) 
smoking 
smokers 
0.0171 
(n=8) 
0.134 
0.0063 
(n=7) 
0.077 
0.0236 
(n=11) 
0.942 
0.0140 
(n=26) 
0.208 
non 
smokers 
0.0212 
(n=32) 
0.0144 
(n=23) 
0.0237 
(n=9) 
0.0184 
(n=64) 
source 
cadaver 
0.0119 
(n=1) 
0.448 
All cervical tissues 
collected from 
surgical donors 
0.0237 
(n=7) 
0.693 
0.0237 
(n=8) 
0.328 
surgical 
0.0193 
(n=39) 
0.0246 
(n=14) 
0.0172 
(n=83) 
gender 
Male 
N/A N/A 
0.0231 
(n=9) 
0.822 
0.0231 
(n=9) 
0.280 
Female 
0.0237 
(n=11) 
0.0172 
(n=81) 
inducer 
yes 
0.0148 
(n=18) 
0.112 
0.0089 
(n=18) 
0.264 
0.0263 
(n=8) 
0.672 
0.0137 
(n=41) 
0.053 
no 
0.0227 
(n=22) 
0.0139 
(n=18) 
0.0237 
(n=12) 
0.0226 
(n=49) 
hormone 
yes 
0.0195 
(n=8) 
0.474 
0.00857 
(n=4) 
0.797 N/A 
0.0192 
(n=12) 
0.845 
no 
0.0192 
(n=32) 
0.0110 
(n=26) 
0.0165 
(n=78) 
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ABCB1 Multivariable Analyses: General Linear Model (GLM) was used to assess variable 
effect on gene expression.  Expression data was log (natural) transformed to meet normality 
assumption. 
Model 1= Surgical and cadaver tissues; Covariates= age, smoker, inducer, hormone 
Model 2= Surgical and cadaver tissues; Covariates= age, smoker, inducer, hormone, race 
Model 3= Surgical tissue only; Covariates= age, smoker, inducer, hormone 
Model 4= Surgical tissue only; Covariates= age, smoker, inducer, hormone, race  
 
 
Model # 1 2 3 4 
 
n 89 80 81 72 
 
R-squared 0.272846 0.323197 0.2556 0.3053 
 
Model p-
value 
0.0002 0.0001 0.001 0.0011 
m
o
d
el
 e
ff
ec
t 
  
p
-v
a
lu
es
 
tissue 0.0002 0.0006 0.0029 0.0087 
age 0.0258 0.0125 0.0282 0.0247 
smoker 0.2864 0.3669 0.5143 0.7492 
inducer 0.3403 0.5236 0.2376 0.2975 
hormone 0.7827 0.9691 0.7739 0.992 
race N/A 0.0142 N/A 0.0186 
T
u
k
ey
's
 p
-v
a
lu
es
 
vaginal v 
rectal 
0.0001 0.0004 0.0031 0.0063 
vaginal v 
cervical 
0.1221 0.5327 0.0954 0.4639 
cervical v 
rectal 
0.0314 0.013 0.1377 0.0699 
L
s 
m
ea
n
s 
 (
ln
 t
ra
n
sf
o
rm
ed
) 
vaginal ls 
means 
-3.4268 -3.7985 -3.3741 -3.7497 
cervix ls 
means 
-3.9394 -4.1 -3.926 -4.0899 
rectum ls 
means 
-4.7844 -5.1194 -4.6748 -5.0609 
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ABCC2 Multivariable Analyses: General Linear Model (GLM) was used to assess variable 
effect on gene expression.  Expression data was log (natural) transformed to meet normality 
assumption. 
Model 1= Surgical and cadaver tissues; Covariates= age, smoker, inducer, hormone 
Model 2= Surgical and cadaver tissues; Covariates= age, smoker, inducer, hormone, race 
Model 3= Surgical tissue only; Covariates= age, smoker, inducer, hormone 
Model 4= Surgical tissue only; Covariates= age, smoker, inducer, hormone, race  
 
Model # 1 2 3 4 
 
n 90 81 82 73 
 
R-squared 0.1927 0.203 0.194399 0.196724 
 
Model p-
value 
0.0058 0.0167 0.0103 0.0391 
m
o
d
el
 e
ff
ec
t 
 
p
-v
a
lu
es
 
tissue 0.0011 0.0041 0.0039 0.02 
age 0.6861 0.9314 0.612 0.8323 
smoker 0.3665 0.3963 0.3208 0.3538 
inducer 0.449 0.6246 0.3373 0.3508 
hormone 0.8431 0.9216 0.8082 0.9418 
race N/A 0.3176 N/A 0.4208 
T
u
k
ey
's
 p
-v
a
lu
es
 
vaginal v 
rectal 
0.0008 0.0028 0.0039 0.0188 
vaginal v 
cervical 
0.1195 0.2915 0.1192 0.2856 
cervical v 
rectal 
0.109 0.127 0.1492 0.2442 
L
s 
m
ea
n
s 
 (
ln
 t
ra
n
sf
o
rm
ed
) 
vaginal ls 
means 
-6.6845 -6.7603 -6.6994 -6.7553 
cervix ls 
means 
-7.1467 -7.1539 -7.1573 -7.1509 
rectum ls 
means 
-7.7319 -7.7771 -7.7749 -7.7615 
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ABCC4 Multivariable Analyses: General Linear Model (GLM) was used to assess variable 
effect on gene expression.  Expression data was log (natural) transformed to meet normality 
assumption. 
Model 1= Surgical and cadaver tissues; Covariates= age, smoker, inducer, hormone 
Model 2= Surgical and cadaver tissues; Covariates= age, smoker, inducer, hormone, race 
Model 3= Surgical tissue only; Covariates= age, smoker, inducer, hormone 
Model 4= Surgical tissue only; Covariates= age, smoker, inducer, hormone, race  
  Model # 1 2 3 4 
  n 90 81 82 73 
  R-squared 0.1247 0.1941 0.123573 0.20148 
  Model p-
value 
0.0791 0.0227 0.1184 0.0339 
m
o
d
el
 e
ff
ec
t 
p
-v
a
lu
es
 
tissue 0.0271 0.1797 0.0538 0.3693 
age 0.4813 0.3278 0.5205 0.5577 
smoker 0.2047 0.2717 0.2719 0.4989 
inducer 0.2285 0.2845 0.1663 0.1453 
hormone 0.7905 0.7317 0.7953 0.758 
race N/A 0.0095 N/A 0.0103 
T
u
k
ey
's
 
p
-v
a
lu
es
 
vaginal v 
rectal 
0.5424 0.6877 0.7112 0.9438 
vaginal v 
cervical 
0.1298 0.4156 0.1365 0.4419 
cervical v 
rectal 
0.0294 0.1697 0.0901 0.4844 
L
s 
m
ea
n
s 
(l
n
 t
ra
n
sf
o
rm
ed
) vaginal ls 
means 
-4.0907 -4.4156 -4.0867 -4.4242 
cervix ls 
means 
-4.5216 -4.7218 -4.52 -4.726 
rectum ls 
means 
-3.8122 -4.1889 -3.837 -4.3133 
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